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Summary 
In over 40% of all cancers, the key tumor suppressor p53 is inactivated via mutation. 
Mutant (mut) p53 can gain new properties (gain-of-function, GOF), which actively 
contribute to tumorigenesis. In many tumors, a massive accumulation of mutp53 protein 
is observed and a prerequisite for the GOF activity. Therefore, tumors often depend on 
sustained high levels of mutp53, which suggests that interfering with mutp53 
accumulation may be exploitable in cancer therapy. However, the mechanisms that 
control excessive mutp53 stabilization are not fully understood. To this end, the main aim 
of this study was to identify regulators of mutp53 accumulation in Burkitt’s lymphoma 
(BL) as a model for a highly aggressive cancer. 
Despite the presence of functional MDM2, the main negative regulator of p53, mutp53 
was found to be stabilized in BL. To identify proteins regulating mutp53 levels in an 
unbiased fashion, a flow cytometry-based RNA interference (RNAi) screen was 
conducted in a mutp53 BL cell line model. The primary screen hit was TRRAP 
(transformation/transcription domain-associated protein), a constituent of several histone 
acetyltransferase (HAT) complexes. TRRAP knock-down and knock-out resulted in 
depletion of mutp53 protein (but not mRNA) in lymphoma and colorectal cancer cell lines 
with a diverse spectrum of p53 mutations. Conversely, TRRAP overexpression increased 
mutp53 levels. Mass spectrometric analysis of the mutp53 interactome after TRRAP 
knock-down indicated that TRRAP silencing caused nuclear export of mutp53 and 
degradation via the MDM2-proteasome axis, suggesting targeting of mutp53 to the 
physiological p53 degradation machinery. Gene expression profiling after TRRAP knock-
down showed a suppression of cell cycle-related genes and an induction of interferon 
signaling, which however did not contribute to mutp53 regulation. To map functional 
regions of TRRAP, a CRISPR/Cas9 mutagenesis approach (“CRISPR scanning”) was 
applied which identified a 109 amino acid region in the N-terminal HEAT repeat region 
crucial for mutp53 accumulation and cell survival. In wild-type p53 BL cells, TRRAP 
silencing attenuated p53 stabilization and activity upon genotoxic stress. Finally, to 
transfer the results from RNAi screening, a drug-based screening was performed and 
identified that inhibition of histone deacetylases (HDAC) and specifically HDAC1/2/3 
decreased mutp53 levels to a surprisingly similar extent as TRRAP knock-down. 
In summary, this study identifies TRRAP as a key regulator of p53 levels and links 
histone-modifying complexes to p53 protein accumulation. Based on the GOF properties 
of mutp53, this may provide a basis for therapeutic targeting of mutp53 in lymphoma and 
other cancers. 
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Zusammenfassung 
Bei über 40% aller Krebsarten wird der zentrale Tumorsuppressor p53 durch Mutationen 
inaktiviert. Mutiertes (mut) p53 gewinnt oft neue Eigenschaften („gain-of-function“, GOF), 
die aktiv zur Tumorentstehung beitragen können. Des Weiteren kann in vielen Tumoren 
eine massive Akkumulation des mutp53-Proteins beobachtet werden. Dies ist eine 
Voraussetzung für die GOF-Aktivität, weswegen Tumore häufig auf ein konstitutiv hohes 
mutp53-Level angewiesen sind. Daher könnte dies für eine gezielte Krebstherapie von 
Nutzen sein; allerdings sind die Mechanismen der fehlerhaften mutp53-Akkumulation nur 
unzureichend bekannt. Aus diesem Grund war das Hauptziel dieser Studie, Regulatoren 
der mutp53-Akkumulation im Burkitt-Lymphom (BL) als Modell für hochaggressiven 
Krebs zu identifizieren. 
Trotz Expression von funktionalem MDM2, dem zentralen negativen Regulator von p53, 
zeigte sich, dass mutp53 im BL akkumulierte. Um Regulatoren des mutp53-Levels zu 
identifizieren, wurde ein Durchflusszytometrie-basierter RNA-Interferenz (RNAi) Screen 
in einem mutp53 BL-Zelllinienmodell durchgeführt. Hierdurch wurde TRRAP 
(transformation/transcription domain-associated protein) identifiziert, welches ein 
Bestandteil von vielen Histonacetyltransferasekomplexen ist. In Lymphom- und 
Kolonkarzinom-Zelllinien mit unterschiedlichen p53-Mutationen verursachten sowohl ein 
TRRAP Knockdown als auch ein Knockout eine Degradierung von mutp53-Protein (aber 
nicht mRNA). Im Gegenzug resultierte eine TRRAP-Überexpression in einem erhöhten 
mutp53-Level. Um den zu Grunde liegenden molekularen Mechanismus zu 
entschlüsseln, wurde eine massenspektrometrische Analyse der mit mutp53-
interagierenden Proteine nach TRRAP Knockdown durchgeführt. Dabei zeigte sich ein 
Abbau von mutp53 mittels der MDM2-abhängigen physiologischen p53-
Degradationsmaschinerie, bestehend aus einem nukleären Export und gefolgt von einer 
proteasomalen Degradierung. Eine anschließende Genexpressionsanalyse zeigte eine 
Suppression von Zellzyklusgenen und eine Induktion des Interferon-Signalweges nach 
TRRAP Knockdown, welches allerdings nicht zur mutp53-Regulation beitrug. Um 
funktionale Domänen von TRRAP aufzufinden, wurde eine CRISPR/Cas9-basierte 
Methode („CRISPR Scanning“) angewandt. Dabei wurde eine aus 109 Aminosäuren 
bestehende Region in der N-terminalen HEAT repeat-Region von TRRAP identifiziert, 
die eine zentrale Rolle für die mutp53-Stabilisierung und für das Zellüberleben spielte. In 
BL-Zellen mit Wildtyp-p53 zeigte sich, dass ein TRRAP Knockdown die p53-
Stabilisierung und –Aktivität nach genotoxischem Stress beeinträchtigte. Bei einem 
abschließenden Medikamenten-Screening wurde herausgefunden, dass eine Inhibition 
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von Histondeacetylasen (HDACs) und insbesondere von HDAC1/2/3 den mutp53-Level 
gleichermaßen beeinträchtigte wie ein TRRAP Knockdown. 
Zusammenfassend identifiziert diese Studie TRRAP als einen zentralen Regulator des 
p53-Levels und verbindet Histon-modifizierende Komplexe mit der Proteinakkumulation 
von p53. Basierend auf der GOF-Aktivität von mutp53 könnte dies die Basis für eine 
zielgerichtete Therapie von Lymphomen und weiteren Krebsarten mit mutp53 darstellen. 
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1 Introduction 
1.1 The tumor suppressor p53 – “guardian of the genome” 
The transcription factor p53, which is encoded by the TP53 gene, is arguably one of the 
most extensively studied proteins and plays a role in almost every aspect of cancer 
biology. Discovered nearly 40 years ago (in 1979) and initially erroneously identified as 
an oncogene, p53’s role as the cell’s most important tumor suppressor is now well 
established1,2, which is why it was entitled “guardian of the genome”3. 
1.1.1 Activation and function of the p53 pathway 
p53 is the master regulator of the cell’s response to stress and mainly exerts its tumor 
suppressive functions by regulating gene expression4. An overview of the p53 activation 
pathway is shown in Figure 1. p53 is activated by a plethora of cellular stresses which 
may cause transformation, including – but not limited to – DNA damage, hypoxia, 
oncogene activation, spindle damage, and nucleotide depletion5. For the sensing of 
stress signals, p53 relies on signal mediators, which transmit the information about the 
type of stress to either p53 or its negative regulator MDM2 (for details about MDM2 see 
1.1.3.1, p. 4) via post-translational modifications such as phosphorylation5. Many 
stresses result in a specific activation of individual mediators: for example, the protein 
ARF is only induced by oncogene activation but not by irradiation4,6, while the protein 
ATM is highly sensitive for sensing DNA breaks7,8. After a stress signal, the half-life of 
p53 substantially increases from minutes to hours and p53 accumulates, which allows 
the formation of homotetramers. Additional post-translational modification finally 
facilitates binding of p53 to its specific response elements (REs) upstream of p53 target 
genes. In concert with auxiliary cofactors such as histone acetyltransferases (HATs), p53 
then mediates or represses gene transcription in order to drive a transcriptional program 
specifically tailored to the cellular insult. Depending on the insult’s severity, p53 typically 
induces DNA repair, cell-cycle arrest, or apoptosis, which ultimately results in tumor 
suppression4,5. While these canonical p53 responses are the mostly described ones, it is 
important to note that recent studies have challenged their role in tumor suppression9. 
For example, Brady et al.10 have described a p53 mutant (L25Q;W26S) which is 
defective in induction of cell cycle arrest and apoptosis but, however, still retains its full 
tumor suppressive function. Therefore, it has been suggested that alternative cellular 
processes downstream of p53, such as autophagy or metabolic reprogramming, may 
play key roles in p53’s tumor suppressive function (Figure 1)9. 
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Figure 1: Activation of p53 and regulation of downstream target genes.  
Cellular insults are detected by specific signal mediators, which both activate p53 and inactivate its negative 
regulator MDM2. With the assistance of additional modifier proteins and cofactors, p53 can bind as a 
tetramer to DNA response elements (REs) and mediate gene transcription. p53 target genes typically induce 
DNA repair, cell-cycle arrest, or apoptosis (classical p53 response). By additionally regulating cellular 
processes as for example autophagy or stemness, p53 activation ultimately results in tumor suppression. 
Adapted by permission from Macmillan Publishers Ltd: Nat Rev Mol Cell Biol, Riley et al.5, copyright 2008, 
and modified based on Bieging et al.9. 
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1.1.2 Structure of the human p53 gene and protein 
The human TP53 gene is located on chromosome 17p13.1, spans about 19 kb, and 
comprises eleven exons (Ensembl release 88)11. It is highly conserved through evolution 
of vertebrates12. Although TP53 can give rise to ten distinct protein isoforms by different 
mechanisms, including alternative splicing and usage of alternative promoters, most 
research has been focused on its canonical and most abundant transcript (also termed 
TAp53α)13, which was also the focus of this study. The canonical p53 protein consists of 
393 amino acids, which can be roughly divided into three distinct functional regions 
(Figure 2)14-16: (1) the N-terminal region (amino acids 1-97), (2) the central core region 
(amino acids 98-292), and (3) the C-terminal region (amino acids 300-393).  
 
Figure 2: Domain structure of the canonical human p53 protein.  
p53 consists of three major domains: (1) the N-terminal domain (including the transactivation domain and the 
SH3 domain), (2) the central core (DNA-binding domain), and (3) the C-terminal domain (containing the 
tetramerization domain, regulatory domain, NLS, and NES). Numbers indicate amino acid positions. SH3, 
Src homology 3-like domain. NLS, nuclear localization signal. NES, nuclear export sequence. Reprinted by 
permission from Macmillan Publishers Ltd: Nat Rev Cancer, Bode and Dong15, copyright 2004. 
The first 42 amino acids of the N-terminal region are part of the transactivation domain, 
which mediates the recruitment of members of the transcription machinery17,18 and is 
therefore essential for p53’s transactivation activity19. Many other interaction partners of 
p53 bind in this region, including p53’s main negative regulator: the E3 ubiquitin ligase 
MDM2 (see 1.1.3.1, p. 4)20. The proline-rich SH3 domain (Src homology 3-like, amino 
acids 63-97)15 has been shown to be important for apoptosis induction (but not growth 
arrest)21 and transcriptional repression22. The central core of p53 comprises arguably the 
most important domain: the DNA-binding domain, which contains four highly conserved 
regions and equips p53 with the property to recognize and to bind to its specific DNA 
target sequences23-26. The C-terminus of p53 contains multiple additional important 
domains. The tetramerization domain (amino acids 324-355) enables tetramerization of 
p53 proteins27, which is required for p53’s transactivation capacity in vivo and for tumor 
suppression by growth inhibition in vitro28. The lysine-rich basic regulatory domain 
(amino acids 363-393) negatively regulates the binding of p53 to its target DNA 
sequences14,29. It can also facilitate binding to DNA breaks30 and is the binding site for 
many p53-interacting proteins14. Finally, the C-terminus of p53 also contains the nuclear 
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localization and export signals needed for shuttling from the nucleus to the cytosol and 
vice versa15.  
1.1.3 Regulation of p53 levels and activity 
Since activation of p53 has detrimental effects on proliferation, its activity is tightly 
controlled in physiological conditions. Therefore, p53 is negatively regulated by diverse 
mechanisms on multiple levels, with direct regulation of the p53 protein levels playing a 
central role4.  
1.1.3.1 MDM2 and the ubiquitin-proteasome pathway 
The E3 ubiquitin ligase MDM2 is the “major physiological antagonist of p53”31 and is 
responsible for keeping p53 levels low in unstressed conditions (Figure 3). MDM2 is a 
direct target gene of p53, thereby forming a negative feedback loop: p53 induces MDM2, 
which in turn both degrades p53 and inhibits its transcriptional activity32-35. 
 
Figure 3: Regulation of p53 levels by MDM2.  
In homeostatic conditions, the E3 ubiquitin ligase MDM2 (a p53 target gene) ubiquitinates p53, which is in 
turn degraded by the 26S proteasome. Upon stress (e.g. DNA damage), signal mediators block the 
formation of the MDM2-p53 complex. This allows p53 accumulation, tetramerization, and activation of its 
target genes after binding to response elements (REs) on the DNA. Under certain conditions, MDM2 can 
additionally undergo autoubiquitination and subsequent proteasomal degradation. Figure based on Metzger 
et al.36. 
The degradation of p53 by MDM2 is dependent on direct physical interaction between 
the N-termini of both proteins31. After binding, MDM2 promotes the ligation of ubiquitin 
via its RING finger domain to multiple lysine residues in p53’s C-terminus37, which results 
in proteasomal degradation of p5338. Upon stress signals, such as exposure to DNA-
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damaging agents or ionizing radiation, the MDM2-mediated degradation of p53 is 
inhibited mainly by blocking of the MDM2-p53 complex formation31. This is, for example, 
achieved by phosphorylation of serine residues in the N-terminus of p53, the region 
where MDM2 is binding. In addition, also MDM2 can be phosphorylated, which 
augments its ability to promote p53 degradation39. Alternatively, other proteins can 
interfere with the binding of MDM2 to p53. The most prominent example for this is the 
tumor suppressor ARF, which binds to MDM2 and thereby shields p5331. Notably, MDM2 
is also capable of self-regulation via autoubiquitination40,41.  
The cellular localization of p53 degradation is still under debate31. When cells are 
stressed, p53 accumulates in the nucleus. In contrast, p53 resides mostly in the cytosol 
in non-stressed conditions, where it is quickly degraded by the proteasome. Therefore, 
early studies suggested that MDM2 carries p53 to the cytosol31,42. However, the 
discovery that p53 harbors its own nuclear export sequence (NES) in the C-terminus43 
(Figure 2) fueled studies that led to the conclusion that ubiquitination by MDM2 changes 
the conformation of p53, which in turn makes the NES accessible for the cellular nuclear 
export machinery31,44,45. While these models are based on the assumption that nuclear 
export of p53 is a prerequisite for its degradation, other studies showed that p53 can in 
fact also be degraded by nuclear proteasomes46,47. 
Interestingly, MDM2 possesses additional functions for regulating p53 activity beyond 
ubiquitination. It can associate with subunits of the 19S proteasome in an ubiquitination-
independent manner and promote the formation of a ternary complex consisting of itself, 
the proteasome, and p5348. Therefore, MDM2 may impact p53 degradation by regulating 
its accessibility to the proteasome machinery.  
1.1.3.2 Post-translational modification of p53 
p53 activation, accumulation, and the induced cellular response are fine-tuned by highly 
complex post-translational modifications (PTMs, Figure 4). The most important 
modifications include phosphorylation and acetylation15. 
Phosphorylation typically increases p53 protein stability and DNA-binding capacity15,49. 
p53 phosphorylation is reported for at least 18 different serine and threonine residues in 
response to stress, while many of these sites can be phosphorylated by different 
kinases. In addition, the same kinase may phosphorylate distinct residues in p53. 
Notably, the impact of dephosphorylation on p53 activity is so far not well understood15,50. 
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Acetylation of p53 is induced after virtually any kind of stress exposure and may 
sometimes be preceded by phosphorylation51. p53 can be acetylated at ten different 
lysine residues by four major HATs: Tip60, CBP/p300, PCAF, and hMOF50,52. In general, 
acetylation of p53 is reported to have a positive effect on its stability and transcriptional 
activity53, for example by shielding the acetylated residues from ubiquitination51. In line 
with this, p53 deacetylation by histone deacetylases (HDAC) usually results in 
ubiquitination and subsequent degradation of p5315. 
Given the high complexity and redundancy of p53 PTMs, single modifications are 
unlikely to have a considerable effect on p53 activity and cellular function. Instead, it is 
assumed that specific stresses induce different phosphorylation and acetylation patterns, 
which then define the appropriate cellular response15.  
 
 
Figure 4: Post-translational modification of p53.  
Summary of all reported modifications of p53, together with their modifying enzymes. TAD, transactivation 
domain; PRD, proline-rich domain; DBD, DNA-binding domain, TD, tetramerization domain; CRD, C-terminal 
regulatory domain. Numbers indicate amino acid positions of p53 protein. Reprinted from Trends Mol Med, 
Dai and Gu52, copyright 2010, with permission from Elsevier. 
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1.1.4 p53 inactivation and gain-of-function in tumors 
Given p53’s role as the cell’s most powerful tumor suppressor, it comes with no surprise 
that its function is compromised in the majority of human tumors. In general, p53 
inactivation can arise via two distinct mechanisms: (1) by alterations in p53 
activation/suppression or (2) by p53 point mutation54. 
About 50% of tumors with compromised p53 function retain wild-type p53 (wtp53) 
expression54. However, the molecular causes for p53 inactivation in these tumors are so 
far not well understood. Overexpression of MDM2 has been reported in some cancer cell 
lines and tumors55,56. Moreover, deletion and promoter hypermethylation of the MDM2 
inhibitor ARF may cause abnormal MDM2 activation57,58. 
In the remaining tumors, p53 is inactivated via mutations in the TP53 gene itself54. 
Overall, p53 mutations can be found in 42% of all tumors, with a highly variable 
frequency between different tumor types (Figure 5A). This makes p53 the most 
frequently mutated gene across all human cancers59. The majority of p53 mutations are 
missense mutations (74%), meaning they cause expression of a full-length protein with 
only a single amino acid substitution (Figure 5B)2. Most of these mutations cluster in the 
DNA-binding domain (Figure 5B)2,60. Mutations in codons R175, G245, R248, R249, 
R273, and R283 are by far the most frequent ones (so-called “hotspot mutations”)61 and 
were shown to be crucial for either establishing DNA contact or for stabilizing the DNA-
binding surface structure (Figure 5B)62. In general, mutations in p53 can be divided into 
two categories63: (1) structural mutations which strongly alter the protein conformation or 
(2) DNA contact mutations which only impact DNA binding. Both kinds of mutations 
typically abrogate p53’s capability to bind to its DNA response elements64, which results 
in a loss of its tumor-suppressive function. This “loss of function” is further enhanced by 
the fact that mutant (mut) p53 has a dominant-negative effect over residual wtp53 (e.g. in 
case of heterozygous p53 mutation). The reason for this is that p53 protein 
heterotetramers, which consist of a mixture of mutp53 and wtp53 proteins, are no longer 
able to bind to DNA65. 
In addition to the loss of the wild-type function, mutp53 proteins often additionally acquire 
novel functions of their own – a phenomenon which is known as “gain of function” 
(GOF)2,65. In fact, a plethora of studies has shown that mutp53 is thus able to actively 
drive tumorigenesis by acting on multiple different pathways. Figure 5C and the following 
examples illustrate this: 
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• mutp53 drives genomic instability, for example by disrupting the spindle 
checkpoint control66. 
• mutp53 renders cells resistant towards pro-apoptotic signals67. 
• mutp53 renders cancer cells resistant towards chemotherapy68. 
• mutp53 drives cell migration and invasion69. 
• mutp53 drives the expression of chromatin regulatory genes, resulting in a global 
increase of histone methylation and acetylation70. 
• mutp53 drives the expression of the proteasome machinery, resulting in a 
degradation of tumor suppressors71. 
Based on these findings, it is not surprising that the presence of p53 mutation is 
associated with poor drug response, poor overall survival, and poor disease-free survival 
in many different cancer types, including hematopoietic cancers (Figure 5D)2.  
 
Figure 5: p53 mutations in human cancer.  
(A) Frequency of p53 mutations in different cancer types. Based on data from Kandoth et al.59. 
(B) Distribution of p53 mutation types (top) and distribution of mutations along p53 protein (bottom) across 
cancer. The six hotspot mutations are highlighted. Domain annotation is similar to Figure 2. Reprinted by 
permission from Macmillan Publishers Ltd: Nat Rev Cancer, Brosh and Rotter2, copyright 2009. 
(C) Overview of key tumorigenic functions of mutant p53. Reprinted by permission from John Wiley and 
Sons: FEBS J, Mantovani et al.72, copyright 2016. (D) Impact of p53 mutation on patient outcome in different 
cancer studies. Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Cancer, Brosh and Rotter2, 
copyright 2009. 
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1.1.5 Mutant p53 accumulation in tumors 
While the protein level of wtp53 is very low due to constant degradation by MDM2 
(Figure 3), mutp53 typically undergoes massive stabilization and accumulates to 
extremely high levels in tumors (Figure 6)73-75. This observation is exploited in cancer 
diagnostics in a way that p53 immunohistochemistry (IHC) can serve as a surrogate for 
p53 sequencing: tumors with a high staining intensity typically harbor p53 missense 
mutations. However, the detection of p53 mutation via IHC has major drawbacks as for 
example tumors with frameshift or nonsense mutations do not accumulate p53 
(Figure 6)2,76.  
 
Figure 6: p53 immunohistochemistry of human breast cancer samples.  
Exemplary staining of tumors with either a missense or a nonsense p53 mutation. Only the tumor with the 
missense mutation is characterized by strong staining. Adapted by permission from John Wiley and Sons: 
J Pathol, Bouchalova et al.77, copyright 2014. 
Despite the fact that mutp53 accumulation in tumors has been a very early discovery in 
the history of p53 research, still very little is known about its mechanistic causes. Knock-
in studies revealed that mutp53 is not intrinsically stable and that it accumulates 
exclusively in tumors but not in normal cells78-80. Since mutp53 is defective in inducing 
MDM2 expression, it has been suggested that the disruption of the MDM2-p53 loop is 
responsible for mutp53 stabilization65,81. However, tumor cells typically show residual 
MDM2 expression82,83 and more importantly, MDM2 is still capable of mutp53 binding 
and ubiquitination84. In addition, massive MDM2 overexpression is able to degrade 
mutp5335. Therefore, alternative mechanisms must contribute to the ability of mutp53 to 
evade degradation in cancer cells. A selection of the most relevant studies and their 
results is given in the following paragraphs. 
Alternative splicing of MDM2 gives rise to several shorter isoforms, some of which are 
overexpressed in different human tumors, especially the MDM2-B isoform85. Recently, a 
study by Zheng et al.86 showed that MDM2-B is able to contribute to mutp53 stabilization 
in tumors by inhibiting the interaction of canonical MDM2 with mutp53. In addition, the 
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expression of MDM2-B and accumulation of mutp53 were found to be highly correlative 
in human colorectal tumors. 
Molecular chaperones are proteins that assist other proteins in proper folding by 
temporarily binding to them. Their function is especially needed in stress conditions such 
as cancer, which is typically characterized by expression of mutant proteins and 
increased proliferation, thus making it difficult to properly control proteostasis87. Among 
the chaperone proteins, heat shock protein 90 (Hsp90) plays a key role in controlling 
proteostasis in health and disease87. In fact, Hsp90 is aberrantly expressed in many 
human cancers and assists in folding of many mutated oncogenes, including BRAF and 
EGFR88. A study by Li et al.83 showed that Hsp90 forms a stable complex with mutp53 
and MDM2, thereby shielding mutp53 from degradation by MDM2 (Figure 7). Additional 
studies recently found that two proteins of the Bcl-2 associated athanogene (BAG) 
family, BAG2 and BAG5, can act as co-chaperones in a similar fashion as Hsp90 to 
stabilize mutp53 in tumor cells89,90.   
 
Figure 7: Chaperoning of mutant p53 by Hsp90.  
Hsp90 forms a complex with mutp53, MDM2, and other chaperones and ubiquitin ligases, which protects 
mutp53 from degradation. Upon disruption of this complex, for example by Hsp90 inhibition, mutp53 is 
released and degraded via the ubiquitin-proteasome pathway. Reprinted from Mol Cancer Res, Li et al.83, 
copyright 2011, with permission from AACR. 
Similar to wtp53 (Figure 4), PTM of mutp53 is suggested to have an impact on its protein 
stability (and activity)91. Analysis of the pattern of p53 mutations across cancer shows 
that the majority of modified residues are not frequently affected by mutations. 
Furthermore, none of the p53 hotspot mutations (Figure 5B) undergo modification and no 
exclusive modifications of mutp53 have been identified. This indicates that PTM function 
is conserved between wtp53 and mutp53. Therefore, modifications which stabilize wtp53 
can be assumed to also enhance mutp53 stability91. In fact, several studies showed that 
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stress stimuli that stabilize wtp53 (e.g. DNA damage, irradiation) also enhance mutp53 
stabilization79,92,93. 
Only a limited number of studies addressed the impact of mutp53 PTM on its stability 
and the results are often contradictory91. Phosphorylation of S392 renders mutp53 
sensitive to MDM2-mediated degradation and is negatively correlated with mutp53 
expression94,95. Constitutive phosphorylation of S15 by ERK shields mutp53 from MDM2 
in mouse skin tumors96. However, S15 phosphorylation was found to be low or absent in 
many different mutp53 cancer cell lines and human skin tumors83,97.  
The impact of mutp53 acetylation on its stability appears to be even more complex and 
remains largely elusive91. Minamoto et al.98 and Yi et al.99 have reported mutp53 
hyperacetylation and subsequent degradation upon deacetylation of residues 
K320/K373/K382. In contrast, Perez et al.100 found that mutp53 acetylation in residues 
K320/K373 by PCAF restored the DNA-binding ability of mutp53 and inhibited 
proliferation100. In addition, Li et al.83 did not find evidence for mutp53 acetylation in basal 
conditions in a panel of cancer cell lines with highly stable mutp53 protein. 
In summary, tumors often accumulate high levels of mutp53 protein but the mechanisms 
that govern this excessive accumulation are not entirely understood. 
1.1.6 Targeting mutant p53 for cancer therapy 
The discovery that p53 is very frequently inactivated by mutation led to the development 
of different mutp53-based cancer therapy approaches (Figure 8), which are discussed in 
detail in the following sections. One promising attempt is arguably aiming at a specific 
degradation of mutp53, which was also the focus of this study. In general, all approaches 
are based on the assumption that targeting mutp53 will have minimal side effects since it 
is exclusively expressed by malignant cells101. 
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Figure 8: Overview of different strategies to target mutant p53 in cancer.  
Drugs and molecular pathways/targets which are under investigation are depicted in red. Figure based on 
Muller and Vousden101. 
1.1.6.1 Promoting mutant p53 degradation/downregulation 
Numerous studies have shown that mutp53 stabilization is a prerequisite for its GOF 
properties2,65,101,102. mutp53 silencing results in suppression of tumor growth, attenuated 
invasion and metastasis formation, and increased chemosensitivity in many tumor cell 
lines and xenografts. Recently, a landmark in vivo study confirmed these results using a 
mutp53 T-cell lymphoma mouse model expressing an inactivatable p53 hotspot mutation 
(R248Q)103. After inactivation, even advanced tumors underwent apoptosis and 
regression. This suggests that interfering with mutp53 accumulation may be exploitable 
in cancer therapy. However, as already mentioned earlier (see 1.1.5, p. 9), the 
mechanisms that govern erroneous accumulation are not well understood. 
Since it has been shown that mutp53 can be aberrantly stabilized by Hsp90 (Figure 7), 
treatment of breast, prostate, and colorectal tumor cells with the Hsp90 inhibitor 17-AAG 
was found to result in mutp53 destabilization and thereby to impair proliferation83. These 
findings have been recently validated in vitro and in vivo by using Ganetespib, a next-
generation Hsp90 inhibitor103. Ganetespib is currently tested (in combination with 
Paclitaxel) in Phase I and II studies in ovarian cancer patients (GANNET53 trial).  
Treatment of mutp53 cells with HDAC inhibitors has been reported to downregulate 
mutp53 expression on diverse levels. While the central function of HDACs is the 
regulation of transcription by removing acetyl groups from histones, they can also 
deacetylate a plethora of non-histone proteins. The finding that HDACs are often 
overexpressed in cancer lead to the development of many HDAC inhibitors104. 
Blagosklonny et al.105 were first in observing mutp53 destabilization and p21 induction 
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upon treatment of breast and prostate cancer cell lines with the pan-HDAC inhibitors 
FK228 and Trichostatin A. Later, it was found that HDAC1, 2, and 8 are crucial for 
maintaining TP53 transcription106,107. However, most attention has recently been paid to 
HDAC6 because it is a key positive regulator of Hsp90. Inhibition of HDAC6 causes 
mutp53 degradation and impairs proliferation in vitro82. Combined inhibition of Hsp90 and 
HDACs was shown to suppress tumor growth and prolong survival of mutp53 mice103. 
Since wtp53 levels are typically kept low via proteasomal degradation, treatment of 
wtp53 cells with proteasome inhibitors results in p53 accumulation108. Surprisingly, a 
study by Halasi et al.109 found that proteasome inhibition causes mutp53 degradation in 
numerous cancer cell lines, most likely via stabilization of MDM2. In fact, it has long been 
known that MDM2 overexpression is able to degrade mutp5335. Later, Choudhury et 
al.110 reported that proteasome inhibition results in mutp53 degradation via autophagy. 
(Macro-)autophagy is the process by which cells degrade unwanted material contained 
in the cytoplasm, including whole cell organelles111. In line with this, Rodriguez et al.112 
found that autophagy induction by glucose starvation specifically depleted mutp53 but 
stabilized wtp53 in various cancer cell lines. In contrast, inhibition of macroautophagy 
with Spautin-1 surprisingly also resulted in degradation of multiple p53 mutants via the 
chaperone-mediated autophagy pathway113. In summary, these results indicate that the 
role of proteasome- and autophagy-mediated degradation of mutp53 levels is multi-
layered and likely to be dependent on the cellular context101. 
Due to the fact that many mutp53 tumors retain MDM2 expression82,83 and that MDM2 
overexpression is able to degrade mutp5335, another appealing therapeutic approach to 
target mutp53 may be to increase MDM2 levels. However, since p53 is the main positive 
regulator of MDM2, this may be challenging because the p53-MDM2-feedback loop is 
disrupted in a mutp53 context65,81. In fact, only a limited number of transcriptional 
regulators of MDM2 besides p53 have been reported so far114. Nevertheless, one 
promising candidate protein is PTEN, which has been shown to promote mutp53 GOF by 
inhibiting MDM2 transcription115. Importantly, PTEN inhibition can cause a reduction of 
both mutp53 levels and tumor growth in vivo115. Notably, a specific small-molecule 
inhibitor against PTEN (SF1670) was developed by Rosivatz et al.116 but has not yet 
been tested in a mutp53 context. 
In summary, multiple different approaches have been developed that aim at degrading 
mutp53 especially in solid tumors. However, a deeper understanding of the mechanisms 
that drive mutp53 accumulation will help in advancing them as well as in developing 
novel approaches. 
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1.1.6.2 Restoring wild-type p53 activity 
Although p53 mutations can be found in virtually any residue in its DNA-binding domain 
(Figure 5B), they all have in common that they impair proper folding of the p53 core 
domain at physiological temperature117. Ultimately, this results in a loss of DNA binding 
capacity. Since mutp53 was shown to regain this capacity at low temperatures63,117-119, 
this led to the hypothesis that the defect in DNA binding is reversible, meaning that 
mutp53 can be refolded and thereby “re-educated” to wtp53120. Due to the fact that tumor 
cells are typically flooded with mutp53 protein, its refolding into wtp53 with potent tumor 
suppressive function is an attractive therapeutic approach120. Moreover, mutp53 tumors 
are expected to be exquisitely sensitive towards wtp53 reactivation since the inactivation 
of p53 has been selected during tumor evolution117. Multiple pioneer studies proved that 
for example binding of antibodies to either the N- or C-terminus of mutp53 successfully 
reactivated DNA binding117. These findings initiated the search for small molecules and 
peptides able to bind to mutp53 and to restore wtp53 activity, which is now pursued by 
many research groups mostly by either chemical screenings or rational 
design101,117,120,121. 
A promising small molecule identified in a cell-based assay is APR-246 (also called 
PRIMA-1MET), which is able to bind mutp53 and to restore its wild-type activity. It has 
been shown to inhibit growth of mutp53 cancer in vitro and in vivo and is now in clinical 
development122. In fact, it has already successfully passed Phase I studies in 
hematological tumors expressing mutp53123,124 and is currently tested in a Phase II study 
in patients with high-grade serous ovarian cancer (Aprea Therapeutics).  
Another promising approach is based on the fact that wtp53 depends on zinc for proper 
folding, while mutp53 is often impaired in zinc binding125. The supply of zinc to cells or 
mice expressing mutp53 has been shown to restore its DNA-binding capacity and to 
suppress tumor growth126. The same effect can be achieved by using small molecule 
zinc chelators (zinc metallochaperones) such as NSC319726 (also called ZMC1)127. 
Some p53 mutants (e.g. the hotspot mutations R175H and R248Q) have been shown to 
form amyloid aggregates, which not only sequester mutp53 but also residual wtp53 
together with additional tumor suppressors such as p63 and p73128. Recently, Soragni et 
al.129 reported a peptide (ReACp53) which inhibits mutp53 aggregate formation and 
rescues wtp53 function, thereby causing cancer cell death in vitro and tumor xenograft 
regression in vivo. However, the specificity towards mutp53 and thereby the mode of 
action of ReACp53 has been challenged recently by Wang and Fersht130. 
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1.1.6.3 Inhibition of signaling pathways deregulated by mutant p53 
Another approach to target mutp53 is to inhibit the signaling pathways downstream of 
mutp53 GOF (Figure 5C). This has, however, only been exploited in few studies so far101 
most likely due to the vast heterogeneity and context-dependency of mutp53 GOF. 
Several mutp53 proteins have been reported to inhibit the function of the tumor 
suppressor proteins p63 and p73 by binding to them, which contributes to 
tumorigenesis101. Kravchenko et al.131 identified a small molecule named RETRA that is 
able to release p73 specifically in mutp53 cancer cells, which results in activation of p73 
target genes and thereby inhibits cancer growth in vitro and in vivo. 
In a 3D culture model of breast cancer cells, mutp53 was shown to drive the expression 
of the mevalonate pathway, which is mainly responsible for cholesterol synthesis. In fact, 
blockage of cholesterol synthesis with Simvastatin or Mevastatin resulted in growth 
inhibition, cell cycle arrest, and apoptosis in mutp53 breast cancer cells132. 
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1.2 Non-Hodgkin lymphoma 
Non-Hodgkin lymphoma (NHL) describes a heterogeneous group of lymphoproliferative 
diseases and can be broadly divided into two subsets which derive from either 
B lymphocytes or T lymphocytes, respectively. Despite equal frequencies of B cells and 
T cells in the human body, the vast majority (85-90%) of NHL originate from B cells 
(B-NHL), indicating that specific processes during B-cell development may be particularly 
tumorigenic133-135.  
1.2.1 Role of the germinal center reaction in lymphomagenesis 
Germinal centers (GCs) play a crucial role in humoral immunity and are compartments in 
which B cells undergo differentiation and harsh selection133,136-139. In general, GCs can be 
roughly divided into two distinct zones (Figure 9): While the dark zone (DZ) is almost 
solely made up of proliferating B cells (“centroblasts”) and reticular cells, the light zone 
(LZ) contains besides non-dividing B cells (“centrocytes”) also macrophages, T cells, and 
follicular dendritic cells138.  
The main task of the GC reaction is the generation of specific B-cell clones able to 
secrete antibodies with the highest affinity (Figure 9)138. To achieve this, activated B cells 
first undergo rapid proliferation and somatic hypermutation (SHM) in the DZ138,139. During 
SHM, the enzyme activation-induced cytidine deaminase (AID) induces DNA breaks in 
the variable region of the immunoglobulin gene (IgV). Erroneous repair mechanisms 
introduce single nucleotide exchanges, which gives rise to a heterogeneous population 
of centroblasts with diverse antigen affinities139. After trafficking to the LZ and 
differentiation into non-dividing centrocytes, cells expressing B-cell receptors (BCRs) 
with the highest affinity are positively selected138. Subsequently, part of the centrocytes 
undergoes immunoglobulin (Ig) class-switch recombination (CSR), which is again 
mediated by AID. During CSR, the C-region of the Ig heavy chain is exchanged with that 
of a different Ig gene via intrachromosomal deletional recombination133,140. This results in 
antibodies with an identical antigen affinity but with a different effector function133,139. 
Finally, centrocytes differentiate into precursors of antibody-secreting plasma cells 
(“plasmablasts”) or memory B cell precursor cells, both of which are needed for an 
effective protection against pathogens133,138,139. Notably, GC B cells often shuttle multiple 
times between the DZ and LZ, thus giving rise to B cells with the highest possible 
antigen affinities138. 
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Figure 9: The germinal center (GC) reaction.  
GCs are formed in peripheral lymphoid organs upon T-cell-dependent antigen exposure. Activated B cells 
undergo massive proliferation and somatic hypermutation (SHM) in the variable region of the 
immunoglobulin gene in the dark zone, resulting in a heterogeneous B-cell population with diverse antigen 
affinities. In the light zone, B cells with a high affinity B-cell receptor are positively selected, mainly by 
interacting with T cells. A subset of selected B cells circles back to the dark zone to further enhance antigen 
affinity, while others undergo immunoglobulin class-switch recombination (CSR) to change their antibody 
effector function. Eventually, GC B cells differentiate into plasmablasts or memory B cell precursor cells. 
Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Immunol, De Silva and Klein138, copyright 
2015. 
For several reasons, errors in the GC reaction are believed to be the major cause for 
most B-NHLs (Figure 10), including Burkitt’s lymphoma (BL), follicular lymphoma (FL), 
and diffuse large B cell lymphoma (DLBCL)141. First, almost all B-NHLs are characterized 
by mutated IgV, indicating that they originate from GC B cells142,143. Second, the gene 
expression profiles of many B-NHLs are highly similar to the profiles of healthy DZ or LZ 
GC B cells144. Third, B-NHLs typically harbor two types of genetic aberrations, namely 
aberrant SHM (ASHM) and chromosomal translocations, both of which are part of the 
physiological Ig remodeling machinery activated specifically in the GC138,139. ASHM 
mostly occurs in DLBCL and typically targets non-Ig loci, thereby introducing activating 
mutations in proto-oncogenes such as MYC145. Chromosomal translocations are 
frequently caused by erroneous CSR and often merge a regulatory region of an Ig gene 
with an oncogene, thereby for example resulting in MYC overexpression in BL146. 
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Figure 10: Cellular origin and oncogenic alterations of B-cell non-Hodgkin lymphomas derived from 
the germinal center (GC) reaction.  
While Burkitt’s lymphoma is derived from GC B cells in the dark zone and characterized by MYC 
overexpression, follicular lymphoma originates from B cells in the light zone and shows BCL2 
overexpression. Both diffuse large B-cell lymphoma (DLBCL) subtypes also stem from light zone B cells and 
constitutively express BCL6. Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Immunol, 
Basso and Dalla-Favera141, copyright 2015. 
 
1.2.2 Burkitt’s lymphoma (BL) 
BL is a highly aggressive NHL which is derived from DZ GC B cells (Figure 10)141. 
In 1985, Guy de Thé termed BL the “Rosetta stone of cancer”147, indicating that the 
mechanisms of BL lymphomagenesis may also play a role in cancer biology in general. 
In fact, BL research has substantially contributed to an improved understanding of 
tumorigenesis due to the fact that148: 
• BL has the highest growth rate (doubling time 24-48 h) among all human 
cancers149. 
• BL was the first human cancer reported to be associated with a virus (Epstein-
Barr virus, EBV)150 and the first human lymphoma shown to be associated with 
human immunodeficiency virus (HIV)151. 
• BL was among the first human cancers identified to show an aberrant oncogene 
activation (MYC) driven by chromosomal translocation152,153. 
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1.2.2.1 Classification, diagnosis & treatment 
Unlike many other cancers, BL is typically a disease of younger patients: approximately 
every second BL patient is less than 40 years old154. Since its discovery in 1958 by the 
surgeon Denis Burkitt155, the World Health Organization (WHO) today discriminates three 
different BL variants with comparable morphology, genetics, and 
immunophenotype148,156,157:  
1. Endemic BL (eBL) is strongly associated with EBV and malaria infection and 
describes the cases occurring only in Africa and Papua New Guinea. In these 
areas, eBL makes up approximately every second cancer diagnosis in children 
and virtually every lymphoma diagnosis148. eBL patients most commonly suffer 
from tumors in the jaw or facial bone, while tumors in the abdomen and bone 
marrow infiltration are rare154. 
2. Sporadic BL (sBL) describes tumors occurring anywhere else in the world, 
usually in the West, and is typically not linked to viral infection. sBL is the most 
common NHL in children up to 14 years (in the United States) and occurs more 
frequently in boys135,148. sBL patients most commonly suffer from tumors in the 
abdomen154.  
3. Immunodeficiency-related BL is typically seen in patients infected with HIV who 
develop acquired immunodeficiency syndrome (AIDS)148. 
Diagnosis of BL is often based on histopathology (Figure 11A)148,154. Typical of BL is its 
“starry sky” appearance in histology, which is caused by macrophages that are 
surrounded by densely packed lymphoma cells158. In addition, BL cells show intensive 
staining for Ki-67 and CD20/CD10, reflecting their very high proliferation rate and B-cell 
lineage148.  
BL can be treated very effectively with high-dose chemotherapy composed of 
Doxorubicin, Vincristine, Etoposide, and alkylators159, which can be combined with the 
anti-CD20 antibody Rituximab160. The overall cure rate for young patients in the range of 
15-40 years is excellent and around 85-90%, but treatment of adult patients remains 
challenging, most likely because of elevated therapy-related toxicity148,154,159. In addition, 
the risk of treatment toxicity due to tumor lysis syndrome is extremely high, especially at 
the beginning of the therapy. Therefore, BL patients require intensive supportive care, 
which is particularly difficult to sustain in low-income countries148. Overall, this suggests 
that novel therapy approaches are needed to treat both elderly BL patients and BL 
patients in low-income countries more efficiently and more safely. 
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Figure 11: Histopathology and lymphomagenesis of Burkitt’s lymphoma.  
(A) Burkitt’s lymphoma (BL) shows a characteristic “starry sky” pattern in hematoxylin and eosin (H&E) 
staining and is positive for the proliferation marker Ki-67 and the B-cell marker CD20. Adapted from The 
Lancet, Molyneux et al.148, copyright 2012, with permission from Elsevier. (B) Overview of the key oncogenic 
pathways. Activation of the proto-oncogene MYC is the hallmark of BL. In addition, tonic B-cell receptor 
signaling via PI3K, AKT, and mTOR is active in most BLs and is further enhanced by mutations in the E2A-
ID3 axis. Cyclin D3 mutations contribute to BL proliferation. In order to evade apoptosis, p53 mutation or 
inactivation is frequent. Adapted by permission from Macmillan Publishers Ltd: Nat Rev Immunol, Basso and 
Dalla-Favera141, copyright 2015. 
1.2.2.2 Lymphomagenesis 
An overview of the oncogenic pathways in BL lymphomagenesis is given in Figure 11B. 
Aberrant expression of the proto-oncogene MYC caused by chromosomal translocation 
can be found in all BL patients and is therefore the hallmark of BL157. The most common 
translocation is t(8;14)(q24;q32) and present in 70-80% of cases148. All translocations put 
MYC under the control of an Ig enhancer region, thus resulting in constitutive MYC 
expression148. MYC is a transcription factor that plays a central role in regulating 
amongst others proliferation, apoptosis, DNA replication, and GC formation141. Although 
mice develop B-cell lymphomas upon ectopic MYC expression161, MYC is assumed to 
require additional oncogenic events in order to induce BL157,162. Interestingly, MYC is also 
the most frequently mutated gene in BL. 70% of BL patients harbor missense mutations 
in MYC, which are often located in the transactivation domain and most likely introduced 
by ASHM (Figure 9)163. Selected MYC mutants have been reported to promote B-NHL 
lymphomagenesis more effectively than wild-type MYC164.  
MYC overexpression has been shown to sensitize cells towards apoptosis, mostly in a 
p53-dependent manner. Therefore, p53 inactivation is essential in MYC-driven tumors in 
order to escape apoptosis (Figure 11B)165. p53 mutations are present in ~35% of BL 
patients (range: 16.7-63.0%, Table 1) and in ~60-80% of BL cell lines166-168 with a high 
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frequency of missense mutations, indicating that mutp53 may be associated with tumor 
progression. Mutations are typically heterozygous166,169 and complete deletion of p53 is 
found in 10% of the patients170,171. The most frequent mutations affect codons 175, 213, 
and 248, while mutations in codon 273 are less common166. Besides p53 mutation, 
overexpression of the negative regulators MDM2 and MDM4 has been reported to 
inactivate the p53 pathway in BL patients with wtp53171,172. Only limited data is available 
on the impact of p53 mutation on BL patient outcome so far. Preudhomme et al.169 
reported a similar chemotherapy response rate in wtp53 and mutp53 BL patients and no 
impact of p53 mutation on survival. This could be explained by the residual wtp53 allele 
in mutp53 patients since this may render cells still sensitive towards apoptosis169,173. 
Therefore, mutp53 may not have a dominant-negative effect on wtp53 in BL169. 
Table 1: Summary of studies reporting frequencies of p53 mutation in Burkitt’s lymphoma patients. 
Study # Burkitt’s lymphoma patients p53 mutation frequency [%] 
Bhatia et al.166 27 37.0 
Gaidano et al.174 27 33.3 
Haberl et al.175 47 60.0 
Kretzmer et al.176 13 61.5 
Leventaki et al.171 28 17.9 
Love et al.177 59 23.7 
Preudhomme et al.169 21 28.6 
Richter et al.178 4 50.0 
Sanchez-Beato et al.179 16 18.8 
Schmitz et al.163 28 + 13 cell lines 34.1 
Wilda et al.172 24 16.7 
TOTAL 307 (incl. cell lines) 34.7 
 
Mutations in cyclin D3 (CCND3) can be found in ~40% of sBL patients but are rare in 
patients suffering from eBL (Figure 11B)157,178. Since CCND3 is important for the 
regulation of cell cycle progression, its mutations have been shown to increase protein 
stability and to confer cells with a proliferation advantage163. Therefore, CCND3 mutation 
is believed to maintain the high proliferation rate of BL157. 
In ~70% of sBL patients, mutations are present in either the transcription factor TCF3 
(E2A) or its negative regulator ID3 (Figure 11B). Mutations in either of the proteins 
disrupt the negative feedback loop of TCF3 and ID3, resulting in aberrant constitutive 
activity of TCF3163,178. TCF3 was shown to not only upregulate CCND3 but also to 
increase BCR expression163. In fact, the majority of BL is dependent on antigen-
independent (tonic) BCR signaling funneled through PI3 kinase (PI3K)163. Interestingly, 
when Sander et al.162 combined overexpression of MYC with constitutively active PI3K in 
GC B cells in mice, they were able to phenocopy human BL to full extent.  
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1.3 RNA interference screens as tools to study gene function 
RNA interference (RNAi) is a simple and powerful mechanism for controlling gene 
expression at the post-transcriptional level180. It was discovered in 1998 by Fire et al.181, 
who found that injection of a double-stranded RNA (dsRNA) complementary to an 
endogenous gene in the roundworm C. elegans resulted in silencing of that particular 
gene. The discovery that the mechanisms of RNAi are conserved in mammals only three 
years later182 has revolutionized the study of gene function in health and disease ever 
since. 
1.3.1 RNAi pathway 
RNAi is believed to be an endogenous cellular defense mechanism against RNA viruses. 
While long dsRNA can be easily used to silence target genes in for example plants and 
C. elegans, introduction of long dsRNA in mammalian cells causes induction of an 
interferon response, which unspecifically inhibits global protein synthesis180. Therefore, 
to use RNAi in mammals, so-called short interfering RNA duplexes (siRNAs) must be 
used, which typically consist of a 19 bp core duplex with 2 bp 3’ overhangs on each 
strand (Figure 12A)183.  
An overview of the RNAi pathway is depicted in Figure 12B. siRNAs can be delivered 
directly to mammalian cells by transfection or electroporation and are subsequently 
loaded into an endogenous multiprotein complex named RNA-induced silencing complex 
(RISC). The antisense strand of the siRNA is then used to guide RISC to its target 
mRNA, while the sense strand is degraded180. Binding of RISC to mRNA can have two 
effects. In case the siRNA is fully complementary to the mRNA, a component of RISC 
(RNase argonaute 2, AGO2) cleaves the mRNA, resulting in degradation of the target 
mRNA. In case of only partial complementarity, translation of the mRNA is inhibited184. 
Both effects result in a “knock-down” of the target gene, i.e. a reduced protein 
expression. 
Using siRNAs has the disadvantage that they are only transiently expressed, meaning 
they become diluted with every cell division and therefore only cause short-term 
silencing of their target genes180. In fact, it has been reported that the majority of siRNA 
duplexes are degraded within 48 h in cells185. To overcome this drawback, cells can be 
stably transduced (by using e.g. lentiviruses186) with small hairpin RNAs (shRNAs), the 
precursors of siRNAs (Figure 12B)187. After integration into the cell’s genome, shRNAs 
are transcribed, exported from nucleus, and finally processed into siRNAs by an 
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RNase III-like enzyme named DICER184. shRNAs do not only cause long-term silencing 
but can also be of advantage when working with cells which are difficult to transfect180. 
 
Figure 12: RNA interference (RNAi).  
(A) Structure of a classic small interfering RNA (siRNA), which is made up of a 19 bp core duplex with 2 bp 
3’ overhangs on each strand. The seed region on the guide strand is indicated. Adapted by permission from 
Macmillan Publishers Ltd: Nat Rev Drug Discov, de Fougerolles et al.183, copyright 2007. (B) Overview of the 
RNAi pathway. Small hairpin RNAs (shRNAs) are transcribed in the nucleus, exported, and loaded as 
siRNAs onto the RNA-induced silencing complex (RISC), which mediates target mRNA knock-down via 
mRNA binding and cleavage or translational repression (not shown). Adapted by permission from Macmillan 
Publishers Ltd: Nat Rev Mol Cell Biol, Mohr et al.184, copyright 2014. (C) Overview of RNAi off-target effects 
(OTEs), which can be broadly categorized into sequence-dependent and –independent OTEs. Reprinted by 
permission from Macmillan Publishers Ltd: Nat Methods, Echeverri et al.188, copyright 2006. (D) Comparison 
of the RNAi on-target and off-target effect. Adapted by permission from Macmillan Publishers Ltd: Nat Rev 
Mol Cell Biol, Mohr et al.184, copyright 2014. (E) Arrayed RNAi screens. Cells are typically grown in multi-well 
plates and transfected or transduced with a single silencing trigger per well, which allows measuring more 
complex phenotypes. Adapted by permission from Macmillan Publishers Ltd: Nat Rev Drug Discov, Iorns et 
al.180, copyright 2007. (F) Pooled RNAi screens. Cells are typically transduced with a pool consisting of a 
large number of shRNAs in a single batch and grown under selective pressure. The shRNAs contributing to 
the phenotype of interest are subsequently identified via PCR and sequencing or microarray (less common). 
Adapted by permission from Macmillan Publishers Ltd: Nat Rev Drug Discov, Iorns et al.180, copyright 2007. 
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1.3.2 Off-target effects 
All RNAi reagents show so-called off-target effects (OTEs), which describe all 
unintended interactions between the silencing triggers and cellular molecules that lead to 
phenotypic changes188. In general, OTEs can be categorized into sequence-dependent 
and sequence-independent effects (Figure 12C). The former are based on the fact that 
RNAi reagents require total complementarity between them and their target mRNAs only 
within the 8 bp siRNA “seed region” (Figure 12A,D), while the remaining base pairs do 
not necessarily have to match188. Several examples exist in the literature where 
investigators report that some of their phenotypes emerged only due to seed match 
effects189. Given that seed regions are very short, it remains an unresolved issue to 
either fully computationally predict OTEs or to design highly specific silencing triggers184. 
Sequence-independent OTEs describe all effects caused by mere introduction of RNAi 
reagents into cells189. Examples in the literature include alterations in microRNA (the 
naturally occurring counterpart of siRNA) processing and expression190, induction of an 
interferon response191, or induction of a cellular stress response192.  
Since OTEs could lead to false results, RNAi experiments require proper controls and 
intensive validation. Sequence-independent OTEs can be easily controlled by including 
“scrambled” or “non-targeting” silencing triggers188. In contrast, the control of sequence-
dependent OTEs is more challenging and is most properly addressed by “redundancy or 
rescue”188 (Figure 12C). Redundancy refers to the fact that multiple independent RNAi 
reagents targeting the same transcript should produce similar phenotype changes. This 
is based on the idea that it is extremely unlikely that silencing triggers with different seed 
regions will share the same OTEs and thereby give rise to the same off-target 
phenotypes. Rescue refers to an approach where the silencing phenotype is reversed 
(“rescued”) by co-expression of a modified version of the targeted transcript that is 
resistant to silencing (e.g. by introduction of silent mutations). Since rescue experiments 
are often difficult to perform, most investigators aim for the redundancy approach by 
testing at least two independent silencing triggers in their experiments188. Besides 
redundancy or rescue, investigators are recently also encouraged to validate their RNAi 
findings by using an orthogonal, non-RNAi method. Mohr et al.184 envision that 
CRISPR/Cas9-mediated knock-out may become routine for validating RNAi experiments 
in the future. However, it is reported that the phenotypes caused by knock-down and 
knock-out, i.e. by reduced transcript expression and complete loss of expression, must 
not always be comparable193.  
  Introduction 
 25
1.3.3 RNAi screens 
While RNAi was initially used to investigate merely single genes of interest in separate 
experiments, it is now possible to use complex RNAi libraries consisting of hundreds of 
thousands of silencing triggers to “screen” the function of many genes in parallel in high-
throughput experiments194. For example, the usage of genome-wide RNAi libraries 
allows probing of every single gene in the genome for a desired phenotype. Today, 
numerous different RNAi libraries are available (both commercially and free of charge) 
and researchers can even generate their own libraries to specifically target their genes of 
interest. RNAi screens are “forward genetic screens” (“phenotype-to-genotype” 
approach), meaning they start with lowering the expression of many genes, followed by a 
selection of cells with a phenotype of interest, which is then ended with the identification 
of the silencing triggers that caused the phenotypic changes194,195. 
RNAi screens can be performed in either arrayed or pooled format180,195. In an arrayed 
format (Figure 12E), silencing triggers (usually siRNAs) are arranged in multi-well plates 
with a single trigger per well. Cells are then seeded directly on top of the triggers, often 
together with a transfection reagent, and the phenotype of each well is determined 
separately. Although arrayed screens are in general more expensive and time-
consuming, they allow a measurement of more complex phenotypes (e.g. cell 
morphology by microscopy). In addition, demultiplexing of arrayed screens is 
straightforward since the silencing triggers can be easily identified via their position on 
the plate. In contrast, in a pooled format (Figure 12F), a large number of silencing 
triggers (usually shRNAs) is mixed and used altogether for transduction of a mass of 
cells in a single batch. Importantly, the reaction conditions are optimized in a way so that 
on average one cell will only harbor a single RNAi reagent. Moreover, in order to 
maintain the library representation, every individual silencing trigger is integrated into a 
large number of cells (typically ~500 cells/RNAi reagent). Cells are then selected for the 
phenotype of interest and the silencing triggers are typically demultiplexed via next-
generation sequencing or microarray. Pooled screens have the advantage of being 
cheaper and being easier to perform, bear however the limitation that they can only be 
used for studying fairly simple phenotypes (e.g. effects on cell growth). In general, 
pooled screens can be categorized as positive selection (e.g. expose cells to a drug, 
select surviving cells) or negative selection screens (e.g. depletion of cells due to a lethal 
knock-down). 
RNAi screens have been used very successfully in the past for an identification of genes 
that play a role in numerous biological processes, including cancer biology with the 
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discovery of novel oncogenes, synthetic lethal interactions, and potential drug 
targets180,184,196. For example, Toyoshima et al.197 performed an arrayed siRNA screen 
and identified the druggable kinase CSNK1e as a novel therapeutic target in MYC-driven 
cancer. One of the most comprehensive RNAi datasets has been generated by the 
Broad Institute of MIT and Harvard (Cambridge, USA) within the scope of the project 
“Achilles”, in which the investigators screened 216 cancer cell lines in parallel to detect 
cancer-specific vulnerabilities198.  
In summary, RNAi screens are powerful and easy tools to unbiasedly probe large 
numbers of genes for their role in a particular phenotype of interest (e.g. regulation of 
protein levels in this study).  
  Introduction 
 27
1.4 Scientific aims 
Missense mutations in p53 cause expression of aberrant mutant p53 (mutp53) proteins 
that not only have lost their tumor suppressive function but also have often gained 
tumorigenic properties. Importantly, tumors depend on sustained and high levels of 
mutp53, suggesting that interfering with mutp53 accumulation may be exploitable in 
cancer treatment. Since the mechanism of mutp53 stabilization in tumors remains largely 
elusive, the main aim of this study was to identify regulators of mutp53 
accumulation. The study was performed in Burkitt’s lymphoma (BL) as a model for a 
highly aggressive cancer with a particularly high incidence of p53 mutations.  
To achieve the aim, this study specifically focused on the following key points: 
1. Identification of candidate regulators of mutp53 accumulation. 
To identify proteins involved in the control of mutp53 levels in an unbiased 
fashion, a large-scale RNA interference (RNAi) screen with flow cytometry-based 
phenotypic readout was performed. 
 
2. Validation of TRRAP as a novel regulator of p53 levels. 
To confirm the role of the primary RNAi screen hit TRRAP (transformation/ 
transcription domain-associated protein) as a critical modulator of p53 levels, 
TRRAP expression was modulated and the impact on p53 accumulation was 
evaluated across cancer types and p53 mutations.  
 
3. Characterization of the functional mechanism underlying p53 regulation by 
TRRAP. 
A set of experiments aimed at exploring the molecular mechanism of p53 
regulation by TRRAP, including mass spectrometry of the mutp53 interactome 
and CRISPR scanning to identify TRRAP’s functional regions. 
 
4. Identification of small molecules interfering with mutp53 accumulation. 
To identify drugs modulating mutp53 levels for a potential clinical application, 
mutp53 cell lines were exposed to a panel of small molecules and their impact on 
mutp53 accumulation was evaluated. 
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2 Material & Methods 
2.1 Material 
2.1.1 Chemicals 
Reagent Supplier 
10x Tris/Glycine/SDS Running Buffer Bio-Rad 
2-Mercaptoethanol Sigma-Aldrich 
4–15% Mini-PROTEAN TGX Precast Protein Gels Bio-Rad 
Adenosine 5'-Triphosphate solution (ATP) GE Healthcare Life Sciences 
Agar  Sigma-Aldrich 
Agarose for DNA Electrophoresis Serva 
AgeI + NEBuffer 1.1 New England Biolabs 
Ampicillin sodium salt Sigma-Aldrich 
Anti-human p53 mouse agarose beads Santa Cruz Biotechnology 
Bbs I (BpiI) + Buffer G Thermo Scientific 
Benzonase Nuclease Merck 
Blasticidin S HCl Gibco 
Bovine Serum Albumin (BSA) GE Healthcare Life Sciences 
BsmBI + NEBuffer 3.1 New England Biolabs 
cOmplete EDTA-free Protease Inhibitor Cocktail Roche 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
DNA Gel Loading Dye Thermo Scientific 
dNTP mix (Na salt) Genaxxon 
Dulbecco’s Modified Eagle Medium (DMEM) Gibco 
Dulbecco's Phosphate-Buffered Saline (PBS) Gibco 
EcoRI New England Biolabs 
Ethanol Sigma-Aldrich 
Ethidium Bromide solution 0.07 % AppliChem 
Fetal bovine serum (FBS) PAN-Biotech 
Formaldehyde solution 30 %, methanol-free Carl Roth 
GenElute Linear Polyacrylamide Sigma-Aldrich 
GeneRuler DNA Ladders 100 bp, 1 kb Thermo Scientific 
Glycine Sigma-Aldrich 
Hexadimethrine bromide (Polybrene) Sigma-Aldrich 
HiMark Pre-stained Protein Standard Thermo Scientific 
IGEPAL CA-630 (NP40 substitute) Sigma-Aldrich 
Interferon Alpha 2a, human Pestka Biomedical Laboratories 
IPA300, immobilized rProtein A agarose beads RepliGen 
Isopropyl-β-D-thiogalactopyranoside (IPTG) Serva 
Laemmli Sample Buffer, 2x Concentrate Sigma-Aldrich 
Laemmli Sample Buffer, 4x Concentrate Bio-Rad 
L-glutamine Gibco 
Lipofectamine Invitrogen 
Luria Broth Base powder Invitrogen 
Methanol Sigma-Aldrich 
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Nicotinamide Sigma-Aldrich 
Normal mouse IgG control beads Santa Cruz Biotechnology 
Opti-MEM I Reduced Serum Medium Gibco 
PageRuler Prestained Protein Ladder Thermo Scientific 
Penicillin-Streptomycin Gibco 
Phosphatase Inhibitor Cocktail 2 Sigma-Aldrich 
Phosphatase Inhibitor Cocktail 3 Sigma-Aldrich 
PLUS Reagent Invitrogen 
Powdered milk Carl Roth 
Power SYBR Green Master Mix Applied Biosystems 
Protease Inhibitor Cocktail Sigma-Aldrich 
Protein A/G PLUS-Agarose beads Santa Cruz Biotechnology 
Puromycin Dihydrochloride Gibco 
QuickExtract DNA Extraction Solution Epicentre 
RIPA Lysis Buffer, 10X Merck 
RNase A Qiagen 
RNase Away Ambion 
RPMI Medium 1640 Gibco 
S.O.C. Medium Invitrogen 
Shrimp Alkaline Phosphatase (rSAP) New England Biolabs 
Sodium acetate Sigma-Aldrich 
Sodium butyrate Sigma-Aldrich 
Sodium chloride AppliChem 
T4 DNA Ligase + buffer New England Biolabs 
T4 Polynucleotide Kinase + buffer New England Biolabs 
T7 Endonuclease I + NEBuffer 2 New England Biolabs 
Taq DNA polymerase + PCR reaction buffer Qiagen 
TBE buffer (10X) Genaxxon 
Titanium Taq DNA polymerase + PCR reaction buffer Clontech Laboratories 
Trans-Blot Turbo Midi PVDF Transfer Packs Bio-Rad 
Tris powder Bio-Rad 
Trypan blue Gibco 
Trypsin-EDTA Gibco 
TWEEN 20 Sigma-Aldrich 
Western Lightning Plus-ECL PerkinElmer 
XL10-Gold Ultracompetent E. coli Cells + β-mercaptoethanol Agilent 
2.1.2 Small molecule inhibitors 
Inhibitor Supplier 
17-AAG Selleck Chemicals 
Bortezomib Selleck Chemicals 
Entinostat (MS-275) Selleck Chemicals 
Etoposide Sigma-Aldrich 
Hydroxychloroquine Selleck Chemicals 
Leptomycin B Sigma-Aldrich 
MG-132 Selleck Chemicals 
Mocetinostat (MGCD0103) Selleck Chemicals 
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Nutlin-3a Selleck Chemicals 
Panobinostat Selleck Chemicals 
PCI-34051 Selleck Chemicals 
Ruxolitinib Selleck Chemicals 
Selinexor Selleck Chemicals 
Trichostatin A (TSA) Selleck Chemicals 
Tubacin Selleck Chemicals 
Tubastatin A Selleck Chemicals 
Verdinexor Selleck Chemicals 
Vorinostat Selleck Chemicals 
2.1.3 Consumables 
Consumable Supplier 
AlumaSeal 96-well sealing film Sigma-Aldrich 
Breathe-Easy sealing membrane Sigma-Aldrich 
Cell culture dishes 10 cm, 15 cm Corning 
Cell culture flasks T225 Starlab 
Cell culture flasks T25, T75 Nunc 
Cell culture plate 384-well, white Greiner Bio-One 
Cell culture plates 6-well, 12-well, 24-well, 48-well, 96-well Greiner Bio-One 
Cell strainer 40 µm, 70 µm BD 
Conical tubes 15 mL, 50 mL BD Falcon 
Countess Cell Counting Chamber Slides Invitrogen 
Cryo vials Nunc 
FACS tubes BD 
Filter pipette tips 10 µL, 20 µL, 200 µL, 1000 µL, 5000 µL Starlab, Eppendorf 
PCR plate sealing foil Steinbrenner 
PCR reaction plate, 96-well Greiner Bio-One 
PCR strips Biozym 
Petri dishes Corning 
Pipettes 2 mL, 5 mL, 10 mL, 25 mL, 50 mL Corning 
Pipetting reservoirs Integra Biosciences 
Plastic bottles 125 mL, 250 mL Nunc 
QIAshredder columns Qiagen 
qPCR plate sealing foil Biozym 
qPCR reaction plate, 96-well Biozym 
Qubit Assay Tubes Invitrogen 
Reaction tubes 0.5 mL, 1.5 mL, 2 mL, 5 mL Eppendorf 
Round-Bottom Polypropylene Tubes 14 mL BD Falcon 
2.1.4 Kits 
Kit Supplier 
DNeasy Blood & Tissue Kit Qiagen 
GeneMATRIX Plasmid Miniprep DNA Purification Kit EURx 
HiSpeed Plasmid Maxi Kit Qiagen 
jetPEI transfection reagent Polyplus Transfection 
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Pierce BCA Protein Assay Kit Thermo Scientific 
Plasmid Maxi Kit Qiagen 
QIAquick Gel Purification Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
Qubit dsDNA BR Assay Kit Invitrogen 
RevertAid First Strand cDNA Synthesis Kit Thermo Scientific 
RNase-Free DNase Set Qiagen 
RNeasy Mini Kit Qiagen 
Zombie UV Fixable Viability Kit BioLegend 
2.1.5 Antibodies 
2.1.5.1 Flow cytometry 
Antibody Host Supplier Cat. no. Fluorophore 
IgG2b Isotype Control Mouse BD Pharmingen 554298 FITC 
IgG2b Isotype Control Mouse BD Pharmingen 556534 PE 
p53 (DO-7) Mouse BD Pharmingen 554298 FITC 
p53 (DO-7) Mouse BD Pharmingen 556534 PE 
2.1.5.2 Western Blot 
Antibody Host Supplier Cat. no. Dilution 
Acetylated-Lysine Rabbit Cell Signaling 9441S 1:1,000 
GAPDH-HRP Mouse Sigma-Aldrich G9295 1:3,000 
Goat-HRP Rabbit Abcam ab6741 1:3,000-1:10,000 
MDM2 Mouse Santa Cruz 
Biotechnology 
sc-965 1:200 
MDM4 Rabbit Merck 04-1555 1:1,000 
Mouse-HRP Rabbit Abcam ab6728 1:3,000-1:10,000 
p21 Mouse BD Pharmingen 556431 1:250 
p53-HRP Goat R&D Systems HAF1355 1:5,000 
PARP Rabbit Cell Signaling 9542S 1:1,000 
Rabbit-HRP Goat Abcam ab6721 1:3,000-1:10,000 
TRRAP Rabbit Cell Signaling 3966S 1:1,000 
2.1.5.3 Immunoprecipitation 
Antibody Host Supplier Cat. no. 
FLAG Mouse Sigma-Aldrich F3165 
Normal IgG control Goat Santa Cruz Biotechnology sc-2028 
Normal IgG control beads Mouse Santa Cruz Biotechnology sc-2343 
p53 (DO-1/1801/421) Mouse Custom-made (gift from Moshe Oren, WIS) - 
p53 beads (DO-1) Mouse Santa Cruz Biotechnology sc-126 AC 
SV40 T antigen (419) Mouse Custom-made (gift from Moshe Oren, WIS) - 
TRRAP Goat Santa Cruz Biotechnology sc-5405 
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2.1.6 Plasmids 
Plasmid Function Source 
CbS-Flag-TRRAP TRRAP expression Addgene #32103,  
Michael Cole/Yardena Samuels 
DECIPHER Pooled Lentiviral 
shRNA library Human Module I 
shRNA library Cellecta 
lentiCas9-Blast Cas9 expression Addgene #52962, Feng Zhang 
lentiCRISPRv2 sgRNA & Cas9 expression Addgene #52961, Feng Zhang 
lentiGuide-Puro sgRNA expression Addgene #52963, Feng Zhang 
pcDNA3 cDNA expression Gift from Moshe Oren, WIS 
pcDNA3-dNp53 ∆N wtp53 expression Gift from Moshe Oren, WIS 
pcDNA3-p53 wtp53 expression Gift from Moshe Oren, WIS 
pCMV-p53-R175H mutp53 R175H expression Gift from Moshe Oren, WIS 
peGFP-C1 GFP expression Gift from Moshe Oren, WIS 
pLKO1-TRC905 
(pLKO_IPTG_3xLacO) 
Inducible shRNA expression Gift from Claudia Scholl, DKFZ 
pLKO5.sgRNA.EFS.tRFP sgRNA expression Addgene #57823, Benjamin Ebert 
pMD2.G Lentiviral packaging Addgene #12259, Didier Trono 
pRSI12-U6-sh-HTS4-UbiC-
TagRFP-2A-Puro 
Constitutive shRNA expression Cellecta 
psPAX2 Lentiviral packaging Addgene #12260, Didier Trono 
2.1.7 Cell lines 
Cell line Entity Source 
Awia Human Burkitt’s lymphoma A. B. Rickinson, University of Birmingham, UK 
BJAB Human Burkitt’s lymphoma DMSZ, Braunschweig, Germany 
BL-2 Human Burkitt’s lymphoma DMSZ, Braunschweig, Germany 
BL-7 Human Burkitt’s lymphoma G. M. Lenoir, IARC, Lyon, France 
BL-28 Human Burkitt’s lymphoma G. M. Lenoir, IARC, Lyon, France 
BL-41 Human Burkitt’s lymphoma DMSZ, Braunschweig, Germany 
BL-60 Human Burkitt’s lymphoma G. M. Lenoir, IARC, Lyon, France 
CA-46 Human Burkitt’s lymphoma DMSZ, Braunschweig, Germany 
Cheptanges Human Burkitt’s lymphoma A. B. Rickinson, University of Birmingham, UK 
Colo320 Human colon adenocarcinoma DMSZ, Braunschweig, Germany 
DG-75 Human Burkitt’s lymphoma DMSZ, Braunschweig, Germany 
HEK 293T/17 Human embryonic kidney Stefan Fröhling, DKFZ, Heidelberg, Germany 
LY-47 Human Burkitt’s lymphoma G. M. Lenoir, IARC, Lyon, France 
Namalwa Human Burkitt’s lymphoma DMSZ, Braunschweig, Germany 
NCI-H1299 Human non-small cell lung carcinoma ATCC, Wesel, Germany 
Raji Human Burkitt’s lymphoma DMSZ, Braunschweig, Germany 
Ramos Human Burkitt’s lymphoma DMSZ, Braunschweig, Germany 
Salina Human Burkitt’s lymphoma A. B. Rickinson, University of Birmingham, UK 
Seraphine Human Burkitt’s lymphoma A. B. Rickinson, University of Birmingham, UK 
SUDHL-4 Human germinal center B-cell diffuse 
large B-cell lymphoma 
DMSZ, Braunschweig, Germany 
Yakobo Human Burkitt’s lymphoma A. B. Rickinson, University of Birmingham, UK 
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The p53 mutation status of all cell lines was determined by high-throughput sequencing 
of TP53 exons 4-10199-201 and/or retrieved from the IARC TP53 Database202. 
2.1.8 Oligonucleotides 
Oligonucleotides were obtained from Eurofins Genomics or Sigma-Aldrich in smallest 
scale with reverse-phase cartridge purification. 
2.1.8.1 shRNA screen 
Name Sequence [5’→3’] Function 
FwdHTS TTCTCTGGCAAGCAAAAGACGGCATA 1st PCR forward primer 
RevHTS1 TAGCCAACGCATCGCACAAGCCA 1st PCR reverse primer 
FwdGex CAAGCAGAAGACGGCATACGAGA 2nd PCR forward primer 
IndA AATGATACGGCGACCACCGAGATCTACACGCAATGCGCA
CAACCGCAA 
2nd PCR reverse indexing primer 
IndB AATGATACGGCGACCACCGAGATCTACACGCAGACTGCA
CAACCGCAA 
2nd PCR reverse indexing primer 
IndC AATGATACGGCGACCACCGAGATCTACACGCATCAGGCA
CAACCGCAA 
2nd PCR reverse indexing primer 
IndD AATGATACGGCGACCACCGAGATCTACACGCACGTAGCA
CAACCGCAA 
2nd PCR reverse indexing primer 
IndE AATGATACGGCGACCACCGAGATCTACACGCAAGCGGCA
CAACCGCAA 
2nd PCR reverse indexing primer 
IndF AATGATACGGCGACCACCGAGATCTACACGCAGATGGCA
CAACCGCAA 
2nd PCR reverse indexing primer 
GexSeqS AGAGGTTCAGAGTTCTACAGTCCGAA HT sequencing read primer 
GexSeqIND ACGACCACCGAGATCTACACGCA HT indexing read primer 
2.1.8.2 qRT-PCR 
Name Sequence [5’→3’] Source 
qPCR_GAPDH_F ACCCAGAAGACTGTGGATGG Self-designed 
qPCR_GAPDH_R TCTAGACGGCAGGTCAGGTC Self-designed 
qPCR_IFNa1_F CCCTCTCTTTATCAACAAACTTGC Madar et al.203 
qPCR_IFNa1_R TTGTTTTCATGTTGGACCAGA Madar et al.203 
qPCR_ISG15_F CGAACTCATCTTTGCCAGTACA Roulois et al.204 
qPCR_ISG15_R GCCTTCAGCTCTGACACC Roulois et al.204 
qPCR_MDM2_F GGCAGGGGAGAGTGATACAGA PrimerBank205 
qPCR_MDM2_R GAAGCCAATTCTCACGAAGGG PrimerBank205 
qPCR_MX1_F GTTTCCGAAGTGGACATCGCA Madar et al.203 
qPCR_MX1_R CCATTCAGTAATAGAGGGTGGGA Madar et al.203 
qPCR_TP53_F GGAGCACTAAGCGAGCACTG Self-designed 
qPCR_TP53_R CACCGGATCTGAAGGGTGAAA Self-designed 
qPCR_TRRAP_F CAGGCCACCGATCACACAA PrimerBank205 
qPCR_TRRAP_R CGCTCCGGGTTGACTTTCA PrimerBank205 
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2.1.8.3 PCR 
Name Sequence [5’→3’] Function 
T7E1_MDM2_e2_F1 GTCCTGACTTGTCTCCAGCT T7E1 assay 
T7E1_MDM2_e2_R1 AGTTACGCCAGAGGTAGCAC T7E1 assay 
2.1.8.4 shRNA sequences 
Name mRNA target sequence [5’→3’] Cellecta ID 
shNT CAACAAGATGAAGAGCACCAA - 
shTP53_85 CGGCGCACAGAGGAAGAGAAT CLL-H-025985 
shTP53_86 TCAGACCTATGGAAACTACTT CLL-H-025986 
shTRRAP_233 GCCCTGTTCTTTCGCTTTGTA CLL-H-026233 
shTRRAP_234 CGCTACTTTGAGAACCCTCAA CLL-H-026234 
shTRRAP_235 CGAGAGCAAATCGAGGAAATA CLL-H-026235 
Unless stated otherwise, shTRRAP_233 was used for TRRAP knock-down experiments. 
2.1.8.5 sgRNA sequences 
Name mRNA target sequence [5’→3’] Source 
sgeGFP GGGCGAGGAGCTGTTCACCG Self-designed 
sgKPNB1_HGLibA_25375 GCTAGCTTCACATTATTACT Human CRISPR Knockout 
Pooled Library (GeCKO v2)206 
sgKPNB1_HGLibB_25338 CAGAGATCCCAGTAAACCAG Human CRISPR Knockout 
Pooled Library (GeCKO v2)206 
sgmCherry CGCCCTCGATCTCGAACTCG Self-designed 
sgMDM2  GTGGTTACAGCACCATCAGT Human CRISPR Knockout 
Pooled Library (GeCKO v2)206 
sgRPA3_MK GATGAATTGAGCTAGCATGC M. Kühn, Mainz University, 
Germany 
sgSF3B4_HGLibB_43659 TCTATAGGCATGCCTCCTCC Human CRISPR Knockout 
Pooled Library (GeCKO v2)206 
sgSF3B4_HGLibB_43660 AGGTTAGTGAACCGCTGCTG Human CRISPR Knockout 
Pooled Library (GeCKO v2)206 
sgTP53 CCATTGTTCAATATCGTCCG Human CRISPR Knockout 
Pooled Library (Brunello)207 
sgTRRAP_Bru8295_2 CCACTGGGGATCGTTCAGTG Human CRISPR Knockout 
Pooled Library (Brunello)207 
sgTRRAP_Bru8295_3 CTTGATCCGCCACTATACGA Human CRISPR Knockout 
Pooled Library (Brunello)207 
The TRRAP sgRNA sequences used for CRISPR scanning are listed in the Appendix 
(see 6.1, p. 103). 
2.1.9 Software 
Software Supplier Function 
Barcode Deconvoluter  Cellecta shRNA bar-code quantification 
FACSDiva v.8 BD FACS analysis 
FlowJo v.10 FlowJo FACS analysis 
Image Lab Software Version 5.2.1 Bio-Rad Western Blot analysis 
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Lasergene DNASTAR in silico cloning,  
Sanger sequencing analysis 
LightCycler 480 Software Version 1.5 Roche qRT-PCR analysis 
R version 3.4.0 R Foundation Statistical analysis 
RStudio Desktop 1.0.143 RStudio Statistical analysis 
 
2.1.10 Equipment / Instruments 
Instrument Supplier 
Agarose gel electrophoresis chambers VWR Peqlab 
Agarose gel electrophoresis power supply Elchrom Scientific 
Analytical balance Sartorius 
Bacteria incubator Sanyo 
Bacteria shaker Infors 
Benchtop centrifuges Eppendorf 
Benchtop centrifuges, cooled Heraeus 
Bioanalyzer Agilent 
Cell culture centrifuge Thermo Scientific 
Cell culture hood Thermo Scientific 
Cell culture incubator Heraeus 
Cell sorter FACSAria II BD Biosciences 
ChemiDoc XRS Imaging System Bio-Rad 
cobas z 480 Roche 
Cooling racks neoLab 
Countess™ II FL Automated Cell Counter Thermo Scientific 
Flow cytometers LSRII, LSRFortessa BD Biosciences 
Freezer -20°C Liebherr 
Freezer -80°C New Brunswick 
Fridge 4°C Liebherr 
Fume hood WALDNER Laboreinrichtungen 
Gel documentation station VWR Peqlab 
Hotplate stirrer VWR 
Ice machine Hoshizaki 
Liquid nitrogen tank German-Cryo 
Microscope Axiovert 40C Zeiss 
Microwave Bartscher 
Mr. Frosty freezing containers Thermo Scientific 
NanoDrop Spectrophotometer ND-1000 Thermo Scientific 
PAGE running chambers Bio-Rad 
pH meter Mettler Toledo 
Pipetboy Integra Biosciences 
Pipettes Eppendorf 
Plate reader Infinite M1000 Pro Tecan 
Qubit 2.0 Fluorometer Invitrogen 
SDS-PAGE power supply Bio-Rad 
TapeStation Agilent 
Thermocycler peqSTAR VWR Peqlab 
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Thermomixer Eppendorf 
Trans-Blot Turbo Transfer System Bio-Rad 
Tube rotator (rotating wheel) Bibby Scientific 
Vacuum pump VACUUBRAND 
Vortexer IKA 
Water bath LAUDA 
Water purification system (for ddH2O) Thermo Scientific 
 
2.2 Cell culture methods 
2.2.1 Cell cultivation 
All cell lines were cultured in RPMI (293T cells: DMEM) supplemented with 10% heat-
inactivated FBS, 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin at 
37°C in a humidified, 5% CO2 atmosphere. Lymphoma cells were maintained at 
3-5x105 cells/mL and were passaged twice per week. Adherent cells were detached with 
Trypsin if necessary. The identity of all cell lines was validated using Multiplex Cell 
Authentication (Multiplexion)208. The SNP profiles matched known profiles or were 
unique. The purity of cell lines was validated using the Multiplex Cell Contamination Test 
(Multiplexion)209. No Mycoplasma, SMRV or interspecies contamination was detected. 
2.2.2 Cell freezing & thawing 
For freezing, cells were collected by centrifugation (400 x g, 5 min), washed once with 
PBS, and resuspended in cell freezing medium (90% FBS, 10% DMSO) at a 
concentration of 3x106 cells/mL. 1 mL cell suspension was transferred into cryotubes and 
stored overnight in a Mr. Frosty container at -80°C before transfer into liquid nitrogen 
(LN2) for long-term storage. 
For thawing, cryotubes were quickly thawed in a 37°C water bath. The thawed cells were 
transferred to 9 mL pre-warmed cell culture medium, collected by centrifugation (400 x g, 
5 min), resuspended in 10 mL pre-warmed cell culture medium, and seeded into 
appropriate cell culture flasks. 
2.2.3 Lentiviral packaging 
One day before transfection, 293T cells were seeded into 6-well plates 
(400,000 cells/well). The next day, for each packaging reaction, the appropriate target 
plasmid (e.g. shRNA or sgRNA expression vector) was mixed with the packaging vector 
psPAX2, the envelope vector pMD2.G, and PLUS reagent as indicated in Table 2 and 
incubated for 15 min at room temperature. After incubation, the Lipofectamine mix was 
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prepared as shown in Table 3, mixed gently, and added to the previously prepared mix 
to generate the final transfection mix. After another incubation of 15 min at room 
temperature, the transfection mix was gently added to the plated cells and mixed by 
gentle swirling. The medium of the cells was replaced with fresh DMEM 12-18 h after 
transfection. 48 h post-transfection, the transfection efficiency was evaluated via 
fluorescence microscopy if possible and the virus-containing medium was collected and 
centrifuged (1,000 x g, 5 min) to pellet cell debris and dead cells. The supernatant was 
then either used directly for transduction or stored in small aliquots at -80°C.  
Table 2: Packaging-PLUS mix for transfection of 293T cells for lentiviral packaging. 
 per well in 6-well plate [µL] 
Target plasmid (50 ng/µL) 5 
psPAX2:pMD2.G 2:1 mix (500 ng/µL) 2.5 
OPTI-MEM 190 
PLUS reagent 2.5 
TOTAL 200 
 
Table 3: Lipofectamine mix for transfection of 293T cells for lentiviral packaging. 
 per well in 6-well plate [µL] 
OPTI-MEM 196 
Lipofectamine 4 
TOTAL 200 
 
2.2.4 Lentiviral transduction 
Lymphoma cell lines were seeded at a density of 5x105 cells/mL and the appropriate 
amount of lentiviral supernatant was added, typically 1/5-1/10 of the seeding volume. 
Cells were splitted 1:2 one day after transduction. If necessary, transduced cells were 
enriched with 0.5-1.0 µg/mL puromycin for 48-72 h. Puromycin selection was repeated 
multiple times whenever needed. For generation of Cas9-expressing cells, transduced 
cells were selected with 10 µg/mL blasticidin for four days. Transduced cells were 
maintained at a concentration of 5x105 cells/mL.  
2.2.5 Flow cytometry (FACS) 
2.2.5.1 Monitoring of fluorescence signals (e.g. GFP, RFP) 
250 µL of a dense cell culture (~5x105 cells) were collected by centrifugation in a 96-well 
PCR plate (400 x g, 5 min), washed once with 100 µL 2% FBS/PBS, resuspended in 
100-200 µL 2% FBS/PBS, and transferred to FACS tubes. Tubes were kept on ice in the 
dark until analysis using an LSRFortessa or LSRII. Gating on living cells was performed 
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using forward/sideward scatter, cell doublet discrimination was done using area and 
height of the forward and sideward scatter. Data was analyzed using FlowJo v.10. 
2.2.5.2 Intracellular p53 staining using paraformaldehyde for fixation 
Using paraformaldehyde (PFA) for fixation preserves fluorescence signals but damages 
DNA. This protocol was used when cells were expressing fluorescent proteins (e.g. after 
shRNA transduction) and the DNA was not needed for further experiments. 
250 µL of a dense cell culture (~5x105 cells) were collected by centrifugation in a 96-well 
PCR plate (400 x g, 5 min) and washed once with 100 µL PBS. To allow for live/dead cell 
discrimination after fixation, cells were stained with 40 µL Zombie staining solution 
(1:100-diluted Zombie UV dye in PBS) and incubated for 15-30 min at room temperature 
in the dark. After incubation, 100 µL PBS was added to the wells and the plate was 
centrifuged (400 x g, 5 min). The supernatant was removed and the cells were washed 
with 100 µL 1% BSA/PBS. Cells were fixed with 100 µL freshly prepared 2% PFA/PBS 
and incubated for 30 min at 4°C. After incubation, cells were pelleted (400 x g, 5 min) 
and washed twice with 100 µL 1% BSA/PBS. Cells were permeabilized with 100 µL ice-
cold 80% EtOH/PBS at -20°C for 30 min (or stored to continue with the staining at a later 
time). Next, cells were pelleted (400 x g, 5 min) and washed twice with 100 µL 
1% BSA/PBS. Fixed cells were stained for p53 levels with 40 µL staining solution (1:10-
1:25-diluted antibody in 1% BSA/PBS) containing anti-p53 clone DO-7 coupled to FITC 
or PE and incubated for 1 h at 4°C in the dark. After incubation, 100 µL 1% BSA/PBS 
were added and cells were pelleted (400 x g, 5 min). The supernatant was removed, 
cells were resuspended in 100-200 µL 1% BSA/PBS, and transferred to FACS tubes. 
Tubes were kept on ice in the dark until analysis as indicated above. 
2.2.5.3 Intracellular p53 staining using methanol for fixation and permeabilization 
Using methanol (MeOH) for fixation and permeabilization quenches fluorescence signals 
but preserves DNA. This protocol was used when cells were not expressing any 
fluorescent proteins and/or when the DNA was needed for further experiments. 
Cells were collected, washed, and stained for viability using Zombie UV as described 
above (see 2.2.5.2). Cells were fixed and permeabilized with 100 µL ice-cold MeOH and 
incubated at -20°C for 30 min (or stored to continue with the staining at a later time). 
After incubation, cells were pelleted (400 x g) and the supernatant was removed. Cells 
were resuspended in 100 µL PBS and incubated for at least 30 min at 4°C. Next, cells 
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were pelleted (400 x g, 5 min), the supernatant was removed, and cells were stained for 
p53 levels and analyzed as indicated above. 
2.2.6 Transfection of adherent cells 
For transfection of Colo320 cells, 500,000 cells/well were seeded in 6-well plates. The 
next day, for each well, 2.5 µg plasmid DNA were mixed with 2.5 µL PLUS reagent and 
125 µL OPTI-MEM. In parallel, 12.5 µL Lipofectamine were added to 125 µL OPTI-MEM. 
Next, both solutions were combined and added gently to the wells after 5 min incubation 
at room temperature. Cells were harvested 48-72 h after transfection.  
For transfection of H1299 cells, 675,000 cells were seeded in 10 cm dishes. The next 
day, 3 µg plasmid DNA were diluted in 150 mM NaCl in a total volume of 150 µL for each 
plate. In parallel, 14 µL PEI were added to 136 µL 150 mM NaCl. Next, both solutions 
were combined and added gently to the plates after 15-30 min incubation at room 
temperature. Cells were harvested 24-72 h after transfection.  
2.2.7 shRNA rescue experiment 
Colo320 cells were detached with Trypsin, transduced with shRNA lentiviruses in 
suspension as described above (see 2.2.4) in the presence of 8 µg/mL polybrene, and 
seeded into 6-well plates (500,000 cells/well). The next day, cells were transfected with 
FLAG-TRRAP as described above (see 2.2.6). Cells were harvested 48 h after 
transfection (= 72 h after transduction).  
2.2.8 Inducible shRNAs 
Namalwa cells were transduced with IPTG-inducible shRNA lentiviruses as described 
above (see 2.2.4) and enriched by multiple rounds of puromycin selection. For induction, 
cells were treated with 2 mM IPTG, which was renewed every two days. 
 
2.3 Molecular biology methods 
2.3.1 DNA extraction 
Genomic DNA was extracted from ~1x106 washed cells using the DNeasy Blood & 
Tissue Kit according to the manufacturer’s guidelines. In brief, cells were lysed using 
buffer AL and the DNA was precipitated with EtOH. Next, the DNA was bound to spin 
columns and washed with buffers AW1 and AW2. Finally, DNA was eluted in 100 µL 
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ddH2O, quantified using a NanoDrop ND-1000 Spectrophotometer or a Qubit 2.0 
Fluorometer (dsDNA BR assay kit), and stored at -20°C. 
2.3.2 Plasmid cloning 
2.3.2.1 Constitutive shRNAs 
All shRNA sequences were extracted from the DECIPHER Pooled Lentiviral shRNA 
library Human Module I and cloned into the shRNA expression vector pRSI12-U6-sh-
HTS4-UbiC-TagRFP-2A-Puro according to the guidelines provided by Cellecta (user 
manual “Cloning of shRNA Templates into shRNA Expression Vector”, 1/2011). Forward 
and reverse oligonucleotides were designed according to the following scheme: 
F: 5’-ACCG-G-NNNNNNNNNNNNNNNNNNNNN-GTTAATATTCATAGC-NNNNNNNNNNNNNNNNNNNNN-TTTT-3’ 
R:      3’-C-NNNNNNNNNNNNNNNNNNNNN-CAATTATAAGTATCG-NNNNNNNNNNNNNNNNNNNNN-AAAA-AAGC-5’ 
sticky end, constant region, sense target sequence, shRNA loop, antisense target sequence 
For linearization of the expression vector pRSI12, 5 µg plasmid DNA were digested with 
50 U BbsI in 1x buffer G for 2 h at 37°C. After the reaction was heat inactivated by 
incubation at 65°C for 20 min, the linearized vector was purified from a 0.5% preparative 
agarose gel using a QIAquick Gel Extraction Kit according to the manufacturer’s 
guidelines.  
For phosphorylation and annealing of shRNA oligonucleotides, 10 pmol of each forward 
and reverse oligo were mixed with 5 nmol ATP and 5 U T4 polynucleotide kinase (PNK) 
in 1x T4 PNK buffer in a total volume of 10 µL. The reaction mix was incubated for 
30 min at 37°C, followed by 2 min at 95°C and gradual cooling to 25°C at a rate of -
0.1°C/s. As a negative control, the oligos were replaced with ddH2O. The reaction mix 
was diluted 1:5 with 1x T4 PNK buffer and was either used directly or stored at -20°C. 
For ligation, 10 ng linearized pRSI12 were mixed with 0.5 µL oligo mix and 40 U T4 DNA 
ligase in 1x T4 ligase buffer in a total volume of 10 µL. The reaction mix was incubated 
for 2 h at 16°C. As a negative control, the oligo mix was replaced with the negative 
control from the previous step. 
For transformation, XL10-Gold ultracompetent E. coli cells were thawed on ice, mixed 
with 4 µL β–mercaptoethanol, and incubated for 10 min on ice. After incubation, 1 µL 
cells was added to the ligation mix and incubated for 30 min on ice. As a negative 
control, the negative control from the previous step was used. After incubation, cells 
were heat-shocked by incubation at 42°C for 30 s, followed by incubation on ice for at 
least 2 min. Next, 30 µL pre-warmed S.O.C. medium were added and cells were 
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incubated at 37°C for 1 h while shaking. Finally, transformed cells were plated on LB 
agar supplemented with 100 µg/mL ampicillin and incubated overnight at 37°C.  
The next day, colonies were picked from each transformation and used for inoculation of 
5 mL ampicillin-containing LB medium to expand cells overnight at 37°C while shaking. 
Plasmids were purified using a GeneMATRIX Plasmid Miniprep DNA Purification Kit 
according to the manufacturer’s instructions and quantified using a NanoDrop ND-1000 
Spectrophotometer. Finally, the sequence of all plasmids was validated via Sanger 
sequencing (GATC Biotech) using a primer which specifically amplified the shRNA 
inserts. 
2.3.2.2 Inducible shRNAs 
shRNA sequences were similar to the ones described above (see 2.3.2.1) and were 
cloned into the IPTG-inducible shRNA expression vector pLKO1-TRC905 
(pLKO_IPTG_3xLacO). Forward and reverse oligonucleotides were designed according 
to the following scheme: 
F: 5’-CCGG-NNNNNNNNNNNNNNNNNNNNN-CTCGAG-NNNNNNNNNNNNNNNNNNNNN-TTTTTG-3’ 
R:      3’-NNNNNNNNNNNNNNNNNNNNN-GAGCTC-NNNNNNNNNNNNNNNNNNNNN-AAAAACTTAA-5’ 
sticky end, sense target sequence, shRNA loop, constant region, antisense target sequence 
For linearization of the expression vector, 2 µg plasmid DNA were digested with 5 U AgeI 
and 20 U EcoRI in 1x NEBuffer 1.1 for 2 h at 37°C. The linearized vector was purified 
from a 0.8% preparative agarose gel using a QIAquick Gel Extraction Kit according to 
the manufacturer’s guidelines. 
Phosphorylation and annealing of the shRNA oligos was performed similarly as 
described above (see 2.3.2.1). 
For ligation, 20 ng linearized vector were mixed with 0.5 µL oligo mix and 40 U T4 DNA 
ligase in 1x T4 ligase buffer in a total volume of 10 µL. The reaction mix was incubated 
for 2 h at 16°C.  
Transformation, plasmid purification, and validation were performed similarly as 
described above (see 2.3.2.1). 
2.3.2.3 sgRNAs 
sgRNA sequences were obtained either from the Human Brunello CRISPR knockout 
pooled library (D. Root and J. Doench, Addgene #73178)207 or were designed based on 
rules defined by Doench et al.207. They were cloned into the sgRNA expression vectors 
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lentiGuide-Puro, lentiCRISPRv2, or pLKO5.sgRNA.EFS.tRFP based on published 
protocols206,210,211 or protocols provided on Addgene. Forward and reverse 
oligonucleotides were designed according to the following scheme: 
F: 5’-CACCG-NNNNNNNNNNNNNNNNNNNN-3’ 
R:     3’-C-NNNNNNNNNNNNNNNNNNNN-CAAA-5’ 
sticky end, sgRNA sequence  
For linearization of the expression vector, 5 µg plasmid DNA were digested with 20 U 
BsmBI in 1x NEBuffer 3.1 for 1.5 h at 55°C. After incubation, the linearized vector was 
dephosphorylated by addition of 2.5 µL rSAP and incubation at 37°C for 1 h, followed by 
heat inactivation at 65°C for 5 min. Next, the linearized vector was purified from a 0.5% 
preparative agarose gel using a QIAquick Gel Extraction Kit according to the 
manufacturer’s guidelines.  
Phosphorylation and annealing of the sgRNA oligos was performed similarly as 
described above for shRNAs (see 2.3.2.1). 
For ligation, 50 ng linearized vector were mixed with 0.5 µL oligo mix and 40 U T4 DNA 
ligase in 1x T4 ligase buffer in a total volume of 10 µL. The reaction mix was incubated 
for 1 h at room temperature.  
Transformation, plasmid purification, and validation were performed similarly as 
described above for shRNAs (see 2.3.2.1). 
2.3.3 RNA extraction 
RNA was extracted from ~1x106 washed cells using the RNeasy Mini Kit according to the 
manufacturer’s guidelines. In brief, cells were disrupted in buffer RLT and homogenized 
using QIAshredder spin columns. Lysates were loaded onto spin columns, followed by 
an on-column DNase digestion. Next, the RNA was washed using buffers RW1 and 
RPE. Finally, the RNA was eluted in 30 µL RNase-free H2O and quantified using a 
NanoDrop ND-1000 Spectrophotometer. Before storage at -80°C, the RNA integrity was 
checked on a 1% agarose gel. Only samples showing sharp, clear 28S and 18S rRNA 
bands were used for further experiments. 
2.3.4 cDNA synthesis 
cDNA synthesis was performed using the RevertAid First Strand cDNA Synthesis Kit 
according to the manufacturer’s instructions. In brief, RNA samples were thawed on ice 
and checked for integrity as described above. 500 ng RNA were mixed with 1 µL random 
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hexamer primers, incubated at 65°C for 5 min, and briefly chilled on ice. Next, reaction 
buffer, RNase inhibitor, dNTPs, and reverse transcriptase were added and the reaction 
was incubated for 5 min at 25°C, followed by 1 h at 42°C and 5 min at 70°C. “No reverse 
transcriptase” controls were included for all samples. The cDNA was diluted 1:10 with 
ddH2O and stored at -20°C.  
2.3.5 qRT-PCR 
qRT-PCR was performed using the Power SYBR Green Master Mix according to the 
manufacturer’s guidelines. In brief, for every gene of interest, a master mix was prepared 
consisting of 10 µL Power SYBR Green Master Mix, 2 µL primer mix (forward + reverse, 
5 µM each), and 8 µL of diluted cDNA. Primers for qRT-PCR were self-designed, taken 
from the literature, or obtained from PrimerBank205. For every sample, the “no reverse 
transcriptase” control was included. For every primer, a “no template” control was 
included (cDNA replaced with ddH2O) to check for potential primer dimer formation. 
Reactions were performed in triplicates in white 96-well PCR plates and run on a 
cobas z 480 Analyzer. The following PCR program was used: 10 min at 95°C, 40 cycles 
of 15 s at 95°C and 1 min at 60°C, followed by a thermal dissociation protocol for SYBR 
green detection for recording of the melting curves. Data were analyzed using 
LightCycler 480 Software Version 1.5. Gene expression was quantified using the ∆∆Ct 
method and GAPDH expression was used as a reference for normalization. 
2.3.6 Gene expression profiling by microarray 
For gene expression profiling by microarray, 1 µg total RNA was submitted to the DKFZ 
Genomics & Proteomics Core Facility for analysis on a Illumina HumanHT-12 v4 
BeadChip, containing >47,000 probes mapping to >31,000 annotates genes. The core 
facility performed quality control, reverse transcription, labeling, and chip hybridization 
and provided normalized relative expression values and adjusted p values. Differentially 
expressed probes were defined as adj. p < 0.05 and |log2 fold change| > 1. Data was 
further processed and analyzed using R version 3.4.0. Gene set enrichment analysis 
was done using the R package “piano”212 (method “PAGE”213, MSigDB214 gene set 
collections “hallmark”215 and “c2cgp”) or using Enrichr216,217 (data set “GO Biological 
Process 2017”). Gene expression data of MDA-MB-231 cells 48 h after treatment with 
3.17 µM Mocetinostat was downloaded from NCBI GEO (GSE65495)218.  
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2.3.7 Western Blot 
For Western Blotting, ~1x106 cells were washed with PBS and snap frozen as pellets on 
dry ice or with LN2. Pellets were resuspended in freshly prepared 1x RIPA Lysis buffer 
supplemented with protease inhibitors and 125 U/mL benzonase and incubated for 
30 min on ice with occasional vortexing. After incubation, lysates were cleared by 
centrifugation (10,000 x g, 15 min, 4°C). If necessary, protein concentration was 
quantified with a Pierce BCA Protein Assay Kit according to the manufacturer’s 
instructions. Samples were mixed with 2x or 4x Laemmli buffer before ~20 µg were 
loaded onto 4-15% gradient polyacrylamide protein gels together with an appropriate 
protein standard. Separation was performed at 90-120 V in 1x Tris/Glycine/SDS running 
buffer for ~1.5 h. Proteins were blotted onto PVDF membranes for 10 min at 2.5 A using 
a Trans-Blot Turbo Blotting System. After blotting, membranes were blocked in 
5% milk/TBST (20 mM Tris, 150 mM NaCl, 0.1% Tween 20, 5% milk powder, pH 7.6) for 
1 h at room temperature or overnight at 4°C while shaking. Primary antibodies were 
diluted according to the manufacturer’s datasheets in 5% milk/TBST or 5% BSA/TBST 
and incubated with the membranes overnight at 4°C while shaking. The next day, blots 
were washed three times with TBST for 5 min at room temperature while shaking and 
incubated with diluted secondary antibodies (1:3,000-1:10,000 in 5% milk/TBST) for 1 h 
at room temperature while shaking. Subsequently, blots were washed again three times 
with TBST for 5 min at room temperature while shaking. Finally, protein expression was 
detected using freshly prepared ECL solution and a ChemiDoc XRS System. Image 
acquisition and analysis was done using Image Lab Software Version 5.2.1.  
2.3.8 Immunoprecipitation 
2.3.8.1 Exogenous (H1299 cells) 
For exogenous immunoprecipitation (IP), protein A agarose beads were first coupled to 
the appropriate antibodies. To this end, for each IP reaction, 50 µL 50% bead slurry were 
pelleted (200 x g, 1 min, 4°C) and washed three times with 800 µL NP40 buffer (50 mM 
Tris pH 8, 150 mM NaCl, 1.0% NP40) supplemented with protease and phosphatase 
inhibitors. Next, 2 µg antibody in 1 mL NP40 buffer were added to the beads, followed by 
incubation at 4°C while rotating for at least 30 min. Meanwhile, for each IP reaction, one 
confluent 10 cm dish of H1299 cells was harvested (~1x107 cells), washed once with 
PBS, resuspended in 800 µL NP40 buffer, and incubated for 30 min at 4°C while rotating 
for lysis. In the meantime, the antibody-coupled beads were washed three times with 
800 µL NP40 buffer and finally resuspended in 100 µL NP40 buffer. A small aliquot of the 
diluted beads was kept as a “beads only” control. After incubation, the cell lysate was 
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cleared by centrifugation (10,000 x g, 10 min, 4°C) and 50 µL were kept and 
supplemented with Laemmli buffer as an “input” control. The remaining lysate was added 
to the readily diluted beads and incubated for 3-5 h at 4°C while rotating. Subsequently, 
beads were washed three times with 800 µL NP40 buffer for 3 min at 4°C while rotating. 
After the final wash, proteins were eluted from the beads by resuspension in 60 µL 
2x Laemmli buffer and incubation at 85°C for 10 min. The eluent was stored at -20°C 
until analysis by Western Blot as described above (see 2.3.7). 
2.3.8.2 Endogenous (BL cell lines) 
For endogenous IP, protein A/G agarose beads were first coupled to the appropriate 
antibodies (this step was skipped when precoupled beads were used). To this end, for 
each IP reaction, 20 µL 50% bead slurry were pelleted (1,000 x g, 2 min, 4°C) and 
washed three times with 800 µL NP40 buffer (50 mM Tris pH 8, 150 mM NaCl, 1.0% 
NP40) supplemented with protease, phosphatase, histone deacetylase inhibitors 
(sodium butyrate + nicotinamide), and benzonase. Next, 2 µg antibody in 1 mL NP40 
buffer were added to the beads, followed by incubation at 4°C while rotating for at least 
30 min. Meanwhile, for each IP reaction, 4x107 cells were harvested, washed twice with 
PBS, resuspended in 800 µL NP40 buffer, and incubated for 30 min at 4°C while rotating 
for lysis. In the meantime, the antibody-coupled beads were washed three times with 
800 µL NP40 buffer and finally resuspended in 100 µL NP40 buffer. A small aliquot of the 
diluted beads was kept as a “beads only” control. After incubation, 20 µL bead slurry 
were added to the cell lysate, followed by incubation for 1 h at 4°C while rotating for pre-
clearing. Next, the lysate was cleared by centrifugation (17,000 x g, 10 min, 4°C) and the 
supernatant was pre-cleared again. After the second pre-clearing, 50 µL of the lysate 
were kept and supplemented with Laemmli buffer as an “input” control. The remaining 
lysate was added to the readily diluted beads and incubated for 4 h at 4°C while rotating. 
Subsequently, beads were washed five times with 800 µL NP40 buffer for 5 min at 4°C 
while rotating. After the final wash, proteins were eluted from the beads by resuspension 
in 40 µL 0.1 M glycine (pH 2.5) and incubation for 5 min at room temperature. Finally, the 
beads were pelleted and the supernatant was neutralized by addition of 4 µL 1.5 M 
Tris-HCl (pH 8.8), supplemented with Laemmli buffer, cooked for 3 min at 95°C, and 
stored at -20°C until analysis by Western Blot as described above (see 2.3.7) or mass 
spectrometry as described below (see 2.3.9). 
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2.3.9 Mass spectrometry 
Namalwa cells with IPTG-inducible TRRAP or control knock-down were induced for 48 h 
or 96 h, respectively, before they were harvested directly or subjected to p53 
immunoprecipitation as stated above (see 2.3.8.2). Mass spectrometry experiments were 
performed by Mandy Rettel and data analysis was performed by Frank Stein (both EMBL 
Proteomics Core Facility, Heidelberg, Germany). The following three sections (2.3.9.1, 
2.3.9.2, and 2.3.9.3) were written jointly by them: 
2.3.9.1 Sample preparation 
“All reagents were prepared in 50 mM HEPES (pH 8.5). Cysteines were reduced using 
dithiothreitol (56°C, 30 min, 10 mM). Samples were cooled to 24°C and alkylated with 
iodacetamide (room temperature, in the dark, 30 min, 10 mM). Subsequently, the 
samples were prepared for LC-MS/MS using the SP3 protocol219, digested with trypsin 
(enzyme to protein ratio, 1:50) at 37°C overnight. TMT 10-plex isobaric label reagents 
(ThermoFisher) were added to the samples following the manufacturer’s instructions. 
Clean up of labeled peptides was performed using OASIS HLB µElution Plate (Waters). 
Offline high pH reverse phase fractionation was performed using an Agilent 1200 Infinity 
high-performance liquid chromatography (HPLC) system, equipped with a Gemini C18 
column (3 µm, 110 Å, 100 x 1.0 mm, Phenomenex). The solvent system consisted of 
20 mM ammonium formate (pH 10.0) as mobile phase (A) and 100% acetonitrile as 
mobile phase (B). In total, 15 fractions for total proteome experiments and 5 fractions for 
IP experiments were obtained and analyzed.” 
2.3.9.2 Liquid chromatography-mass spectrometry/mass-spectrometry (LC-MS/MS) 
“Peptides were separated using the UltiMate 3000 RSLC nano LC system (Dionex) fitted 
with a trapping cartridge (µ-Precolumn C18 PepMap 100, 5µm, 300 µm i.d. x 5 mm, 
100 Å) and an analytical column (Acclaim PepMap 100 75 µm x 50 cm C18, 3 µm, 
100 Å). The outlet of the analytical column was coupled directly to a QExactive plus 
(Thermo) using the proxeon nanoflow source in positive ion mode. Solvent A was water, 
0.1% formic acid and solvent B was acetonitrile, 0.1% formic acid. Trapping time was 
6 min with a constant flow of solvent A at 30 µL/min onto the trapping column.  Peptides 
were eluted via the analytical column a constant flow of 0.3 µL/min. During the elution 
step, the percentage of solvent B increased in a linear fashion from 2% to 4% B in 4 min, 
from 4% to 8% in 2 min, then 8% to 28% for a further 96 min, and finally from 28% to 
40% in another 10 min. Column cleaning at 80% B followed, lasting 3 min, before 
returning to initial conditions for the re-equilibration, lasting 10 min. 
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The peptides were introduced into the mass spectrometer (QExactive plus, 
ThermoFisher) via a Pico-Tip Emitter 360 µm OD x 20 µm ID; 10 µm tip (New Objective) 
and a spray voltage of 2.3 kV was applied. The capillary temperature was set at 320°C. 
Full scan MS spectra with mass range 350-1400 m/z were acquired in profile mode in 
the FT with resolution of 70,000. The filling time was set at maximum of 100 ms with a 
limitation of 3x106 ions. DDA was performed with the resolution of the Orbitrap set to 
35,000, with a fill time of 120 ms and a limitation of 2x105 ions. Normalized collision 
energy of 32 was used. A loop count of 10 with count 1 was used and a minimum AGC 
trigger of 2e2 was set. Dynamic exclusion time of 30 s was applied. The peptide match 
algorithm was set to ‘preferred’ and charge exclusion ‘unassigned’, charge states 1, 5 - 8 
were excluded. Isolation window was set to 1.0 m/z and 100 m/z set as the fixed first 
mass.  MS/MS data was acquired in profile mode.” 
2.3.9.3 Data analysis 
“Raw mass spectrometry data was processed with IsobarQuant220 and peptide and 
protein identification was performed with the Masot 2.4 (Matrix Science) search engine. 
R was used to analyze the raw output data from IsobarQuant. First, the output files of 
IsobarQuant were loaded into R and merged. Only proteins that were quantified with 
using at least two unique peptide matches were kept for the downstream analysis. Only 
proteins which were identified in all three replicates were used for the statistical analysis. 
The raw data was then saved in an ExpressionSet R object. Subsequently, potential 
batch effects were removed using limma221 and data was normalized using variance 
stabilization, vsn strategy222. To identify proteins that were significantly different between 
the various conditions, limma was again used. Proteins annotated as hit if either a false 
discovery rate below 5% or a p-value smaller then 0.01 was obtained.”  
2.3.10 T7 endonuclease I (T7E1) assay 
The T7E1 assay was performed for monitoring of CRISPR/Cas9-mediated modification 
of the appropriate genomic loci. For DNA extraction, 250 µL of a dense cell culture 
(~5x105 cells) were collected by centrifugation (400 x g, 5 min), resuspended in 20 µL 
QuickExtract solution, and vortexed for 15 s. The mixture was incubated for 6 min at 
65°C, vortexed for 15 s, and incubated for 2 min at 98°C. The DNA-containing lysate was 
then used as a template together with PCR primers specific for the targeted locus in the 
PCR reaction indicated in Table 4 below. 
Two 8.5 µL aliquots were taken from the PCR reaction, mixed with 1 µL NEBuffer 2, and 
denatured and slowly reannealed using the following thermocycler program: 95°C for 
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10 min, ramp to 85°C at a rate of -2°C/s, ramp to 25°C at a rate of -0.1°C/s, store at 4°C. 
After incubation, 0.5 µL (5 U) T7E1 were added to every second aliquot and incubated 
for 20 min at 37°C. Finally, the reaction products were resolved on a 2% agarose gel by 
electrophoresis.  
Table 4: Master mix and PCR reaction for T7 endonuclease I (T7E1) assay. 
Reaction mix per rnx [µL] PCR program  
10x PCR reaction buffer 5 1. 94°C, 3 min  
dNTPs (10 mM each) 1 2. 94°C, 30 s  
Primer forward (10 µM) 1 3. 58°C, 30 s  
Primer reverse (10 µM) 1 4. 72°C, 30 s → go to 2. for 35x 
DNA 5 5. 72°C, 10 min  
ddH2O 36.5 6. 8°C, forever  
Taq polymerase 0.5   
TOTAL 50   
 
2.3.11 CRISPR scanning 
CRISPR scanning was performed according to the original publication by Shi et al.223. 
sgRNAs targeting TRRAP were designed based on rules defined by Doench et al.207, 
aiming for comparable on-target scores (median: 70.0, see 6.1). sgRNAs were cloned 
into pLKO5.sgRNA.EFS.tRFP and packaged into lentiviral particles as described above 
(see 2.3.2.3 and 2.2.3). Namalwa-Cas9 cells were transduced at a transduction 
efficiency of ~25% (see 2.2.4) and tagRFP657 expression (= APC channel in FACS) and 
p53 levels were monitored by flow cytometry over time (see 2.2.5). CRISPR scanning 
was kindly performed by Marius Jentzsch. 
 
2.4 Patient data 
Lymphoma patient data was generated by the ICGC MMML (Molecular Mechanisms of 
Malignant Lymphoma)-Seq consortium and approved by the ethics commission of the 
University of Göttingen, Germany. Patients were classified into lymphoma subtypes 
based on their gene expression profiles224. p53 mutations were determined by Sanger 
sequencing of exons 4-10. Tissue microarray (TMA) data were provided and analyzed by 
Wolfram Klapper (University of Kiel, Germany). TMA scores were assigned based on the 
percentage of p53-positive cells as given in Table 5 below. Parts of the data have been 
published previously201,224-226. 
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Table 5: Definition of the tissue microarray scores for quantification of p53 protein levels in 
lymphoma patient samples. 
p53-positive cells in tumor [%] Tissue microarray (TMA) score 
0 0 
1-25 1 
26-50 2 
51-75 3 
>75 4 
 
2.5 shRNA screen 
The shRNA library packaging and screening procedure was performed based on the 
manufacturer’s instructions (“Cellecta Pooled Bar-Coded Lentiviral shRNA Libraries User 
Manual”) and previous publications227,228 with modifications. 
2.5.1 shRNA library 
For the shRNA screen, the DECIPHER Pooled Lentiviral shRNA Library Human Module I 
consisting of 27,500 shRNAs targeting 5,043 genes was used. In this library, each 
shRNA was labeled with a unique bar-code sequence. The plasmid backbone of the 
library (pRSI12) contained a TagRFP gene and a puromycin resistance gene for labeling 
and selection purposes.  
2.5.2 Lentiviral packaging of the shRNA library 
One day before transfection, 1.2x107 293T cells were seeded per plate in a total of ten 
15-cm cell culture plates. The next day, the shRNA library plasmids were mixed with the 
packaging vector psPAX2, the envelope vector pMD2.G, and PLUS reagent as indicated 
in Table 6 and incubated for 15 min at room temperature. After incubation, the 
Lipofectamine mix was prepared as shown in Table 7, mixed gently, and added to the 
previously prepared mix to generate the final transfection mix. After another incubation of 
15 min at room temperature, the transfection mix was gently added to the plated cells 
and mixed by gentle swirling. The medium of the cells was replaced with fresh DMEM 
24 h after transfection. 48 h post-transfection, the transfection efficiency was evaluated 
via fluorescence microscopy and the virus-containing supernatant was collected and 
filtered using a 0.45 µm filter. The supernatant was stored in small aliquots at -80°C. The 
packaging was kindly performed by Mikołaj Słabicki (DKFZ/NCT). 
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Table 6: Packaging-PLUS mix for transfection of 293T cells for lentiviral packaging of the shRNA 
library. 
 per 10 cm dish [µL] 
pRSI12 shRNA library (500 ng/µL) 12 
psPAX2:pMD2.G 2:1 mix (500 ng/µL) 60 
OPTI-MEM 1168 
PLUS reagent 60 
TOTAL 1300 
 
 
Table 7: Lipofectamine mix for transfection of 293T cells for lentiviral packaging of the shRNA 
library. 
 per 10 cm dish [µL] 
OPTI-MEM 1310 
Lipofectamine 90 
TOTAL 1400 
 
2.5.3 shRNA library titration 
To determine the amount of lentiviral supernatant needed for achieving the appropriate 
transduction efficiency, Raji cells were seeded in a 24-well plate at a concentration of 
5x105 cells/mL and transduced with increasing amounts of lentiviral supernatant. 24 h 
post-transduction, cells were splitted 1:2. Three days post-transduction, the transduction 
efficiency was quantified by measurement of the RFP+ population by flow cytometry (see 
2.2.5.1).  
2.5.4 Cell transduction, culturing & sorting 
In order to achieve an infection rate of 400 cells/shRNA, 2.75x107 Raji cells (at a 
concentration of 5x105 cells/mL) were transduced with the appropriate amount of 
lentiviral supernatant to reach a transduction efficiency of ~50% (MOI 0.7). One day after 
transduction, cells were splitted 1:2 by addition of fresh medium. The next day, the 
transduction efficiency was determined via flow cytometry (see 2.2.5.1) and cells were 
selected with 0.8 µg/mL puromycin for 48 h. After puromycin selection, cells were splitted 
into two separate flasks and handled separately as technical duplicates. Cells were 
maintained at a concentration of ~5x105 cells/mL during the screen. On day eight after 
transduction, cells were collected and washed once with PBS. One quarter of the cells 
(~1x108) were pelleted, snap frozen on dry ice, and stored at -20°C (input control). The 
remaining cells were fixed with ice-cold MeOH and stained for intracellular p53 levels as 
described previously (see 2.2.5.3). Stained cells were filtered with a 40 µm cell strainer 
and subjected to flow cytometry sorting using a FACSAria II, collecting p53-low and p53-
high cells, each representing ~15% of the original population. Efficient sorting was 
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ensured by reanalysis of the sorted populations. Finally, sorted cells were counted, 
pelleted, snap frozen on dry ice, and stored at -20°C. 
2.5.5 Genomic DNA extraction & precipitation 
Genomic DNA was extracted using the DNeasy Blood & Tissue Kit according to the 
manufacturer’s instructions as described above (see 2.3.1). Max. 4x106 cells were used 
per spin column and an additional RNase digestion step was performed. DNA was eluted 
using 100 µL buffer AE and the eluent was reused for a second elution. 
In order to increase the DNA concentration and to remove the buffer AE, the genomic 
DNA was precipitated after purification. In brief, 0.1 volumes 3 M NaOAc (pH 5.2), 1 µL 
linear polyacrylamide, and 2 volumes 95% EtOH were added to the genomic DNA, 
followed by 0.5-1 h incubation at -80°C. After incubation, the solution was centrifuged 
(17,000 x g, 15 min) and the supernatant was decanted. The DNA was washed with 
1 mL 70% EtOH, incubated for 5 min at room temperature, and centrifuged. The 
supernatant was decanted and the DNA pellet was air-dried for a few minutes at room 
temperature. Finally, the pellet was dissolved in 50-100 µL ddH2O and quantified by 
Qubit. 
2.5.6 shRNA bar-code amplification, purification & quantification 
The shRNA bar-code sequences were amplified by nested PCR in order to decrease 
contamination with genomic DNA and to attach adapter sequences for high-throughput 
sequencing.  
For the 1st PCR, ~160-180 µg DNA from the input samples and the entire DNA from the 
sorted samples (~10-30 µg) were used as a template in the PCR reactions denoted 
below in Table 8, each containing maximal 25-30 µg DNA. As a positive control, 10 ng of 
the shRNA plasmid library were used. As a negative control, DNA was replaced with 
ddH2O. 
Table 8: Master mix and PCR program for the 1st PCR for shRNA bar-code amplification. 
Reaction mix per rnx [µL] PCR program  
10x PCR reaction buffer 5 1. 94°C, 3 min  
dNTPs (10 mM each) 1 2. 94°C, 30 s  
Primer FwdHTS (10 µM) 1.5 3. 65°C, 10 s  
Primer RevHTS1 (10 µM) 1.5 4. 72°C, 20 s → go to 2. for 16x 
DNA (max. 25-30 µg) 40.5 5. 68°C, 2 min  
Titanium Taq polymerase 0.5 6. 8°C, forever  
TOTAL 50   
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After the PCR reaction was finished, all reactions from the same sample were pooled 
and used directly (unpurified) as a template in the 2nd PCR reaction as indicated below in 
Table 9. For each sample, four separate reactions were performed using an optimized 
number of cycles to obtain equal bar-code amplification for all samples and to avoid the 
generation of PCR fusion products. 
Table 9: Master mix and PCR program for the 2nd PCR for shRNA bar-code amplification. 
Reaction mix per rnx [µL] PCR program  
10x PCR reaction buffer 5 1. 94°C, 3 min  
dNTPs (10 mM each) 1 2. 94°C, 30 s  
Primer FwdGex (10 µM) 2.5 3. 65°C, 10 s  
Indexing primer IndA-F  
(unique for each sample, 10 µM) 
2.5 4. 72°C, 10 s → go to 2. for 14-18x 
1st PCR reaction product 2 5. 68°C, 2 min  
ddH2O 36.5 6. 8°C, forever  
Titanium Taq polymerase 0.5   
TOTAL 50   
 
After the PCR reaction was finished, all reactions from the same sample were pooled 
and purified using a QIAquick PCR Purification Kit according to the manufacturer’s 
guidelines. Briefly, PCR products were mixed with buffer PB, bound to a spin column, 
washed with buffer PE, and eluted in 30 µL ddH2O. Purified PCR products were 
quantified by Qubit and stored at -20°C. 
2.5.7 High-throughput sequencing 
For high-throughput sequencing of shRNA bar-codes, purified PCR products were 
adjusted to a concentration of 10 nM, pooled equimolarly, and submitted to the DKFZ 
Genomics & Proteomics Core Facility for 50 bp single read Illumina HiSeq 2000 
sequencing. Before sequencing, the core facility performed quality control, quantification, 
and mixed the samples with 40% PhiX Control. Sequencing was done using 10 pmol per 
sample for cluster generation, 500 nM of the custom sequencing primer GexSeqS, and 
500 nM of the custom indexing primer GexSeqIND. The core facility provided 
demultiplexed FASTQ files for further analysis. 
2.5.8 Data analysis 
Data analysis was performed based on Slabicki et al.228. Raw sequencing reads were 
unzipped and trimmed to 18 bp in order to contain only the shRNA bar-codes using R. 
Bar-codes were quantified using the “Barcode Deconvoluter” software provided by 
Cellecta with a tolerance of one error and correction of N symbols. Details are given 
below in Table 10. 
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Table 10: Cell yield, DNA yield, and high-throughput sequencing statistics of shRNA screen samples. 
Replicate Sample # cells 
[x106] 
DNA [µg] # mapped 
reads 
# shRNAs 
detected 
reads/ 
shRNA 
1 Input 100 186.6 10,011,029 27,470 364 
1 p53 low 6.8 25.6 9,248,424 27,312 339 
1 p53 high 7.0 25.3 12,558,639 26,467 475 
2 Input 100 163.3 9,841,530 27,473 358 
2 p53 low 6.9 28.4 10,097,383 27,344 369 
2 p53 high 9.5 10.0 9,604,804 24,186 397 
 
shRNA bar-code counts were processed with R for further analysis. First, ten reads were 
added to all shRNAs to minimize the number of false positives in the low-abundance tail 
of the shRNA distribution229. Next, control shRNAs targeting luciferase or nine essential 
genes and shRNAs with a low abundance in the input samples (< 0.25 normalized reads 
and < 6 cpm) were deleted. After each sample was normalized, the dispersion was 
calculated and a negative binomial generalized log-linear model was fitted to the read 
counts using the R package “edgeR”230,231. For each shRNA, the fold change was 
calculated and used to determine robust z-scores (  = 	
	 ). P values were 
calculated with a likelihood ratio test, comparing p53-low or p53-high samples against 
the input samples, and adjusted for multiple testing by employing the Benjamini-
Hochberg method. To collapse all  shRNAs targeting the same gene  into a single 
score, weighted z-scores were calculated with the weighted z-transformation method232: 
() = ∑ ∗ ∑ ! , with " = (1 − %) 
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3 Results 
3.1 Characterization of p53 mutations and levels in Burkitt’s 
lymphoma 
To characterize the frequency of p53 mutation and the impact of mutations on protein 
accumulation in aggressive B-cell lymphoma, sequencing and protein expression data 
from the ICGC MMML-Seq consortium were analyzed (Figure 13A). 43% (n=29/67) of 
patients diagnosed with Burkitt’s lymphoma (BL) carried at least one mutation in p53. All 
mutations except one were found to be missense mutations located in the DNA-binding 
domain, including the typical hot spot mutations (i.e. R248, R273). Malignant lymphoma 
patient samples (p<0.0001) as well as BL patient samples (p<0.05) with p53 mutation 
showed higher p53 levels and therefore aberrant p53 stabilization compared to wild-type 
p53 patient samples (Figure 13B).  
To identify representative disease models, p53 levels were characterized in a panel of 
BL cell lines with either wild-type p53 (wtp53) or mutant p53 (mutp53) by intracellular 
flow cytometry. This allowed quantification of the protein accumulation and identification 
of populations with heterogeneous expression levels (Figure 13C). While cell lines 
retaining wtp53 showed a low basal p53 protein level, p53 levels were higher but also 
more variable in mutp53 cell lines, which is in line with the findings from BL patients 
(Figure 13B). In a subset of mutp53 cell lines (BL-41, BL-60, Yakobo), a heterogeneous 
pattern of p53 protein expression was observed, i.e. the population was a mixture of p53-
low and p53-high cells. Since all cell lines carried homozygous TP53 mutations, this 
heterogeneity was not caused by retention of a wild-type allele, but was rather 
suggestive of differences in the degradation of mutp53. 
To test whether p53 accumulation in BL cell lines with mutp53 was caused by TP53 
mRNA overexpression, qRT-PCR was performed which indicated no correlation of p53 
mRNA expression with protein expression (Figure 13D). All mutp53 BL cell lines except 
CA-46 were found to have low mRNA expression, suggesting a translational or post-
translational mechanism of mutp53 stabilization. 
  
Results   
 56
 
Figure 13: Characterization of p53 mutations and levels in Burkitt’s lymphoma (BL).  
(A) Frequency and distribution of p53 mutations in BL patients (n=67 or n=22, respectively). The DNA-
binding domain of p53 is highlighted. Data from the ICGC MMML-Seq consortium. (B) p53 protein 
expression (determined by tissue microarray) in malignant B-cell lymphoma (n=134) and BL (n=20) samples 
stratified by p53 mutation status. The score indicates the percentage of p53-positive cells (Table 5, p. 50). 
P values were determined by Student’s t-test. Data from the ICGC MMML-Seq consortium. (C) Basal p53 
protein expression in wtp53 and mutp53 BL cell lines determined by intracellular flow cytometry. The p53 
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mutations are specified. (D) Comparison of p53 mRNA (qRT-PCR) and protein (flow cytometry) expression 
in wtp53 and mutp53 BL cell lines. (E) Protein level of p53, MDM2, and MDM4 in BL cell lines stratified by 
p53 mutation status. Expression was determined by Western Blot. GAPDH, loading control. Experiment 
performed by Jennifer Hüllein and reprinted with permission from Hüllein201. (F) p53 flow cytometry of BL cell 
lines after treatment with 0.1% DMSO (grey) or 10 µM of the MDM2 inhibitor Nutlin-3a (red) for 24 h or 48 h. 
Values denote the ratio of the p53 median fluorescence intensity (MFI) between treated and control cells. 
Experiment performed jointly with Sophie Rabe. 
Since mutp53 stabilization in tumors may be caused by loss of expression of the E3 
ubiquitin ligase MDM265,81, the major negative regulator of p53, basal MDM2 protein 
expression was assessed (Figure 13E). MDM2 expression was confirmed in both wtp53 
and mutp53 cell lines, which suggests that mutp53 is stabilized despite the presence of 
MDM2. To evaluate whether mutp53 stabilization was caused by a functional defect in 
MDM2, BL cell lines were exposed to the MDM2 inhibitor Nutlin-3a and p53 levels were 
quantified by flow cytometry (Figure 13F). As expected, a ~6-8-fold increase in p53 was 
observed in the wtp53 cell line Seraphine upon Nutlin-3a exposure. In mutp53 cell lines, 
Nutlin-3a treatment also resulted in mild p53 stabilization (1.15-1.94-fold), albeit to 
variable extent.  
In summary, although part of the mutp53 population may still be subject to MDM2-
mediated degradation, the overall ability of endogenous MDM2 to promote mutp53 
degradation in BL appears to be markedly compromised. 
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3.2 shRNA screen for regulators of mutant p53 protein 
accumulation 
To identify proteins involved in the control of mutp53 accumulation in an unbiased 
fashion, a positive selection RNA interference (RNAi) screen with flow cytometry-based 
phenotype readout was performed in a mutp53 BL cell line model (Raji). The screening 
strategy is depicted in Figure 14 below.  
 
Figure 14: shRNA screening strategy for identification of regulators of mutant p53 protein 
accumulation. 
The mutp53 Burkitt’s lymphoma (BL) cell line Raji was transduced with a lentiviral shRNA library targeting 
~5,000 genes with 5-6 shRNAs each. After selection of transduced cells with puromycin and in total 8 d in 
culture, part of the cells was harvested as input control (“unsorted”, grey). The remaining cells were stained 
for their intracellular p53 levels and subjected to flow cytometry-based sorting in order to collect two distinct 
populations: p53-low (green) and p53-high cells (red), each representing ~15% of the total population. After 
sorting, the genomic DNA was extracted and the shRNA bar-codes were amplified and subjected to high-
throughput (HT) sequencing. Finally, hits were identified by using the weighted z-score method. The 
experiment was performed in technical duplicates. 
In brief, cells were transduced with a complex lentiviral shRNA library targeting ~5,000 
genes with 5-6 shRNAs per gene. Cells were infected with an efficiency of ~50% 
(MOI 0.7) in order to assure delivery of a single silencing trigger per cell in the majority of 
cells (Figure 15A). After eight days in culture, part of the cells was collected as input 
control. The remaining cells were stained for their intracellular p53 levels and subjected 
to flow cytometry-based sorting to collect two distinct populations: p53-low and p53-high 
cells, each representing ~15% of the bulk population. Reanalysis of the sorted 
populations indicated efficient sorting based on p53 levels without introduction of a size 
bias, i.e. p53-low cells were not smaller than p53-high cells as indicated by comparable 
forward/sideward scatter (FSC/SSC) properties (Figure 15B). After sorting, the genomic 
DNA was extracted from all populations and the bar-codes that uniquely correspond to 
every shRNA were amplified using nested PCR (Figure 15C,D). PCR products were then 
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subjected to high-throughput sequencing in order to determine and quantify the shRNAs 
contributing to the phenotype of both sorted populations. 
 
Figure 15: Performance and results of the shRNA screen. 
(A) Transduction efficiency (%RFP+ cells) of shRNA library-transduced cells 3 d post-transduction as 
determined by flow cytometry. (B) Reanalysis of cell size/granularity (FSC/SSC) and p53 levels of sorted 
populations by flow cytometry. Values denote the p53 median fluorescence intensity (MFI) normalized to 
input. (C) Agarose gel electrophoresis of PCR-amplified shRNA bar-codes. (D) Quality control (TapeStation) 
of the high-throughput sequencing library of shRNA bar-codes before sequencing. (E) Reproducibility of 
technical replicates. For each sample pair, raw read counts were log2-transformed and plotted against each 
other. The Pearson correlation coefficient (r) is indicated. (F) Distribution of the gene level z-score (top three 
shRNAs) for all genes targeted in the screen (black) and for genes classified as “constitutive core essentials” 
(CCE, red) or non-essential (NE, green) based on Hart et al.233. (G) Distribution of weighted z-scores for all 
genes targeted in the screen, comparing the p53-low population or the p53-high population with the input. 
Boxes highlight the top ten or bottom ten genes, respectively. 
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To assess the initial quality of the screen data, the shRNA bar-code counts in technical 
replicates of all samples were correlated, which showed that measurements were 
reproducible (Pearson correlation r=0.53-0.87, Figure 15E). As expected, essential 
genes (as defined by Hart et al.233) were depleted in the input samples compared to the 
initial plasmid library (Figure 15F). Notably, cyclin-dependent kinase 6 (CDK6) was the 
second most depleted gene (data not shown) and has been reported previously to be 
essential in BL163.  
To identify screen hits, the weighted z-score method was used, which combined all 
shRNAs targeting the same gene into a single score. Using this method, only genes 
targeted by multiple enriched shRNAs were assigned a high score, while genes targeted 
by a single enriched shRNA got a low score. Weighted z-scores (wZ) were calculated for 
both populations, p53-low and p53-high cells, by comparing them against the input 
sample in separate analyses (Figure 15G). Importantly, TP53 was the top scoring hit 
(rank 1/5033, wZ = 6.38) in the p53-low population and the most depleted gene in the 
p53-high population (rank 5033/5033, wZ = -6.21), validating the feasibility of the 
experimental approach. The focus was put on genes behaving in a similar fashion as 
p53 (enriched in one population while depleted in the other population). Among the top 
ten genes in both populations, TRRAP (transformation/transcription domain-associated 
protein) was the only candidate meeting these very stringent criteria (Figure 15G), of 
both strong enrichment in the p53-low population (rank 2/5033, wZ = 5.24) and depletion 
in the p53-high population (rank 5026/5033, wZ = -4.97). Therefore, TRRAP was chosen 
for further validation and investigation. 
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3.3 TRRAP regulates mutant p53 levels across entities and p53 
mutations 
TRRAP (transformation/transcription domain-associated protein) is a member of the 
phosphatidylinositol 3-kinase-related kinase (PIKK) family234-236, which includes well-
characterized p53 regulators such as ATM, ATR, and DNA-PKcs. As a common 
component of multiple histone acetyltransferase (HAT) complexes, TRRAP’s main 
function is the recruitment of HATs to chromatin during transcription and DNA repair237. 
To confirm the impact of TRRAP silencing on mutp53 levels, the two top scoring shRNAs 
from the RNAi screen were studied. shRNAs were packaged into lentiviral particles and 
transduced into a mutp53 BL cell line (Namalwa). Both silencing triggers caused strong 
downregulation of TRRAP on both mRNA and protein level (Figure 16A,B). While a 
depletion of mutp53 protein to 20-50% of the basal level was observed upon TRRAP 
knock-down (Figure 16B), no changes of TP53 mRNA levels were found (Figure 16A), 
suggesting that TRRAP regulates mutp53 on a translational or post-translational level. 
To validate these findings, TRRAP was knocked-down in additional mutp53 BL cell lines 
with different p53 mutations and p53 levels were quantified by flow cytometry. TRRAP 
silencing resulted in mutp53 depletion in all seven tested BL cell lines, regardless of their 
kind of p53 mutation (Figure 16C, red). However, the extent of downregulation was 
variable. For example, an almost complete loss of mutp53 was observed in Namalwa 
cells after TRRAP knock-down, while only a subpopulation of cells lost mutp53 in CA-46. 
Next, it was tested whether silencing of TRRAP would also impair mutp53 accumulation 
in diffuse large B-cell lymphoma (DLBCL). TRRAP knock-down caused mutp53 
downregulation to 32-36% of the basal level in SU-DHL4 (Figure 16C, green). To study 
whether TRRAP's role in mutp53 regulation would be limited to lymphoma, TRRAP was 
silenced in the colorectal cancer (CRC) cell line Colo320, which caused a phenotype 
comparable to BL and DLBCL, i.e. mutp53 downregulation to 41-78% of the basal level 
(Figure 16C, blue). These data suggest that TRRAP regulates mutp53 levels across a 
diverse set of cancers. To confirm the RNAi effects with an independent technique, 
TRRAP was knocked out in Namalwa-Cas9 BL cells via CRISPR/Cas9 genome editing 
(Figure 16D). In agreement with the previous results, TRRAP knock-out resulted in 
depletion of mutp53 to 51-67% of the basal level. 
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Figure 16: TRRAP silencing depletes mutant p53 across entities and p53 mutations. 
(A) mRNA level of TRRAP and TP53 in Namalwa cells transduced with shRNAs against TRRAP and p53. 
Cells were selected with puromycin for 48 h and harvested 3 d post-transduction. Expression values were 
determined by qRT-PCR and normalized to GAPDH and to cells transduced with a non-targeting shRNA 
(NT). (B) Protein level of TRRAP and p53 in Namalwa cells transduced with shRNAs against TRRAP and 
p53. Cells were selected with puromycin for 48 h and harvested 7 d post-transduction. Expression was 
determined by Western Blot and normalized to GAPDH and to cells transduced with a non-targeting shRNA 
(NT). (C) p53 flow cytometry 7 d or 8 d after shRNA-mediated knock-down of TRRAP in different mutp53 
cancer cell lines: Burkitt’s lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and colorectal cancer 
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(CRC). For each cell line, the p53 mutation is specified. Values denote the ratio of the p53 median 
fluorescence intensity (MFI) between transduced (red) and untransduced cells (grey). shNT, non-targeting 
shRNA. (D) p53 flow cytometry 7 d after sgRNA-mediated knock-out of TRRAP in Namalwa-Cas9 cells. 
Values denote the ratio of the p53 median fluorescence intensity (MFI) between transduced (red) and 
untransduced cells (grey). sgmCherry, negative control. Experiment performed by Marius Jentzsch. 
(E) Depletion of TRRAP-silenced BL cells over time. BL cells were transduced with two independent shRNAs 
against TRRAP and the proportion of transduced cells (RFP+) was followed over time by flow cytometry. 
Depletion of transduced cells is shown as log2 fold change (FC) normalized to d 4 after transduction. Red, 
mutp53 BL; green, wtp53 BL. (F) Depletion of TRRAP knock-out Namalwa-Cas9 mutp53 BL cells over time. 
Cells were transduced with two independent sgRNAs against TRRAP and the proportion of transduced cells 
(APC+) was followed over time by flow cytometry. Depletion of transduced cells is shown as log2 fold 
change (FC) normalized to d 4 after transduction. sgmCherry, negative control. Experiment performed by 
Marius Jentzsch. 
To investigate whether interfering with TRRAP expression would impact cell proliferation 
and to test a potential p53 dependency, cell growth competition assays were performed. 
BL cell lines were transduced at an efficiency of ~50% with fluorescently-labeled shRNAs 
(Figure 16E) or sgRNAs (Figure 16F) against TRRAP and the proportion of transduced 
cells was followed over time by flow cytometry. In all cases, the transduced cells were 
outgrown by their untransduced counterparts, indicating that interfering with TRRAP 
expression impaired cell growth. Notably, TRRAP silencing equally affected cell growth 
in mutp53 and wtp53 BL cells. 
In summary, these results suggest that TRRAP is a regulator of mutp53 levels 
independent of cancer entity and p53 mutation. In addition, TRRAP appears to be crucial 
for cell growth in both mutp53 and wtp53 cells. 
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3.4 TRRAP overexpression increases mutant p53 levels 
To further understand the role of TRRAP in regulating mutp53 levels, the impact of 
TRRAP overexpression on mutp53 accumulation was tested. These experiments were 
performed in the CRC cell line Colo320 since the TRRAP overexpression construct was 
too large for lentiviral packaging (17 kb) and satisfactory transfection efficiencies could 
not be achieved in the BL cell lines. Transfection of FLAG-TRRAP resulted in 
upregulation of TRRAP but not TP53 mRNA (Figure 17A), which translated into mild 
upregulation of TRRAP protein compared to untransfected cells (Figure 17B). 
Importantly, p53 flow cytometry showed that TRRAP overexpression resulted in an 
increased level of mutp53 (Figure 17C). Finally, in order to prove the on-target effect of a 
previously used shRNA against TRRAP (shTRRAP_233, Figure 16), TRRAP silencing 
was performed in the context of TRRAP overexpression, which resulted in a rescue of 
the p53 phenotype to basal levels (Figure 17D). In summary, these findings are in strong 
support of the silencing and knock-out experiments (Figure 16) and thus provide further 
evidence that TRRAP regulates mutp53 levels. 
 
Figure 17: TRRAP overexpression increases mutant p53 levels. 
(A) mRNA level of TRRAP and TP53 in Colo320 cells 48 h post-transfection with FLAG-TRRAP using 
different amounts of transfection reagent (Lipofectamine). Expression values were determined by qRT-PCR 
and normalized to GAPDH and to untransfected cells. (B) Protein level of TRRAP and p53 in Colo320 cells 
48 h post-transfection with FLAG-TRRAP using different amounts of transfection reagent (Lipofectamine). 
Expression was determined by Western Blot and normalized to GAPDH and to untransfected cells. (C) p53 
flow cytometry 72 h post-transfection with FLAG-TRRAP in Colo320 cells. Values denote the ratio of the p53 
median fluorescence intensity (MFI) between transfected (red) and untransfected cells (grey). (D) Molecular 
rescue of the TRRAP knock-down phenotype by FLAG-TRRAP overexpression in Colo320 cells. Cells were 
transduced with either a non-targeting shRNA (shNT, grey) or with an shRNA against TRRAP (blue). 24 h 
after transduction, part of the TRRAP-silenced cells was transfected with FLAG-TRRAP (red). Cells were 
analyzed by p53 flow cytometry 4 d after transduction. Values denote p53 median fluorescence intensities 
(MFI) normalized to cells transduced with the NT. 
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3.5 Investigation of the physical interaction of TRRAP and 
mutant p53 
Previous studies showed that mutp53 can be stabilized by the binding of chaperones 
such as Hsp9083. Since TRRAP has been reported to bind to wtp53238, it was explored 
whether TRRAP stabilized mutp53 via physical interaction. To this end, the p53-null cell 
line H1299 was used and both FLAG-tagged TRRAP (Figure 17) and mutp53 (mutation 
R175H) were introduced by transfection (Figure 18A). Immunoprecipitation (IP) of both 
FLAG-TRRAP and mutp53 resulted in co-IP of mutp53 or TRRAP, respectively, 
indicating binding of TRRAP to mutp53.  
To address whether TRRAP bound preferentially to mutp53 compared to wtp53, FLAG-
TRRAP was transfected together with either mutp53 or wtp53 in H1299 cells 
(Figure 18B). FLAG-TRRAP IP resulted in stronger co-IP of mutp53 than wtp53, 
suggesting enhanced binding of TRRAP to mutp53. Notably, TRRAP also bound to a 
truncated form of wtp53, which lacked the 40 N-terminal amino acids (∆N in Figure 18B), 
suggesting that TRRAP binds p53 outside of its N-terminus. 
To confirm these results in an endogenous setting, the experiment was repeated in 
mutp53 BL cells (Figure 18C). However, in contrast to the previous results in the 
exogenous system, neither IP of p53 nor IP of TRRAP resulted in co-IP of the respective 
other protein. Notably, mutp53 co-immunoprecipitated with MDM2.  
In summary, this suggests that TRRAP may not bind to mutp53 in BL, indicating that 
mutp53 is unlikely to be stabilized by physical interaction with TRRAP. 
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Figure 18: Investigation of the binding of TRRAP to mutant p53 and MDM2 by immunoprecipitation. 
(A) Western Blot after immunoprecipitation of FLAG and p53 48 h after transfection of p53-null H1299 cells 
with FLAG-TRRAP and mutp53 (R175H). *, unspecific band; ►, specific band; GAPDH, loading control. 
(B) Western Blot after FLAG immunoprecipitation 24 h after transfection of p53-null H1299 cells with FLAG-
TRRAP and different p53 constructs: mutp53 (R175H), wtp53, and ∆Np53 lacking the first 40 amino acids. 
GAPDH, loading control. (C) Western Blot after immunoprecipitation of mutp53 and TRRAP in Namalwa 
mutp53 BL cells. 419, anti-SV40 T-antigen mouse (negative control for IP p53); IgG, normal goat IgG 
(negative control for IP TRRAP); exp., exposure time; GAPDH, loading control. 
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3.6 TRRAP silencing exports mutant p53 from the nucleus to 
the cytosol 
To obtain a global view on the alterations in protein expression and mutp53-interacting 
proteins upon TRRAP silencing, total proteome and mutp53 immunoprecipitates (IPs) 
were quantified by mass spectrometry after TRRAP or control knock-down in mutp53 BL 
cells (Figure 19A). Flow cytometry indicated that mutp53 protein was depleted in a time-
dependent manner upon TRRAP silencing (Figure 19B). Accordingly, mass spectrometry 
of the total proteome samples showed that both TRRAP and mutp53 protein were 
depleted upon TRRAP silencing (Figure 19C). In total, TRRAP knock-down significantly 
altered the expression of 44 proteins (23 down-, 21 upregulated, adj. p<0.05 & 
|log2FC|>0.5; Figure 19D), suggesting that the TRRAP-dependent mutp53 degradation 
was relatively specific. Gene set enrichment analysis showed that TRRAP silencing 
suppressed mTOR signaling and MYC targets, while it induced interferon signaling 
(Figure 19E). 
To identify mutp53 binding partners in each condition (control or TRRAP knock-down, 
Figure 19A), the focus was set on proteins significantly enriched in p53 IPs compared to 
IgG control IPs. Overall, 37 proteins binding to mutp53 were found across all samples 
(Figure 19F), which were significantly enriched for previously reported p53 interactors239 
(Figure 19G, 8/37, 21.6%, p=0.0002, hypergeometric test). For example, the protein 
methyltransferase CARM1 has been shown to physically interact with p53 and to 
regulate p53-dependent transcription via histone methylation240.    
To quantify changes upon TRRAP knock-down, mutp53-bound proteins in TRRAP-
silenced samples were compared to proteins in control knock-down samples 
(Figure 19G). TRRAP silencing induced major alterations in mutp53-binding proteins, 
which could be categorized into 2 classes: (1) 18 mutp53 interactors lost upon TRRAP 
knock-down and (2) 19 interactors gained upon TRRAP silencing. To gain insights into 
the molecular function of the proteins in both categories, gene set enrichment analysis 
was performed (Figure 19H). Proteins recruited to mutp53 upon TRRAP silencing were 
significantly enriched for functions related to translational initiation. Accordingly, seven of 
the thirteen subunits of the eukaryotic translation initiation factor 3 (eIF3) were found in 
this group (EIF3E,F,G,H,I,L,M). In contrast, proteins lost upon TRRAP knock-down 
mainly participated in mRNA biogenesis. In fact, six members of the spliceosome were 
detected in this group (SF3A1, SF3B1, SF3B2, HNRNPA0, HNRNPC, HNRNPDL).  
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Figure 19: TRRAP silencing exports mutant p53 from the nucleus to the cytosol. 
(A) Experimental design. Namalwa mutp53 BL cells were transduced with an IPTG-inducible shRNA against 
TRRAP or a non-targeting control (NT). 48 h or 96 h after induction, cells were lysed and either collected 
immediately (total protein) or subjected to immunoprecipitation with antibodies against p53 or IgG (negative 
control) before mass spectrometry. The experiment was performed in biological triplicates. (B) p53 flow 
cytometry of Namalwa cells 48 h or 96 h after IPTG induction of an shRNA against TRRAP or non-targeting 
control (NT). Values denote p53 median fluorescence intensities (MFI) normalized to cells transduced with 
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the NT. (C) Normalized enrichment of p53 and TRRAP protein in mass spectrometry samples. Grey bars 
indicate mean intensity values. Analysis performed by Arne Smits. (D) Volcano plots for differential total 
protein expression 96 h (right) after TRRAP knock-down in Namalwa cells, normalized to a non-targeting 
control (NT). Proteins denoted in black were significantly differentially expressed (adj. p < 0.05, 
|log2FC| > 0.5). p53 is highlighted in red. P values were calculated using moderated t-statistic (R package 
“limma”221) and adjusted for multiple testing using the Benjamini-Hochberg procedure. Analysis performed by 
Arne Smits. (E) Gene set enrichment analysis of significantly differentially expressed genes from panel D. 
Upregulated gene sets are denoted in red, downregulated in green. Analysis was performed using 
Parametric Analysis of Gene Set Enrichment (PAGE)213 with the MSigDB214 gene set collection 
“Hallmark”215. Only significantly altered gene sets are shown (adj. p < 0.05). (F) Venn diagram showing the 
overlap of mutp53-bound proteins (proteins significantly enriched in p53 IPs compared to IgG control IPs) 
after control or TRRAP knock-down. Analysis performed by Frank Stein. (G) Heatmap of all mutp53-bound 
proteins from panel F. Values denote hierarchically clustered log2 fold changes of protein abundances in 
TRRAP-silenced samples compared to control knock-down samples. The cellular localization241 and known 
p53 interactions239 are indicated, XPO1 is highlighted with an arrow (◄). Analysis performed by Frank Stein. 
(H) Gene set enrichment analysis of proteins contained within each cluster from panel G. Gene sets from 
interactors gained are denoted in orange, gene sets from interactors lost in blue, respectively. Analysis was 
performed using Enrichr198,199 with “GO Biological Process 2017” data set. Values indicate enrichment 
scores. Only annotations with an enrichment score >20 are shown. (I) Rescue of the TRRAP silencing-
mediated mutp53 depletion by treatment with nuclear export inhibitors. Namalwa cells were transduced with 
an IPTG-inducible shRNA against TRRAP or a non-targeting control (NT). 48 h after induction, cells were 
treated with DMSO (0.005%), Leptomycin B (20 nM), Selinexor (500 nM), or Verdinexor (500 nM) for 14 h 
before they were subjected to p53 flow cytometry. Values denote p53 median fluorescence intensities (MFI) 
normalized to DMSO-treated cells transduced with the NT. 
Since mRNA splicing takes place in the nucleus and translation in the cytoplasm, the 
cellular localization of all mutp53-interacting proteins lost and gained upon TRRAP 
knock-down was annotated241 (Figure 19G). While the vast majority of the former 
proteins were annotated to be localized in the nucleus (16/18, 88.9%), the latter proteins 
were mainly reported to be in the cytosol (18/19, 94.7%). Importantly, exportin 1 
(XPO1/CRM1), the key protein for facilitating protein export from the nucleus to the 
cytosol, was among the proteins recruited to mutp53 after TRRAP knock-down (red in 
Figure 19G). Therefore, it was hypothesized that mutp53 was exported from the nucleus 
to the cytosol upon TRRAP knock-down and that the export was a prerequisite for 
mutp53 degradation. To test this, TRRAP was silenced in the context of the nuclear 
export inhibitors Leptomycin B, Selinexor, and Verdinexor (all targeting XPO1/CRM1) 
and mutp53 levels were quantified by flow cytometry (Figure 19I). Treatment with the 
inhibitors resulted in mild mutp53 upregulation (1.44-1.79-fold) in control knock-down 
samples. TRRAP silencing resulted in a mutp53 downregulation to 23% of the basal 
level, which was rescued to full extent by co-treatment with all nuclear export inhibitors. 
In summary, this suggests that nuclear export is required to mediate TRRAP effects on 
mutp53 levels. Thus, TRRAP may stabilize mutp53 by retaining it in the nucleus. 
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3.7 TRRAP silencing destabilizes mutant p53 via the MDM2-
proteasome axis 
The nuclear export and cytosolic degradation of mutp53 observed upon TRRAP 
silencing (Figure 19) were evocative of the final steps of physiological wtp53 
degradation, where these steps are mediated by MDM2 and the proteasome31,37,38. 
Therefore, the involvement of the MDM2-proteasome axis in the degradation of mutp53 
after TRRAP knock-down was tested. To this end, TRRAP was silenced in the context of 
the MDM2 inhibitor Nutlin-3a and p53 levels were quantified by flow cytometry 
(Figure 20A). While TRRAP knock-down alone reduced the mutp53 level to 17% of the 
basal level, co-treatment with Nutlin-3a was able to fully rescue the phenotype. 
To confirm these findings with an independent technique, MDM2 knock-out cells were 
generated by transducing Namalwa-Cas9 cells with sgRNAs targeting either MDM2 or 
GFP (negative control) (Figure 20B). Efficient cutting of the correct genomic locus was 
confirmed by T7E1 assay, which indicated indel formation in MDM2 exon 2 in case of 
sgMDM2-transduced cells. Notably, a minor subpopulation still retained the uncut wild-
type MDM2 allele. In support of the previous findings, mutp53 depletion upon TRRAP 
silencing was almost completely rescued in cells harboring MDM2 knock-out but not in 
control cells. The small subpopulation of MDM2 knock-out cells which still showed 
mutp53 downregulation most likely retained MDM2 expression as already indicated by 
the T7E1 assay. 
Although mutp53 was stabilized despite the presence of MDM2 (Figure 13E), it has been 
reported that MDM2 overexpression can cause degradation of mutp5335. Therefore, 
MDM2 expression was investigated after TRRAP knock-down (Figure 20C,D). While 
TRRAP silencing caused mild upregulation (1.54-1.66-fold) of MDM2 protein in wtp53 
cells, MDM2 mRNA and protein expression were slightly reduced (0.76-0.82-fold) after 
TRRAP knock-down in mutp53 cells. This suggests that mutp53 destabilization upon 
TRRAP silencing is not caused by increased MDM2 expression. 
Given the fact that MDM2 typically drives proteasomal degradation of p53, the role of the 
proteasome in TRRAP-driven mutp53 degradation was investigated. To this end, TRRAP 
was silenced in the context of the proteasome inhibitor Bortezomib and p53 levels were 
quantified by flow cytometry (Figure 20E). Bortezomib treatment resulted in mild mutp53 
upregulation (1.20-fold) in control knock-down samples. TRRAP silencing resulted in a 
reduction of mutp53 expression to 59% of the basal level, which was rescued to full 
extent by proteasome inhibition. 
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In summary, these results suggest that TRRAP silencing targets mutp53 to the 
physiological MDM2-dependent wtp53 degradation machinery, including nuclear export 
followed by proteasomal degradation. 
 
Figure 20: TRRAP silencing destabilizes mutant p53 via the MDM2-proteasome axis. 
(A) Rescue of the TRRAP silencing-mediated mutp53 degradation by treatment with the MDM2 inhibitor 
Nutlin-3a. Namalwa cells were transduced with an shRNA against TRRAP or a non-targeting control (NT). 
4 d after transduction, cells were treated with DMSO (0.1%) or Nutlin-3a (10 µM) for 48 h before they were 
subjected to p53 flow cytometry. Values denote p53 median fluorescence intensities (MFI) normalized to 
DMSO-treated cells transduced with the NT. (B) Rescue of the TRRAP silencing-mediated mutp53 
degradation by CRISPR/Cas9-mediated knock-out of MDM2. Knock-out cells were transduced with an 
shRNA against TRRAP or a non-targeting control (NT) and subjected to p53 flow cytometry 4 d after 
transduction (left). Values denote p53 median fluorescence intensities (MFI) normalized to GFP knock-out 
cells transduced with the NT. In order to generate knock-outs, Namalwa cells were transduced with 
constructs harboring both Cas9 and sgRNAs against MDM2 or GFP (negative control). After selection with 
multiple rounds of puromycin, targeting of the appropriate MDM2 locus (exon 2) was monitored by T7E1 
assay (right). The wild-type allele is indicated with an arrow (◄). (C) mRNA level of TRRAP and MDM2 in 
Namalwa cells transduced with shRNAs against TRRAP or a non-targeting control (NT). Cells were selected 
with puromycin for 48 h and harvested 3 d post-transduction. Expression values were determined by qRT-
PCR and normalized to GAPDH and to cells transduced with the NT. (D) Protein level of MDM2 in Namalwa 
(mutp53) and Seraphine (wtp53) cells transduced with shRNAs against TRRAP, p53, and a non-targeting 
control (NT). Cells were selected with puromycin for 48 h and harvested 6 d post-transduction. Expression 
was determined by Western Blot and normalized to GAPDH and to cells transduced with the NT. (E) Rescue 
of the TRRAP silencing-mediated mutp53 degradation by treatment with the proteasome inhibitor 
Bortezomib. Namalwa cells were transduced with an IPTG-inducible shRNA against TRRAP or a non-
targeting control (NT). 24 h after induction, cells were treated with DMSO (0.1%) or Bortezomib (100 nM) for 
14 h before they were subjected to p53 flow cytometry. Values denote p53 median fluorescence intensities 
(MFI) normalized to DMSO-treated cells transduced with the NT. 
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3.8 TRRAP silencing induces interferon signaling and 
suppresses cell cycle-related genes 
To investigate TRRAP-mediated transcriptome changes on a global scale and a potential 
p53-dependence, microarray-based gene expression profiling after TRRAP silencing 
was performed in BL cell lines with mutp53, wtp53, or p53 knock-out (Figure 21A). While 
the number of significantly deregulated genes was comparable between the mutp53 and 
wtp53 cell line (614 vs. 680), less genes were altered in the p53KO line (495). When the 
overlap of differentially expressed genes between cell lines was calculated (Figure 21B), 
it was found that a small subset of genes (89/1224, 7.3%) was shared among all cell 
lines. To investigate this further and to reveal expression patterns, hierarchical clustering 
was performed, which showed that genes clustered in two different groups (Figure 21C): 
(1) 43 genes (48.3%) upregulated and (2) 46 genes (51.7%) downregulated in all cell 
lines. The expression pattern of these clusters was similar in all cell lines, indicating that 
TRRAP-dependent expression of these genes was not affected by p53 status. 
To gain insights into the molecular function, gene set enrichment analyses was 
performed for the genes within the two major clusters (Figure 21D). Genes 
downregulated upon TRRAP knock-down were enriched for functions related to the cell 
cycle and included for example CDC20, CCNA2, and CCNB2 (Figure 21C). Genes 
upregulated upon TRRAP silencing mainly participated in interferon signaling and 
included for example ISG15, IRF9, and STAT1 (Figure 21C,D), which is in line with the 
results from mass spectrometry (Figure 19E). Since interferon (IFN) beta can regulate 
mutp53 levels203, the role of IFN signaling in TRRAP-mediated mutp53 degradation was 
investigated. First, qRT-PCR of two IFN signaling pathway members (ISG15 and MX1) 
was performed in the context of TRRAP silencing to validate the transcriptome data 
(Figure 21E). The expression of both genes was increased ~2-4-fold upon TRRAP 
knock-down, which was suppressed in the presence of the JAK/STAT inhibitor 
Ruxolitinib given that JAK/STAT is the main node of the IFN signaling pathway242. Next, 
the impact of IFN alpha treatment on mutp53 levels was quantified by flow cytometry 
(Figure 21F), which showed a mild depletion of mutp53 to 83% of the basal levels that 
was salvaged by co-treatment with Ruxolitinib. Finally, to address whether IFN signaling 
contributed to TRRAP-driven mutp53 degradation, TRRAP was silenced in the context of 
Ruxolitinib and mutp53 levels were quantified by flow cytometry (Figure 21G). Ruxolitinib 
treatment did not rescue mutp53 depletion upon TRRAP knock-down, indicating that 
mutp53 regulation by TRRAP is not mediated via IFN signaling. 
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Figure 21: TRRAP silencing induces interferon signaling and suppresses cell cycle-related genes. 
(A) Volcano plots for differential gene expression 8 d after TRRAP knock-down in Namalwa (mutp53), 
Seraphine (wtp53), and Seraphine p53KO cells, normalized to a non-targeting control (NT). Numbers denoted 
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in blue or red indicate the number of genes significantly down- or upregulated, respectively (adj. p < 0.05, 
|log2FC| > 1). (B) Venn diagram showing the overlap of significantly differentially expressed genes after 
TRRAP knock-down from panel A. (C) Heatmap of the 89 significantly differentially expressed genes upon 
TRRAP knock-down shared between all cell lines from panel B. log2 fold changes were subjected to 
hierarchical clustering. Genes part of interferon signaling (R-HSA-909733) or cell cycle (R-HSA-69278) are 
indicated (Reactome)243 and TRRAP is highlighted with an arrow (◄). (D) Gene set enrichment analysis of 
genes within the two major clusters from panel C. Upregulated gene sets are denoted in orange, 
downregulated in blue, respectively. Analysis was performed using Enrichr216,217 with the “GO Biological 
Process 2017” data set. Values indicate enrichment scores. Only annotations with an enrichment score >30 
are shown. (E) mRNA level of type I interferon signaling pathway members in Namalwa cells 96 h after IPTG 
induction of an shRNA against TRRAP. Part of the cells was treated for 24 h with the JAK/STAT inhibitor 
Ruxolitinib (Rux, 2 µM). Expression values were determined by qRT-PCR and normalized to GAPDH and to 
cells transduced with a non-targeting shRNA (NT). (F) p53 flow cytometry of Namalwa cells (non-targeting 
control (NT) transduced) after treatment for 24 h with interferon alpha alone (IFNa, 1,000 U/mL) or IFNa 
together with the JAK/STAT inhibitor Ruxolitinib (Rux, 2 µM). Values denote p53 median fluorescence 
intensities (MFI) normalized to DMSO-treated cells (0.1%). (G) No rescue of the TRRAP silencing-mediated 
mutp53 degradation by treatment with the JAK/STAT inhibitor Ruxolitinib (Rux). Namalwa cells were 
transduced with an IPTG-inducible shRNA against TRRAP or a non-targeting control (NT). 72 h after 
induction, cells were treated with DMSO (0.1%) or Ruxolitinib (2 µM) for 24h before they were subjected to 
p53 flow cytometry. Values denote p53 median fluorescence intensities (MFI) normalized to DMSO-treated 
cells transduced with the NT. 
In summary, this suggests TRRAP silencing induces an IFN response, which is 
unrelated to its effect on mutp53 levels. In basal conditions, TRRAP maintains a cell 
cycle-related transcriptional program independent of p53 status. 
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3.9 Identification of TRRAP’s domain crucial for mutant p53 
stabilization and cell survival 
To identify functional regions of TRRAP important for mutp53 stabilization and to assess 
whether TRRAP’s role for cell survival (Figure 16E,F) was mediated by independent 
domains, a recently developed CRISPR/Cas9 mutagenesis approach (“CRISPR 
scanning”) was used, which was designed to identify functionally relevant protein 
domains223. CRISPR/Cas9 induces DNA double-strand breaks at its target locus, which 
is specified by the small guide RNA (sgRNA)195,244. When targeted to protein-coding 
genes, error-prone repair mechanisms can cause both frameshift mutations (i.e. deletion 
of 1,2,4,... bp) and single amino acid deletions (i.e. deletion of 3,6,9,... bp)195,245. CRISPR 
scanning is based on the fact that while in domains irrelevant for the protein function only 
frameshift mutations will be detrimental, in domains crucial for the protein function both 
mutations causing frameshifts and single amino acid deletions will be harmful. Therefore, 
cells transduced with sgRNAs targeting functionally important protein domains will be 
more quickly outcompeted by untransduced cells than cells infected with sgRNAs 
targeting irrelevant protein domains223. 
For CRISPR scanning, Namalwa-Cas9 cells were transduced with an efficiency of ~25% 
with fluorescently-tagged sgRNAs spanning the entire TRRAP protein, including all 
annotated domains and the N-terminal HEAT repeat region. The proportion of 
transduced cells and mutp53 levels were monitored over time by flow cytometry 
(Figure 22A). As expected for an essential protein and in agreement with previous 
results (Figure 16E,F), cells transduced with any sgRNA targeting TRRAP were 
outcompeted by their untransduced counterparts. Targeting of a 109 aa region (residues 
1050-1158) within TRRAP’s HEAT repeat region (HEAT repeats 21/22)246 resulted in 
significantly stronger depletion of transduced cells (mean: 15.9-fold vs. 3.5-fold, p<0.05) 
and p53 protein (3.7-fold vs. 1.5-fold, p<0.05) than targeting of any other domain of 
TRRAP (yellow in Figure 22A,B). Notably, targeting of a region in TRRAP previously 
reported to be important for wtp53 binding238 was neither severely toxic nor caused 
strong mutp53 depletion. Interestingly, a strong linear correlation between cell depletion 
and mutp53 depletion was observed (Pearson correlation coefficient r=0.73, Figure 22C), 
indicating that TRRAP’s ability to support cell survival and to regulate mutp53 levels are 
tightly linked and potentially mediated by the same region. Finally, to validate the cell 
survival function of the newly identified TRRAP domain, it was targeted with two sgRNAs 
in five additional BL cell lines, which again caused a strong depletion of transduced cells 
over time compared to controls (Figure 22D). 
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Figure 22: CRISPR scanning to identify TRRAP’s domain mediating mutant p53 stabilization and cell 
survival. 
(A) Namalwa-Cas9 cells were transduced with sgRNAs targeting different regions of TRRAP protein, 
including all annotated domains. The proportion of transduced cells (APC+) and p53 levels were quantified 
by flow cytometry over time. Negative cell selection (top, cyan) and mutp53 depletion (bottom, red) is shown 
as fold depletion of transduced cells or mutp53 protein after 21 d or 7 d in culture, respectively. Every bar 
represents an independent sgRNA and the location of each sgRNA relative to TRRAP protein is indicated 
along the x-axis. P values were determined by Student’s t-test (* indicates P < 0.05). Domain “X” is 
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highlighted in yellow. Pro, Proline-rich region; NLS, nuclear localization signal; wtp53-binding, wtp53-binding 
region; FAT, focal adhesion targeting domain; FRB, FKBP12-rapamycin binding domain; PI3K, 
phosphatidylinositol 3-kinase domain; PRD, PIKK regulatory domain; FATC, FRAP, ATM, TRRAP C-terminal 
domain. Experiment performed by Marius Jentzsch. (B) p53 flow cytometry 7 d after TRRAP knock-out in 
Namalwa-Cas9 cells. TRRAP sgRNAs (X1-4) are highlighted in yellow in panel A. Values denote the ratio of 
the p53 median fluorescence intensity (MFI) between transduced (red) and untransduced cells (grey). 
sgGFP, negative control; sgTP53, positive control. Experiment performed by Marius Jentzsch. 
(C) Correlation of toxicity (APC depletion) and mutp53 protein depletion after TRRAP knock-out using 
sgRNAs targeting different protein domains. Each data point represents a single sgRNA from panel A. 
Colors indicate the targeted domains. The Pearson correlation coefficient (r) is indicated. (D) Heatmap 
showing negative selection of TRRAP sgRNA-transduced BL cell lines. Values indicate log2 fold depletion of 
transduced cells after 24 d in culture. sgGFP & sgmCherry, negative controls; sgPLK1, positive control. 
Experiment performed by Vineet Dalal. (E) p53 flow cytometry 7 d and 10 d after knock-out of essential 
genes in Namalwa-Cas9 cells. Values denote the ratio of the p53 median fluorescence intensity (MFI) 
between transduced (red) and untransduced cells (grey). sgmCherry, negative control. Experiment 
performed by Marius Jentzsch. 
 
To address whether mutp53 depletion upon TRRAP knock-out would be an unspecific 
side effect caused by cellular stress or toxicity, three essential genes (RPA3, SF3B4, 
KPNB1) were targeted by CRISPR/Cas9 and mutp53 levels were quantified by flow 
cytometry (Figure 22E). None of the knock-outs caused a consistent reduction of mutp53 
levels, suggesting that the degradation of mutp53 upon TRRAP ablation is not due to 
general toxicity. 
In summary, these results indicate that TRRAP’s amino acids 1050-1158 represent a 
novel functional domain crucial for promoting both cell survival and mutp53 stabilization. 
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3.10 TRRAP silencing attenuates stabilization and activity of 
wild-type p53 upon genotoxic stress 
Proteins stabilizing mutp53 have been reported to also chaperone wtp53, as for example 
Hsp9083,247. To explore a potential role of TRRAP in stabilization of wtp53, TRRAP was 
silenced with two independent shRNAs in two wtp53 BL cell lines, wtp53 was induced 
using the MDM2 inhibitor Nutlin-3a, and wtp53 levels were quantified by flow cytometry 
(Figure 23A). As expected, wtp53 levels were low in basal conditions and increased 
~6-8-fold upon Nutlin-3a treatment. In context of TRRAP knock-down, wtp53 induction 
was attenuated to ~3-6-fold in both cell lines upon Nutlin-3a exposure. To confirm these 
results, the experiment was repeated with the DNA damaging agent Etoposide 
(Figure 23B). In support of the previous results, Etoposide treatment resulted in 4.34-fold 
wtp53 stabilization, which was decreased to 2.55-2.84-fold in context of TRRAP 
silencing. 
To examine whether the reduced wtp53 accumulation translated into attenuated wtp53 
pathway activity, expression of the wtp53 target gene p21 and apoptosis induction via 
cleavage of PARP was monitored in TRRAP-silenced wtp53 cells after Etoposide 
treatment (Figure 23C). In line with the previous results, Etoposide treatment resulted in 
induction of the wtp53 pathway in control cells as indicated by increased wtp53 and p21 
protein expression and PARP cleavage. As expected, induction of wtp53 and p21 upon 
Etoposide treatment was suppressed in wtp53-silenced cells. In line with the flow 
cytometry results (Figure 23B), wtp53 induction was attenuated in TRRAP-silenced cells 
for two independent shRNAs. For one of the shRNAs, p21 was less induced compared 
to control cells. More importantly, both TRRAP shRNAs resulted in a strong suppression 
of PARP cleavage, indicating that wtp53’s function to induce apoptosis was markedly 
reduced. 
In summary, this suggests that TRRAP regulates the stability and activity of wtp53 upon 
exposure to genotoxic stress. 
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Figure 23: TRRAP silencing attenuates stabilization and activity of wild-type p53 upon genotoxic 
stress. 
(A) Seraphine and Salina wtp53 BL cells were transduced with shRNAs against TRRAP or a non-targeting 
control (NT). 4 d after transduction, cells were treated with DMSO (0.1%) or the MDM2 inhibitor Nutlin-3a 
(10 µM) for 24 h before they were subjected to p53 flow cytometry. Values denote p53 median fluorescence 
intensities (MFI) normalized to DMSO-treated cells transduced with the NT. (B) Seraphine wtp53 cells were 
transduced with shRNAs against TRRAP or a non-targeting control (NT). 5 d after transduction, cells were 
treated with DMSO (0.1%) or Etoposide (25 µM) for 5 h before they were subjected to p53 flow cytometry. 
Values denote p53 median fluorescence intensities (MFI) normalized to DMSO-treated cells transduced with 
the NT. (C) Protein level of p53, p21, and PARP in Seraphine wtp53 cells transduced with shRNAs against 
TRRAP, p53, or a non-targeting control (NT). Cells were selected with puromycin for 72 h. 6 d after 
transduction, cells were treated with DMSO (0.1%) or Etoposide (25 µM) before they were harvested at the 
indicated time points. Expression was determined by Western Blot and normalized to GAPDH and to cells 
transduced with the NT (2 h sample). ◄, specific band. 
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3.11 Histone deacetylase inhibition decreases mutant p53 levels 
and phenocopies TRRAP silencing 
To identify small molecule inhibitors able to modulate mutp53 levels similarly to TRRAP 
silencing, p53 levels were quantified in mutp53 lymphoma cell lines after exposure to a 
panel of inhibitors targeting various proteins/cellular pathways (Figure 24A): MDM2 
(Nutlin-3a), Hsp90 (17-AAG), histone deacetylases (Vorinostat), autophagy 
(Chloroquine), and the proteasome (MG-132). The pan-histone deacetylase inhibitor 
(HDACi) Vorinostat was the only inhibitor resulting in strong and consistent depletion of 
mutp53 levels across all cell lines (Figure 24B). 
To address whether Vorinostat would also cause specific mutp53 degradation via the 
MDM2-proteasome axis (Figure 20), cells were treated with either Vorinostat alone or in 
combination with Nutlin-3a and p53 protein and mRNA expression was quantified 
(Figure 24C,D). The Vorinostat phenotype was salvaged to nearly full extent by co-
treatment with Nutlin-3a. Notably, Vorinostat caused strong downregulation of TP53 and 
MDM2 mRNA, which was not rescued by combination treatment with Nutlin-3a, while no 
change in TRRAP mRNA expression was observed. These findings indicate that 
Vorinostat regulates mutp53 expression on both the transcriptional level and the 
translational or post-translational level. 
Since Vorinostat is a broad range HDAC inhibitor248, it was aimed to identify HDAC 
subgroups crucial for regulating mutp53 accumulation. To this end, a panel of subgroup-
specific HDAC inhibitors was tested for their effect on mutp53 levels by flow cytometry 
(Figure 24E). Inhibition of HDAC6 with Tubacin and Tubastatin A249 and HDAC8 with 
PCI-34051250 resulted in only mild reduction of mutp53 accumulation (53-91% of the 
basal level), suggesting that these HDACs do not contribute to mutp53 stabilization in a 
major way. In contrast, treatment with the HDAC1/2/3-specific inhibitors Entinostat and 
Mocetinostat248,251 caused strong depletion of mutp53 (12-42% of the basal level), 
indicating that these HDACs are main drivers of mutp53 stabilization.  
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Figure 24: Histone deacetylase inhibition decreases mutant p53 levels and phenocopies TRRAP 
silencing. 
(A) Impact of different small molecule inhibitors on mutp53 levels. Cells were treated with 0.1% DMSO or the 
indicated inhibitors. 24 h after treatment, cells were subjected to p53 flow cytometry. Values denote log2 fold 
changes (FC) of p53 median fluorescence intensities (MFI) normalized to DMSO-treated cells. Nutlin-3a 
(10 µM), MDM2 inhibitor; 17-AAG (5 µM), Hsp90 inhibitor; Vorinostat (5 µM), histone deacetylase inhibitor; 
Chloroquine (10 µM), autophagy inhibitor; MG-132 (5 µM), proteasome inhibitor. Experiment performed 
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jointly with Sophie Rabe. (B) p53 flow cytometry of mutp53 lymphoma cell lines after treatment with 0.1% 
DMSO (grey) or 5 µM of the histone deacetylase inhibitor Vorinostat (red) for 24 h. Values denote the ratio of 
the p53 median fluorescence intensity (MFI) between treated and control cells. Experiment performed jointly 
with Sophie Rabe. (C) Rescue of the Vorinostat-mediated mutp53 degradation by combination treatment 
with the MDM2 inhibitor Nutlin-3a. Namalwa cells were treated with DMSO (0.1%), Vorinostat (5 µM), or a 
combination of Vorinostat and Nutlin-3a (10 µM) for 24 h before they were subjected to p53 flow cytometry. 
Values denote p53 median fluorescence intensities (MFI) normalized to DMSO-treated cells. (D) mRNA level 
of TRRAP, TP53, and MDM2 in Namalwa cells treated with DMSO (0.1%), Vorinostat (5 µM), or a 
combination of Vorinostat and Nutlin-3a (10 µM). Cells were harvested 24 h post-treatment. Expression 
values were determined by qRT-PCR and normalized to GAPDH and to DMSO-treated cells. (E) p53 flow 
cytometry of Namalwa cells after treatment with 0.1% DMSO (grey) or different histone deacetylase 
inhibitors (HDACi, red) for 24 h and 48 h. The targets of the different inhibitors are indicated. Values denote 
the ratio of the p53 median fluorescence intensity (MFI) between treated and control cells. Concentrations 
used: Tubacin, 7.5 µM; Tubastatin A, 7.5 µM; PCI34051, 10 µM; Entinostat, 500 nM; Mocetinostat, 500 nM. 
(F) Correlation of the impact of TRRAP silencing (8 d post-transduction) and Vorinostat treatment (5 µM, 
24 h) on mutp53 levels. p53 protein levels were determined by flow cytometry. Values denote normalized 
p53 median fluorescence intensities (MFI) normalized to either untransduced cells (shTRRAP) or DMSO-
treated cells (Vorinostat), respectively. The Pearson correlation coefficient (R2) and the corresponding P 
value are indicated. (G) Gene set enrichment analysis of significantly differentially expressed genes (adj. P < 
0.05 & |log2FC| > 1) upon TRRAP knock-down in mutp53 Namalwa cells. Upregulated gene sets are 
denoted in red, downregulated in green. Analysis was performed using Parametric Analysis of Gene Set 
Enrichment (PAGE)213 with the MSigDB214 gene set collection “c2cgp” filtered for the term “HDAC”. Only 
significantly altered gene sets are shown (adj. P < 0.1). (H) Venn diagram showing the overlap of 
significantly differentially expressed genes after TRRAP knock-down in the mutp53 BL cell line Namalwa and 
after Mocetinostat treatment in the mutp53 breast cancer cell line MDA-MB-231. Mocetinostat data were 
downloaded from NCBI GEO, accession number GSE65495218. ***, P value = 2.6e-9 (hypergeometric test). 
(I) Heatmap of all 175 significantly differentially expressed genes shared between TRRAP knock-down and 
Mocetinostat treatment from panel H. log2 fold changes were subjected to hierarchical clustering. Numbers 
below the clusters indicate the number of genes. BRCA, breast cancer cell line (MDA-MB-231); BL, Burkitt’s 
lymphoma cell line (Namalwa). 
Upon comparison of the mutp53 phenotypes after pan-HDAC inhibition and after TRRAP 
silencing, a highly similar response pattern was observed (Pearson correlation R2=0.63, 
p<0.05), i.e. cell lines responded either strongly (e.g. BL-41) or weakly (e.g. CA-46) to 
both perturbations (Figure 24F). To evaluate whether TRRAP silencing and HDAC 
inhibition altered transcription of similar genes, gene expression data after TRRAP 
knock-down in a mutp53 model (Figure 21A) was reanalyzed with a specific focus on 
gene sets known to be altered by HDAC inhibition (Figure 24G). In fact, five HDAC-
related gene sets were found to be differentially expressed upon TRRAP silencing 
(2 down, 3 up). Interestingly, the most significant gene set consisted of genes 
downregulated upon HDAC3 knock-down (SENESE_HDAC3_TARGETS_DN, 
adj. p = 0.0035)252, which is in support of the finding that HDAC1/2/3 inhibition using 
Entinostat or Mocetinostat had the strongest impact on mutp53 levels (Figure 24E). To 
investigate this further, published gene expression data of mutp53 breast cancer cells 
treated with Mocetinostat218 were analyzed and compared to expression data after 
TRRAP silencing in mutp53 BL cells. To find similarities, the focus was set on the subset 
of 175 genes significantly differentially expressed in both data sets (Figure 24H). 
Strikingly, expression of the vast majority of genes (154/175, 88%) was changed in a 
similar fashion in both data sets (Figure 24I, 97/175 shared down, 57/175 shared up, 
21/175 not shared) and the overlap was highly significant (p=6.6e-5, hypergeometric 
test). This indicates that TRRAP silencing and HDAC1/2/3 inhibition regulate mutp53 
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levels potentially by sharing a subset of target genes. Alternatively, there may be 
additional functional convergence for both perturbations beyond mutp53 regulation. 
Finally, it was investigated whether TRRAP silencing or HDAC inhibition (using 
Vorinostat, Mocetinostat, or Entinostat) directly regulated acetylation of mutp53 in BL 
cells (Figure 25). Since p53 can potentially be acetylated on ten different lysine 
residues50,52 (Figure 4), mutp53 was immunoprecipitated and acetylation was quantified 
by Western Blot using a pan-anti-acetylated lysine antibody. In basal conditions, mutp53 
acetylation was not detectable. Strikingly, mutp53 acetylation remained undetectable 
upon HDAC inhibition and TRRAP silencing. Merely treatment of cells with high doses of 
the pan-HDAC inhibitors sodium butyrate and nicotinamide resulted in a detectable 
mutp53 acetylation. This indicates that TRRAP and HDACs are unlikely to regulate 
mutp53 stabilization via direct acetylation. 
 
Figure 25: Impact of HDAC inhibition and TRRAP silencing on mutant p53 acetylation. 
Namalwa cells were treated with DMSO (0.05%) or different HDAC inhibitors before they were subjected to 
p53 or control (419) immunoprecipitation (IP). Silencing experiments were performed using Namalwa cells 
with IPTG-inducible shRNAs against TRRAP or a non-targeting control (NT). Cells were harvested 5 h after 
drug exposure or 48 h after shRNA induction. Protein expression was determined by Western Blot. 
Acetylation (Ac) was detected by using an anti-acetylated lysine antibody. Concentrations used: Vorinostat, 
1 µM; Entinostat, 500 nM; Mocetinostat, 500 nM; Sodium butyrate (NaB), 5 mM; Nicotinamide (NAM), 
10 mM. 419, anti-SV40 T-antigen mouse (negative control for IP p53); GAPDH, loading control. 
 
In summary, these results suggest that histone-modifying complexes, including TRRAP-
containing HAT complexes and HDAC1/2/3, participate in regulation of mutp53 levels. 
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4 Discussion 
4.1 p53 mutations and levels in Burkitt’s lymphoma 
In the beginning of this study, the frequency of p53 mutation was investigated in a panel 
of 67 BL patients, which identified mutations in 43% of cases. Most previous BL studies 
reported a slightly lower frequency of p53 mutations (mean: 34.7%, Table 1, p. 21), but 
frequencies were highly variable between studies (16.7-63.0%). In general, BL is among 
the B-NHLs with the highest frequency of p53 mutation170, while mutations are for 
example rare in FL (8%)170 and DLBCL (ABC subtype: 3.5%, GCB subtype: 11.5%)163. 
The high frequency of p53 mutation in BL may be explained by the fact that BL is a 
MYC-driven lymphoma157. Since MYC overexpression results in p53-dependent 
apoptosis induction165, p53 mutation and thus inactivation could be a way to circumvent 
this. In BL patients retaining wtp53, alternative mechanisms of p53 inactivation include 
overexpression of the negative regulators MDM2 and MDM4171,172. The pattern of p53 
mutations that was found in this study, i.e. a high frequency of missense mutations that 
clustered in the DNA-binding domain, has been reported previously in BL163. In fact, this 
pattern is typical for p53 in cancer in general and is assumed to be a proof for the 
oncogenic GOF of mutp53253. Although Bhatia et al.166 reported differences in the pattern 
of p53 mutations between BL and solid tumors (i.e. most mutations in codons 213-248, 
codon 273 mutations very rare), this study and a meta-analysis of more recent studies254 
could not confirm this. 
This study found a massive accumulation of mutp53 protein in BL patients and cell lines, 
which is a hallmark of mutp53 in most cancers73-75 but has not been specifically reported 
for BL so far. While a significant correlation between presence of p53 mutation and 
accumulation was observed here in B-NHL and BL patients, contradictory results are 
reported in the literature171,255-258. In this study, evidence was found for a translational or 
post-translational mechanism of mutp53 stabilization in BL since p53 protein expression 
was not correlated with TP53 mRNA expression. This is in support of the ubiquitin-
proteasome pathway being the major node of p53 regulation31. In contrast, Balint and 
Reisman259 reported elevated levels of TP53 mRNA in a panel of mutp53 BL cell lines 
(BL-41, DG-75, Raji, Namalwa) caused by an increased rate of transcription. This conflict 
may be explained by the fact that the investigators used immortalized B lymphoblastoid 
cell lines with unknown p53 status as a reference, while this study specifically compared 
mutp53 to wtp53 BL cells. 
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The use of flow cytometry allowed identification of heterogeneous p53 accumulation in a 
subset of mutp53 BL cell lines in spite of homogeneous p53 mutation. Similar 
observations have already been made with p53 immunohistochemistry in B-NHL 
patients256 and various cancer cell lines, even after generation of single cell clones77. The 
extent of mutp53 stabilization was found to neither correlate with protein conformation 
nor with mutation severity77. It has been suggested that the heterogeneity is a result of 
variable stabilization of mutp53 in response to local stress factors provided by the 
cellular tumor environment77,260. In line with this, it has been shown that mutp53 can be 
stabilized by stress signals such as irradiation261. However, this was unlikely to occur 
under in vitro conditions that were used in this study. Instead, it was hypothesized that 
part of mutp53 was actively degraded by MDM2. In support of this, all tested mutp53 BL 
cell lines retained basal MDM2 expression and further stabilized mutp53 upon MDM2 
inhibition by Nutlin-3a treatment, which both has been also demonstrated in several 
cancer cell lines77,82,83. Importantly, this strongly argues against a usage of Nutlin-3a (or 
wtp53-stabilizing therapy in general) in patients with tumors harboring p53 mutations 
since this may actually promote tumorigenesis262.  
 
4.2 shRNA screen for regulators of mutant p53 protein 
accumulation 
To get an unbiased view on the regulation of mutp53 accumulation, an shRNA screen 
was performed which used flow cytometry to readout p53 levels. This allowed direct 
quantification of endogenous p53 levels and thereby avoided the usage of an exogenous 
reporter system (e.g. p53-GFP), which not only is often challenging to establish but also 
merely provides an indirect quantification of the protein of interest. The approach 
presented here is instead highly flexible and may be adapted for investigating the 
regulation of any protein for which quantification by flow cytometry is possible228. In 
support of this, screens with a similar experimental approach have been successfully 
used in the past to, for example, identify regulators of cell surface AC133 expression263, 
CD20 expression228, and tumor necrosis factor (TNF) in response to lipopolysaccharide 
(LPS)264. The study presented here is the first one investigating the regulation of mutp53 
accumulation in lymphoma on a comprehensive level. 
With the shRNA library used in this study, the ~5,000 best characterized coding genes 
were probed for their potential to regulate mutp53 levels. The fact that the human 
genome comprises ~20,000 genes265 calls therefore for additional screenings in the 
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future. For example, it is believed that non-coding RNAs such as microRNAs play a 
major role in directly and indirectly regulating mutp53 levels266.  
The high performance of the screening was not only supported by the high reproducibility 
of technical replicates but also by the drop-out of core essential and BL-specific viability 
genes (CDK6). This indicates that the presented approach may additionally be used for 
the identification of cancer-specific vulnerabilities. Since the culturing time of cells after 
library transduction before harvesting was rather short (8 days), the degree of drop-out 
and thus the detection power are expected to increase with prolonged culturing time 
(typically >14 days). 
For identification of candidate genes potentially regulating mutp53 levels, the weighted 
z-score method was employed to reduce the chance of false positive hits. Further 
confidence in hit selection was gained by separate analysis of the p53-low and p53-high 
population and by making use of their “opposing behavior”. Strong support for the 
analysis method was provided by the shRNAs targeting TP53, which were strongly 
enriched in the p53-low population and highly depleted in the p53-high population. 
Attention was focused on the p53-low population, i.e. proteins driving aberrant mutp53 
stabilization, due to their potential use as therapeutic targets103. Nevertheless, the 
identification and characterization of proteins with the potential to keep mutp53 levels 
low, i.e. hits from the p53-high population, will be crucial to gain a comprehensive picture 
of mutp53 regulation. 
The molecular chaperone Hsp90 has been reported to stabilize mutp53 in breast, 
prostate, and colorectal cancer83,103. However, Hsp90 was not enriched in the p53-low 
population in the shRNA screen performed in BL. In line with this, Hsp90 inhibition using 
17-AAG did not result in mutp53 destabilization in the tested B-NHL cell lines and Hsp90 
was also not detected in the basal mutp53 interactome in BL using mass spectrometry. 
This suggests that Hsp90 is unlikely to contribute to mutp53 accumulation in BL.  
 
4.3 Identification of TRRAP as a regulator of mutant p53 levels 
Using stringent hit selection criteria, the focus was set on characterization of the top hit 
TRRAP. TRRAP silencing had no impact on TP53 mRNA expression, thus hinting 
towards a translational or post-translational regulation of p53 levels, which is in line with 
the finding that mutp53 is stabilized on the protein level in BL. To confirm TRRAP as a 
regulator of mutp53 accumulation, a set of comprehensive validation experiments was 
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performed. While TRRAP silencing consistently downregulated mutp53 levels in multiple 
cancer cell lines (BL, DLBCL, CRC) across p53 mutations, TRRAP overexpression 
increased mutp53 levels. In addition, mutp53 depletion upon TRRAP silencing could 
successfully be reversed by TRRAP overexpression, thus providing important evidence 
for the shRNA on-target effect188. The RNAi phenotype was further validated with an 
independent technique184,188 via CRISPR/Cas9-mediated TRRAP knock-out, which 
phenocopied shRNA-mediated TRRAP silencing.  
The finding that TRRAP impacts mutp53 accumulation independent of p53 mutation 
residue and cancer entity suggests that TRRAP is key positive regulator of p53 levels in 
physiological conditions. This is supported by the finding that TRRAP was found to also 
positively regulate wtp53 levels and function. Thus, this indicates that stabilization of 
mutp53 in BL is not achieved by proteins that specifically gain a p53-stabilizing function 
in tumors but rather by hijacking the physiological machinery of wtp53 regulation. 
A striking example supporting this idea and acting in a similar fashion as TRRAP is 
Hsp90, which functions as a chaperone to stabilize wtp53 in response to stress in non-
transformed human fibroblasts247 but also contributes to mutp53 stabilization in 
tumors83,103.  
Despite the fact that TRRAP knock-down caused mutp53 depletion across different p53 
mutations, the extent of depletion was variable. Since this study and others found that 
MDM2 at least in part retains its ability to degrade mutp5335,84, it was hypothesized that 
the degree of mutp53 depletion upon TRRAP silencing was most likely a function of 
residual MDM2 activity. Accordingly, cell lines which strongly stabilized mutp53 upon 
MDM2 inhibition with Nutlin-3a (= high MDM2 activity; e.g. BL-41, Namalwa) also 
strongly downregulated mutp53 upon TRRAP knock-down and vice versa (e.g. CA-46, 
Raji). 
Both TRRAP knock-down and knock-out were found to impair cell growth independent of 
p53 mutation status. This is in line with a study by Herceg et al.267 that characterized 
TRRAP knock-out mice and found that TRRAP is mandatory for early embryonic 
development and cell proliferation. In addition, TRRAP was also shown to be essential 
for proper B-cell development in vivo268 and was found to be a “common essential gene” 
across entities on the basis of previous RNAi and CRISPR/Cas9 screens233,269. 
Therefore, this suggests that therapeutic targeting of TRRAP may be challenging. 
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4.4 Physical interaction of mutant p53 and TRRAP 
To investigate whether TRRAP mediated its stabilizing effect towards mutp53 via 
physical interaction, co-IP was performed. This experiment showed binding of mutp53 to 
TRRAP in an exogenous, p53-deficient model in which a FLAG-tagged version of 
TRRAP and mutp53 were artificially introduced. Furthermore, evidence was found for a 
preferred binding of TRRAP to mutp53 over wtp53. However, no evidence was found for 
a binding of mutp53 and TRRAP in an endogenous, mutp53 BL model. This is in contrast 
to Ard et al.238 who showed binding of TRRAP to wtp53 in basal conditions in 293 
(human embryonic kidney, HEK) cells. There are several reasons which may explain the 
difference between the results from the exogenous and endogenous model system. 
First, the observed interaction may have been an artifact caused by introduction of 
mutp53 and TRRAP in a p53-null model. For example, overexpression may result in 
protein expression in a wrong cellular compartment or protein aggregation, especially in 
the case of massive overexpression270. Second, different mutp53 proteins were studied 
in both systems, which may vary in their ability to bind to mutp53. While the endogenous 
model system harbored p53 with a R248Q mutation, experiments in the exogenous 
system were performed with a R175H mutation. However, both mutp53 proteins are 
conformational mutants prone to aggregation129 and, more importantly, TRRAP’s 
capability to regulate mutp53 level was found to be independent of the kind of p53 
mutation. Third, the binding of TRRAP to mutp53 may be of catalytic nature and 
therefore only transient, which may be difficult to reliably detect via classical IP without 
crosslinking271. Fourth, co-IP may not be sensitive enough in an endogenous setting, 
which may be caused by for example lower IP efficiency of endogenous proteins as 
compared to overexpressed exogenous proteins. 
In conclusion, it is suggested that mutp53 and TRRAP do not interact in BL, thereby 
ruling out the possibility that TRRAP chaperones mutp53. 
 
4.5 TRRAP silencing exports mutant p53 from the nucleus to 
the cytosol 
Total proteome profiling by mass spectrometry after TRRAP silencing showed that 
expression of only 44 proteins was significantly altered, including mutp53. This suggests 
that TRRAP-mediated p53 degradation is highly specific and unlikely to be a secondary 
effect, for example caused by cellular stress. Against the background that TRRAP is a 
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constituent of many HAT complexes237, this indicates that TRRAP may not regulate 
histone acetylation on a global scale but rather sequence-specifically, i.e. on a small 
scale for a very limited set of specific target genes. Accordingly, Wurdak et al.272 showed 
specific downregulation of H3K9 promoter acetylation for the TRRAP target gene 
CCNA2 after TRRAP knock-down, while global H3K9 acetylation levels were unchanged. 
Jin et al.273 reported that loss of KAT2A and KAT2B, the catalytic subunits of two 
TRRAP-containing HAT complexes, caused differential expression of only 6% of active 
genes in fibroblasts, providing further support for a gene-specific instead of a global 
function. Among the 44 proteins, no candidates or cellular pathways became apparent 
that could have been linked to regulation of mutp53 levels with the exception of the 
interferon signaling, which will be discussed later (see 4.6, p. 92). 
Mass spectrometry of p53 immunoprecipitates in mutp53 BL cells showed that TRRAP 
silencing induced major changes in the mutp53 interactome. Proteins lost upon TRRAP 
knock-down, i.e. proteins binding in basal conditions to mutp53, mainly participated in 
mRNA splicing. Against the background of mutp53 GOF, this suggests that mutp53 may 
play a role in mRNA processing. Accordingly, it has been reported that p53 can 
physically interact with and regulate the protein stability of SF3B2 (SAP145)274, one of 
the core components of the spliceosome. More importantly, two studies showed that 
silencing of several members of the mRNA splicing machinery (including SF3B1 and 
HNRNPL) can activate wtp53 via decreased MDM4 expression and increased MDM2 
degradation275 or via alternative splicing of MDM4276. Based on this, it is tempting to 
hypothesize that mutp53 maintains its own stabilization by exploiting the splicing 
machinery to regulate MDM2 or MDM4 expression. However, this study found no 
evidence for differential MDM2 expression between mutp53 and wtp53 BL cell lines. 
Alternatively, mutp53 may alter mRNA splicing to improve conditions for tumorigenesis, 
tumor growth, and survival. In fact, alternative splicing is exploited by many tumors for 
their own benefit, for example by specifically altering splicing of oncogenes and tumor 
suppressors277. Therefore, the findings of this study warrant testing the impact of mutp53 
on mRNA splicing in the future, which may help in delineating mutp53 GOF in 
lymphoma.  
TRRAP silencing caused translocation of mutp53 from the nucleus to the cytosol, 
indicating that TRRAP usually retains mutp53 in the nucleus. Along with this, mutp53 
was then found to physically interact with the eukaryotic translation initiation factor 3 
(eIF3), a multiprotein complex important for promoting translation initiation278. Since this 
interaction was not found in basal conditions, it is unlikely that mutp53 has an impact on 
protein translation. However, numerous studies have shown that eIF3 interacts with the 
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26S proteasome279-281. Given that mutp53 is degraded via the proteasome upon TRRAP 
knock-down, mutp53 may first bind to eIF3 before being funneled into the proteasome. 
However, mass spectrometry did not identify binding of proteasomal proteins to mutp53 
upon TRRAP knock-down. 
Mass spectrometry showed that nuclear export of mutp53 after TRRAP silencing was a 
prerequisite for its destabilization. Since p53 can in general be degraded in both the 
cytosol31,44,45 and the nucleus46,47, this indicates that mutp53 is protected from nuclear 
degradation but sensitive to cytosolic destruction. Importantly, this study and others113 
found that nuclear export inhibition results in augmented mutp53 stabilization, suggesting 
that part of mutp53 is constantly exported and degraded in the cytosol. From a clinical 
point of view, this finding may argue against a usage of nuclear export inhibitors (CRM1 
inhibitors) in patients with mutp53. Accordingly, acute myeloid leukemia, hepatocellular 
carcinoma, and mantle cell lymphoma cells harboring p53 mutation are less sensitive 
towards CRM1 inhibition than their wtp53 counterparts282-284. 
mutp53 has been reported to localize to the cytosol upon ubiquitination84,285. In line with 
this, the usage of small-molecule inhibitors and knock-out models showed that TRRAP-
driven mutp53 degradation was strictly dependent on the ubiquitin ligase MDM2 and the 
proteasome. This indicates that TRRAP silencing unleashes the classical wtp53 
degradation machinery on mutp53, which is again in support of the idea that MDM2 in 
general retains the capacity to degrade mutp5384. However, the specific role of MDM2 in 
mutp53 degradation is still under debate and not limited to ubiquitination37 but may also 
include facilitating access to the proteasome48 and nuclear export31,42,286. Notably, 
several other ubiquitin ligases are assumed to play a role in mutp53 ubiquitination84. For 
example, mutp53 degradation upon Hsp90 inhibition was shown to additionally depend 
on CHIP83, suggesting distinct mechanisms of TRRAP and Hsp90 for mutp53 
stabilization.  
Ard et al.238 reported that TRRAP is crucial for maintaining p53-dependent MDM2 
transcription in wtp53 cells. In addition, massive MDM2 overexpression has been shown 
to degrade mutp5335. Given the strict MDM2 dependence of TRRAP-mediated mutp53 
regulation, MDM2 levels were investigated after TRRAP silencing, which showed no 
major alterations in mutp53 BL cells. This indicates that TRRAP does not regulate MDM2 
expression in a mutp53 context, which may be explained by disruption of the p53-MDM2 
feedback loop65,81. Therefore, it is hypothesized that TRRAP silencing exposes mutp53 
to MDM2 without altering MDM2 expression. 
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4.6 TRRAP silencing induces interferon signaling and 
suppresses cell cycle-related genes 
To investigate the role of TRRAP in regulation of global transcription, gene expression 
profiling of mutp53, wtp53, and p53KO BL cell lines was performed after TRRAP knock-
down. In each cell line, TRRAP silencing altered the expression of only a small number 
of genes, which again provides evidence for the idea that TRRAP specifically regulates 
expression of a small subset of target genes272. In all cell lines, TRRAP silencing caused 
downregulation of genes related to cell cycle and chromosome segregation, which is in 
line with previous studies which showed that TRRAP knock-down in fact causes 
chromosomal missegregation and defects in the mitotic checkpoint267,272,287. 
Both gene expression profiling and mass spectrometric analysis indicated that TRRAP 
silencing resulted in a strong type I interferon (IFN) response across cell lines. IFNs are 
cytokines which trigger a potent antiviral response in cells242. Since IFN responses are 
typically only induced by double-stranded RNA present after viral infections288, the 
finding that TRRAP knock-down caused activation of IFN signaling is at first surprising. 
TRRAP is a common component of many HAT complexes, including the STAGA and the 
PCAF complex237. Importantly, knock-out of the catalytic subunits of these two HAT 
complexes (KAT2A, KAT2B) has been shown to induce IFN-β signaling without the need 
of viral infection273. In fact, both proteins were found to be negative regulators of IFN-β 
production since they inhibit activity of TBK1, the key kinase needed for activation of the 
IFN pathway273. Against the background that TRRAP is assumed to play a 
“nonredundant role”237 in HAT complexes, TRRAP ablation may thus trigger IFN 
signaling via disruption of the IFN-inhibitory complexes STAGA and PCAF. Worthy of 
note is that the observed IFN response after TRRAP knock-down may also be an 
unspecific side-effect caused by lentiviral transduction, which has been reported to 
occasionally trigger IFN activation289. However, since the transcriptome data after 
TRRAP knock-down was normalized to cells transduced with a non-targeting shRNA, 
lentiviral shRNA expression is unlikely to be the sole cause of the IFN response. 
Importantly, IFN signaling did not contribute to mutp53 downregulation upon TRRAP 
silencing in BL, which is in contrast to a study performed by Madar et al.203. 
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4.7 Identification of TRRAP’s domain crucial for mutant p53 
stabilization and cell survival 
For a systematic assessment of the role of TRRAP’s different protein domains in 
promoting both cell survival and mutp53 accumulation, the recently described “CRISPR 
scanning” technique was employed223. The traditional way of testing protein domains for 
a specific function includes the characterization of truncation/deletion mutants 
specifically lacking the domain of interest. The generation of these mutants is typically 
done via site-directed mutagenesis290, which is not only technically challenging but also 
depends on availability or generation of an overexpression construct. Moreover, 
characterization of these mutants is done by artificially introducing them into cells, which 
often does not reflect physiological conditions270. This is especially the case for massive 
overexpression, which can for example cause protein aggregation and result in a false 
positive loss-of-function270. CRISPR scanning overcomes all of these limitations since it 
acts directly on the endogenously expressed protein and only depends on the proper 
design of sgRNAs targeting the domain of interest. It has been successfully used in the 
past to identify protein domains essential for cell survival in for example chromatin 
regulatory proteins in MLL-AF9 leukemia223 or in MLL1 in NPM1-mutant leukemia291. This 
study describes the first usage of CRISPR scanning for studying a phenotype beyond 
cell survival, namely mutp53 levels. 
TRRAP belongs to the phosphatidylinositol 3-kinase-related kinase (PIKK) family, which 
in humans consists of six members (Figure 26A): ATM, ATR, DNA-PKcs, SMG1, mTOR, 
and TRRAP235. PIKKs play a role in diverse biological processes235, including DNA 
repair292, cell growth293, and RNA surveillance294. They are very large proteins with 
molecular weights in the range of ~280-470 kDa and the structural architecture is shared 
between all family members236. Typically up to 90% of the protein length of PIKKs is 
made up of a very long stretch of HEAT repeats235. This is followed by a short conserved 
C-terminus, which contains three domains (FAT, PI3K, and FATC)235. Some PIKK 
members, including TRRAP, contain an additional small domain between the FAT and 
PI3K domain termed FRB236. Electron microscopy and X-ray crystallography experiments 
identified the three-dimensional organization of PIKKs to be divided into a compact 
“head” formed by the C-terminus and into “arms” formed by the HEAT repeats that 
assemble as helical scaffolds (Figure 26B)236. The “arms” are suggested to play a crucial 
role in regulating PIKK function as they promote interaction with other proteins and 
DNA236. 
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Figure 26: Phosphatidylinositol 3-kinase-related kinase (PIKK) family. 
(A) Schematic representation of the domain organization and total number of amino acids of all human PIKK 
family proteins. Domain annotation according to Figure 22A. Adapted by permission from AIMS Press: AIMS 
Biophysics, Rivera-Calzada et al.236, copyright 2015. (B) Schematic model of the three-dimensional structure 
of PIKK family proteins. The overall structure can be divided into “head” and “arms”. Domain annotation 
according to Figure 22A. Adapted by permission from AIMS Press: AIMS Biophysics, Rivera-Calzada et 
al.236, copyright 2015. 
Due to the fact that high-resolution structural information is rare236, the molecular function 
of the different PIKK domains is especially in the case of TRRAP not well understood 
and based on only a very limited number of studies. Knutson and Hahn246 performed a 
large scale deletion mutant study in yeast and identified regions in Tra1 (TRRAP 
homolog in yeast) essential for cell viability, which were all defective for interacting with 
HAT complexes. Ard et al.238 identified a small region (residues 1992-2370) capable of 
binding to wtp53. While all PIKKs possess kinase activity, TRRAP lacks the conserved 
kinase motifs responsible for ATP binding and is therefore kinase-dead234. 
CRISPR scanning confirmed TRRAP’s crucial function for cell survival267 since cells 
transduced with sgRNAs targeting TRRAP were depleted over time. None of the 
annotated domains of TRRAP protruded in terms of toxicity upon targeting, indicating 
that they are equally important for maintaining TRRAP’s essential function. The lack of 
severe toxicity upon targeting of the wtp53-binding region may be explained by the fact 
that this study did not find evidence for a physical interaction of mutp53 and TRRAP in 
BL. Interestingly, a 109 aa stretch mapping to HEAT repeats 21 and 22 in the N-terminus 
of TRRAP246 could be identified, whose targeting was highly fatal. Accordingly, deletion 
of this region was also identified to be detrimental in yeast (HEAT repeats 20 and 21)246. 
Single HEAT repeats (or motifs) are 30-40 amino acids in length and consist of two 
α-helices which are connected by a linker region295. It is challenging to speculate on the 
function of the identified region due to the fact that HEAT repeat domains can play a 
plethora of different roles295. Importantly, also single repeats within long HEAT repeat 
regions can be essential for proper functioning of the whole protein296. Based on 
observations made in other PIKKs236, it is suggested that HEAT repeats 21 and 22 in 
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TRRAP either facilitate protein-protein interaction or are modulated by post-translational 
modification. 
Using flow cytometry for the phenotypic readout of the CRISPR scanning allowed a 
simultaneous monitoring of cell and mutp53 depletion upon TRRAP targeting. Both 
phenotypes were highly correlative, indicating that TRRAP’s survival-promoting and 
mutp53-stabilizing function are tightly linked and mediated by similar domains. In other 
words, no evidence could be found for a specific mutp53-regulatory domain in TRRAP. 
This suggests that therapeutic targeting of TRRAP to specifically downregulate mutp53 
levels may be challenging and compromised by general toxicity. 
 
4.8 TRRAP silencing attenuates stabilization and activity of 
wild-type p53 upon genotoxic stress 
In a TRRAP-deficient context, wtp53 accumulation after exposure to genotoxic stress 
was impaired which may be caused by three distinct mechanisms. First, TRRAP may 
directly bind to wtp53 and assist in its stabilization for example by recruiting chaperones. 
This is partially supported by a study by Ard et al.238 that showed binding of TRRAP to 
wtp53 in basal conditions in 293 (human embryonic kidney, HEK) cells. However, this 
study was unable to find evidence for a direct interaction of TRRAP and (mut)p53 in BL. 
Second, this may be explained by the increased MDM2 protein expression that was 
observed upon TRRAP knock-down in basal conditions in wtp53 BL cells. This is in 
contrast to the finding that TRRAP is essential for maintaining MDM2 transcription238. 
Again, this controversy may be explained by the usage of different experimental models 
(HEK vs. BL). Third, similar to mutp53, TRRAP may retain wtp53 in the nucleus in 
stressed conditions and may thereby protect it from cytosolic proteasomal degradation. 
TRRAP deficiency also resulted in reduced wtp53 pathway activity upon DNA damage 
induction as indicated by reduced p21 induction. In support of this, Barlev et al.53 showed 
that TRRAP is recruited to the p21 promoter upon irradiation. This suggests that TRRAP 
may be important for facilitating p21 expression, potentially by modification of histone 
acetylation. In fact, binding of wtp53 to many of its target gene promoters was shown to 
result in an increased histone H3 and H4 acetylation with differences in the acetylation 
patterns between different promoters297,298. This indicates that promoter acetylation is not 
only crucial for driving wtp53 target gene expression but also important for differential 
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target gene expression in response to different stress signals297, i.e. expression of the 
correct genes in response to a certain stress.  
The fact that TRRAP silencing protected wtp53 cells from apoptosis after exposure to 
Etoposide may be best explained by the impaired p53 protein accumulation. Multiple 
independent studies showed that a certain threshold of p53 protein level has to be 
reached in the cell in order to induce p53-dependent apoptosis299-302. Low p53 levels, 
however, can still be sufficient to induce cell cycle arrest.  
Cell’s TRRAP dependence for full activation of wtp53 has important consequences for 
potential therapeutic targeting of TRRAP. Irrespective of TRRAP’s essential role for cell 
survival discussed previously, TRRAP inhibition is hence expected to not only destabilize 
mutp53 in tumor cells but to also impair wtp53 function in healthy cells. Although wtp53 
knock-out mice and humans with wtp53 germline mutations (Li-Fraumeni syndrome) are 
viable and fertile, they suffer from a tremendously increased cancer risk303-305. Therefore, 
TRRAP inhibition in patients will either have to be targeted specifically to mutp53 cancer 
cells or will have to be administered only short-term, potentially with treatment breaks, in 
order for wtp53 cells to recover. 
One may ask why TRRAP does not constantly stabilize wtp53, i.e. also in non-stressed 
conditions, since TRRAP appears to stabilize mutp53 in basal conditions. This can 
probably be best explained by the fact that tumors often experience chronic DNA 
damage and are hence under constant stress65. In line with this, mutp53 has been shown 
to be intrinsically instable and to require additional oncogenic events such as genotoxic 
stress to be stabilized78-80. Therefore, TRRAP is likely to exert its stabilizing effect on p53 
only under stressed conditions, potentially by preventing the nuclear export of p53. 
 
4.9 Histone deacetylase inhibition decreases mutant p53 levels 
and phenocopies TRRAP silencing 
Small-scale drug screening identified that pan-HDAC inhibition using Vorinostat resulted 
in MDM2-dependent mutp53 downregulation in BL on both the RNA and protein level. 
Several studies have previously described a link between HDACs and the regulation of 
p53 expression. In line with this study, pan-HDAC inhibition in multiple mutp53 cancer 
cells was shown to deplete p53 protein in a MDM2-dependent manner82,105,107. While 
Blagosklonny et al.105 found no impact on mutp53 RNA expression upon Vorinostat 
treatment, this could not be confirmed by more recent studies in which strong mutp53 
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mRNA depletion was observed upon HDAC inhibition107,163. The results presented here 
are in agreement with the latter studies and hint towards an HDAC-mediated p53 
regulation on both the transcriptional and translational or post-translational level, 
probably by independent mechanisms. Interestingly, impaired wtp53 mRNA expression 
upon HDAC inhibition has been reported repeatedly306-309, indicating that the 
transcriptional regulation of wtp53 and mutp53 may be similar. 
To assess the contribution of individual HDACs to mutp53 regulation, HDAC inhibitors 
with a high specificity towards single HDACs were used. The HDAC6-specific inhibitors 
Tubacin and Tubastatin A resulted in only mild depletion of mutp53 in BL. Since HDAC6 
was shown to stabilize mutp53 via positive regulation of Hsp9082,83, this indicates again 
that Hsp90 does not contribute to mutp53 stabilization in BL. This is supported by the 
findings presented here that Hsp90 inhibition did not cause mutp53 degradation in B-
NHL cell lines and that Hsp90 was not detected in the mutp53 interactome in BL. Similar 
to HDAC6 inhibition, also HDAC8 inhibition with PCI-34051 caused only mild depletion of 
mutp53 in BL. Due to the fact that previous studies showed that HDAC8 regulates 
mutp53 on the transcriptional level via HOXA5163 and YY1107, this provides further 
evidence that mutp53 is mainly regulated on the protein level in BL. Importantly, an 
almost complete depletion of mutp53 protein was observed in BL in this study upon 
inhibition of HDACs 1, 2, and 3 using Entinostat and Mocetinostat. This is in agreement 
with a recent study performed by Stojanovic et al.106 which showed that HDAC1 and 
HDAC2 act in concert to positively regulate mutp53 on the transcriptional level in 
pancreatic cancer. Worthy of note is that both HDACs were also reported to play a 
crucial role in B-cell lymphomagenesis in vivo310. 
Surprisingly, HDAC inhibition and TRRAP silencing caused mutp53 protein depletion to a 
very comparable degree. In general, both proteins share their role in regulating protein 
acetylation. However, while HDAC inhibition should globally increase both histone and 
non-histone acetylation104,311, silencing of the HAT complex member TRRAP is expected 
to cause reduced histone H3 and H4 target gene promoter acetylation272,287,312. TRRAP’s 
role beyond histone acetylation, for example in acetylation of non-histones or a potential 
acetylation-independent function, has been suggested but not proven so far237. 
Interestingly, HDAC inhibition and TRRAP silencing appear to share more functions 
beyond mutp53 regulation since gene expression profiling showed that TRRAP knock-
down altered expression of a subset of HDAC target genes. This suggests that HDAC 
and HAT inhibition impinge on expression (or regulation) of similar genes by unknown 
but potentially diverse mechanisms, which may in turn regulate mutp53 levels.  
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Strikingly, mutp53 acetylation was not detectable in basal conditions and also not upon 
HDAC inhibition or TRRAP knock-down. This suggests that mutp53 acetylation may not 
contribute to its stabilization in BL, which is in support of a study performed by Li et al.83 
in different cancer cell lines. In line with this, Ard et al.238 found no evidence for TRRAP-
mediated acetylation of wtp53. Given the MDM2 dependence of TRRAP- and HDAC-
dependent mutp53 regulation, it is tempting to speculate that they alter MDM2 
acetylation, which may in turn regulate its ability to promote p53 degradation. In fact, 
MDM2 has been shown to be acetylated by CBP but not PCAF (on residues K466/467) 
which blocks its ability to degrade p53313. In addition, Nihira et al.314 showed recently that 
p300-mediated acetylation (on residues K182/185) stabilizes MDM2. In combination with 
the findings of this study, this warrants testing the impact of histone-modifying complexes 
on MDM2 acetylation and activity in the future. 
Based on the GOF properties of mutp532,65, the finding that HDAC inhibition causes 
mutp53 depletion may provide a basis for therapeutic targeting of mutp53 in lymphoma 
and other cancers. In fact, a plethora of HDAC inhibitors is currently under clinical 
development since HDACs are known to contribute to tumorigenesis via aberrant 
acetylation of both histones and non-histones104. Notably, two studies found evidence for 
preferential toxicity of pan-HDAC inhibition in mutp53 cancer cells compared to wtp53 
cells82,105. Importantly, and similar to TRRAP inhibition, HDAC inhibitors may inhibit 
wtp53 function15, suggesting that long-term treatment of patients may have undesirable 
side effects. 
 
4.10 Known links between p53 and TRRAP 
This study identified TRRAP as a key regulator of mutp53 and wtp53 levels. In fact, there 
are several lines of evidence for a specific link between TRRAP and p53 regulation and 
function, which are briefly summarized below: 
1. All the other five members of the PIKK family (Figure 26A), the protein family to 
which TRRAP belongs235, are either direct regulators of p53 or are under the control 
of p53: 
a. Ataxia telangiectasia mutated (ATM) is a central regulator of the cellular 
response to DNA double-strand breaks292,315. It mediates not only the 
activating phosphorylation of p53 both directly7 and indirectly (via CHK2)316,317 
but also the inactivating phosphorylation of MDM239. 
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b. Ataxia telangiectasia and Rad3-related protein (ATR) is activated mainly in 
response to replication stress and phosphorylates CHK1318, which mediates 
the appropriate cellular response for example by phosphorylating p53317.  
c. DNA-dependent protein kinase catalytic subunit (DNA-PKcs) plays a crucial 
role in the non-homologous end joining (NHEJ) pathway of DNA repair319. It is 
required for p53 phosphorylation at S18 and p53-mediated apoptosis 
induction320,321.   
d. Suppressor with morphogenetic effect on genitalia 1 (SMG1) regulates the 
mRNA surveillance pathway but also upregulates p53 upon genotoxic stress 
by phosphorylation322,323. 
e. Mammalian target of rapamycin (mTOR) is the key regulator of nutrient and 
growth factor signaling and its activation upregulates cell proliferation324. 
While wtp53 typically inhibits the mTOR pathway325, mutp53 can stimulate 
mTOR signaling326,327.   
2. TRRAP has been repeatedly reported to take part in the p53 downstream effector 
machinery: 
a. TRRAP is essential for p53-dependent MDM2 expression238.  
b. TRRAP is recruited to the p21 promoter upon irradiation53. 
c. TRRAP is recruited to and necessary for the proper repair of DNA double-
strand breaks, most likely because histone acetylation facilitates access of 
repair proteins to chromatin237,328. Notably, upstream signaling to ATM and 
ATR is not affected by TRRAP depletion328.  
3. Three of the four human HAT complexes of which TRRAP is a member of329 have a 
reported role in regulating p53: 
a. The p300/CBP-associated factor (PCAF) complex controls p53 expression via 
its intrinsic ubiquitination activity towards MDM2330. Accordingly, 
overexpression of the PCAF complex member ADA3 stabilizes p53 protein331. 
b. The TIP60 complex is required for p53-mediated expression of p21, binds to 
both p53 and MDM2, and interferes with MDM2-mediated p53 degradation, 
potentially by affecting its nuclear export332. In addition, TIP60 is stabilized 
upon irradiation and is also a substrate of MDM2333. 
c. The STAGA complex physically interacts with p53 and is required for p53-
dependent activation of p21, PUMA, and GADD45334. Notably, this study 
could not detect a physical interaction between (mut)p53 and TRRAP. 
4. TRRAP and p53 levels show a strong positive correlation in breast cancer patient 
samples335. 
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5 Conclusions & Perspectives 
Tumors often accumulate high levels of mutp53, which contribute to mutp53 GOF 
properties and thereby to tumorigenesis. The mechanisms that control this excessive 
accumulation are not completely understood. By using subgenome-wide RNAi, this study 
identified a crucial role of the PIKK family member TRRAP in regulating both mutp53 and 
wtp53 levels, potentially by preventing the MDM2-dependent nuclear export and 
proteasomal degradation of p53.  
Since TRRAP is a constituent of many HAT complexes, future studies will have to 
elucidate its specific function in these complexes. In line with this, it will be tempting to 
probe each complex (member) for its potential to regulate p53 levels. Against the 
background that tumors often become addicted to constitutively high levels of mutp53, 
therapeutic targeting of TRRAP in cancer may be appealing but challenging given that 
TRRAP is an essential protein. However, since inhibition of HDACs was found to 
phenocopy TRRAP silencing, HDAC inhibitors may be used as surrogates – especially 
because many HDAC inhibitors are currently under clinical development. Additional 
investigations are needed to test whether HDAC inhibition is suitable to preferentially 
target mutp53 over wtp53 cells. In general, the finding that inhibition of a HAT complex 
member resulted in a similar phenotype as inhibition of HDACs is striking and should be 
investigated more deeply in the future. For example, investigating the impact of TRRAP 
and HDAC inhibition on non-histone protein acetylation, especially MDM2, may yield 
novel insights into the functional mechanism underlying p53 regulation. 
Despite the fact that this study focused on the characterization of TRRAP, the performed 
RNAi screen identified a number of hits with a potential role in regulating mutp53 levels, 
which may be investigated in the future. Given the advance of the CRISPR/Cas9 
technology and its potential superiority compared to RNAi (e.g. less off-target effects), a 
CRISPR/Cas9 screen may shed additional light on the regulation of mutp53 
accumulation. 
In summary, this study provides a link between histone-modifying complexes and 
regulation of p53 levels, which may be exploitable in cancer therapy. 
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6 Appendix 
6.1 CRISPR scanning – TRRAP sgRNA sequences 
The order of the sgRNA sequences in Table 11 below is according to the x-axis in 
Figure 22A ascending from left to right, i.e. from TRRAP’s N-terminus to C-terminus. 
Table 11: sgRNA sequences used for CRISPR scanning. 
# Name Sequence [5’→3’] # Name Sequence [5’→3’] 
1 sgTRRAP 
_98878173 
AGTGGTCTGGTCAACCACCG 29 sgTRRAP 
_98884240 
CCTGGGCAGAATCCACGGAC 
2 sgTRRAP 
_98878703 
ATCATACCAACCATTTCTGG 30 sgTRRAP 
_98884251 
CCTGTCCGTGGATTCTGCCC 
3 sgTRRAP 
_98879290 
GCTGGCGGACATGGTGCACG 31 sgTRRAP 
_98884374 
CAAGCAGCACACAGACACTG 
4 sgTRRAP 
_98879515 
GCTGGTACCGAGCAATTGTG 32 sgTRRAP 
_98884395 
GGTGAACTTCCTTATCCGCG 
5 sgTRRAP 
_98879609 
CCAGGAGCTGCAGGGGCAGT 33 sgTRRAP 
_98884428 
TAATGACAACACCAACACAG 
6 sgTRRAP 
_98879617 
GAGCAGGGCCAGGAGCTGCA 34 sgTRRAP 
_98884487 
ACCTTCTGAAGACTGCGTTG 
7 sgTRRAP 
_98879656 
GCGGGGGTGGAGGTGGGGCA 35 sgTRRAP 
_98884704 
CATGACATGTGGAAACACCA 
8 sgTRRAP 
_98879697 
CACGGGGGCCGGGGTCACAG 36 sgTRRAP 
_98884860 
AGGGCTCACCAACTACGAGA 
9 sgTRRAP 
_98879700 
ACCTGCCACCCCTGTGACCC 37 sgTRRAP 
_98885226 
GGTCAAGAATAACTCCCCAA 
10 sgTRRAP 
_98879712 
CTTCTCGAAGGGAGGCACGG 38 sgTRRAP 
_98885751 
GGAGAACAGCGAGTCCAAAG 
11 sgTRRAP 
_98879988 
TGGACAGACATACATCCGTG 39 sgTRRAP 
_98885895 
GTTTCTGGACACTCTCCGAG 
12 sgTRRAP 
_98880635 
CCATTGAGTGCAGACACCAA 40 sgTRRAP 
_98886656 
TCGTCCTGGAGTGCGCCTGG 
13 sgTRRAP 
_98881019 
ACACTGAGCCCTACTACCGG 41 sgTRRAP 
_98886748 
TGGAAGGTGAACATGTACCG 
14 sgTRRAP 
_98881141 
GATGTGAGATGATAACATTG 42 sgTRRAP 
_98887007 
AGACGGTGGTGAAGACCTGG 
15 sgTRRAP 
_Bru8295_3 (X1) 
CTTGATCCGCCACTATACGA 43 sgTRRAP 
_98887637 
ATCAGAACGAGAGCAAATCG 
16 sgTRRAP 
_98881473 (X2) 
GGAGCTTTGCAAAATCGGGG 44 sgTRRAP 
_98888100 
CCTGGCGAAATGTTACTCCG 
17 sgTRRAP 
_98881579 (X3) 
GTTCATAACAACATGCACAC 45 sgTRRAP 
_98888217 
GGAGAACATGGTCGAGACGT 
18 sgTRRAP 
_98881615 (X4) 
GCGTGGTATGCAAAGCTGGG 46 sgTRRAP 
_98888316 
GCTGAAAGGCCAGTTCACGA 
19 sgTRRAP 
_98882094 
GAAGAGCCTGGGCTGCAACG 47 sgTRRAP 
_98888669 
ACGCCTGCCTCACAGAGTCA 
20 sgTRRAP 
_98882571 
GCGCAAGTGGATGGAAGTGG 48 sgTRRAP 
_98888719 
CCTTTCTCTTCTCCAAACAG 
21 sgTRRAP 
_98882714 
AGGTTGTCATGAAAACGGAG 49 sgTRRAP 
_98888745 
GAAAAACAAGTGCCTCTTGG 
22 sgTRRAP 
_Bru8295_2 
CCACTGGGGATCGTTCAGTG 50 sgTRRAP 
_98888806 
AAGAGGGGTTGTCCTCCACG 
23 sgTRRAP 
_98882837 
ATAAACATTCTGCTCCACTG 51 sgTRRAP 
_98888836 
GCTGCTTGTAGATCTCCACA 
24 sgTRRAP 
_98883119 
TGAGTGAGAACTTCCAAGAG 52 sgTRRAP 
_98889444 
CATGTTCTCTGGCTGCCCGG 
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25 sgTRRAP 
_98883484 
TTGGGACCTCCCAATCCAGA 53 sgTRRAP 
_98889486 
GGTGACGGCTTTCTGAACCA 
26 sgTRRAP 
_98883873 
GATGGCCATTCTGACCCCGG 54 sgTRRAP 
_98889507 
GTGCAGGCGGGTCATGATGG 
27 sgTRRAP 
_98883936 
CTGGACCCGGAAGATCATTG 55 sgTRRAP 
_98889567 
AAGCAAGGTGAACACCCTGG 
28 sgTRRAP 
_98884189 
GATATGGACCCAAATTCCAG 56 sgTRRAP 
_98889579 
ATTGTCCAGGCTGTTTGCCG 
Median TRRAP sgRNA on-target score207: 70.0. 
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8 Abbreviations 
AACR American Association for Cancer Research 
ABC DLBCL Activated B-cell like diffuse large B-cell lymphoma 
AIDS Acquired immunodeficiency syndrome 
APC Allophycocyanin 
ASHM Aberrant somatic hypermutation 
ATCC American Type Culture Collection 
ATP Adenosine triphosphate 
BCA Bicinchoninic acid 
BCR B-cell receptor 
BL Burkitt’s lymphoma 
B-NHL B-cell non-Hodgkin lymphoma 
BRCA Breast cancer 
BSA Bovine serum albumine 
CCE Constitutive core essential 
cDNA Complementary deoxyribonucleic acid 
CRC Colorectal cancer 
CRISPR Clustered regularly interspaced short palindromic repeats 
CSR Class-switch recombination 
ddH2O Double-distilled water 
DKFZ Deutsches Krebsforschungszentrum (German Cancer Research Center), Heidelberg, 
Germany 
DLBCL Diffuse large B-cell lymphoma 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleotide 
DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany 
dsRNA Double stranded ribonucleic acid 
DZ Dark zone (germinal center) 
eBL Endemic Burkitt’s lymphoma 
EBV Epstein-Barr virus 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
EMBL European Molecular Biology Laboratory, Heidelberg, Germany 
EtOH Ethanol 
FACS Fluorescence activated cell sorting (flow cytometry) 
FAT Focal adhesion targeting domain 
FATC FRAP, ATM, TRRAP C-terminal domain 
FBS Fetal bovine serum 
FC Fold change 
FITC Fluorescein isothiocyanate 
FL Follicular lymphoma 
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